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3.    Abstract 
 
The pathogenic mechanisms and the origins of neurodegenerative diseases 
remain unclear on molecular level. Increasing evidences postulate alterations in 
miRNA signatures as critical factor in pathogenesis, progression and prognosis of 
neurodegenerative disorders. miRNAs are a class of small non-coding RNAs 
shaping gene expression post-transcriptionally. As a regulator of cellular functions 
and homeostasis, miRNAs maintain brain cell integrity and their dysregulation 
contributes to neuropathological conditions. 
In our studies, we demonstrated strong evidences for disease-associated miRNA 
expression changes during critical disease stages in brain regions vulnerable to 
neurodegeneration. In publication I, we gained a comprehensive picture of global 
miRNA expression changes in frontal cortex and cerebellum during clinical stage 
of sporadic Creutzfeldt–Jakob disease, the most prevalent human prion disease. 
We observed marked miRNA expression alterations highly changed in a regional 
and disease subtype-dependent manner in sporadic Creutzfeldt–Jakob disease. 
We additionally revealed complex impairments of key proteins involved in the 
miRNA silencing machinery and biogenesis that might underlie miRNA 
dysregulation in sporadic Creutzfeldt–Jakob disease. We clearly validated the 
miRNA expression signatures observed in sporadic Creutzfeldt–Jakob disease, in 
a mouse model highly relevant to human pathology. In cross-disease validation 
studies, we detected that specific sporadic Creutzfeldt–Jakob disease-regulated 
miRNAs are commonly altered in alternative neurodegenerative disease shedding 
light into potential common miRNA-related mechanisms in the neurodegenerative 
conditions. 
In publication II, we provided crucial insights into temporal miRNA expression 
alterations in brain regions vulnerable to early Alzheimer’s disease-type pathology. 
Therefore, we performed targeted expression profiling of miRNAs implicated in 
Alzheimer’s disease pathogenesis in the locus coeruleus, entorhinal cortex, 
hippocampal CA1 region and dentate gyrus during early and mid-stages of Braak 
neurofibrillary tangles pathology. In this way, we provided for the first time insights 
into crucial miRNA expression alterations in the locus coeruleus during early 
Alzheimer’s disease-type pathology before disease-associated neuronal death is 
evident. 
By a combination of different miRNA quantification approaches we provided a 
state-of-art methodology for a comprehensive screening and reliable validation of 
disease-associated miRNA signatures. Thereby, we emphasized the importance of 
a more holistic understanding in temporal, spatial and cellular aspects of miRNA 
alterations during neurodegenerative conditions, which will help to unravel 
biological consequences of miRNA dysregulation in disease.  
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4.    Introduction 
 
Neurodegenerative diseases (NDs) represent a heterogeneous group of incurable 
and debilitating conditions that are characterized by the progressive degeneration 
of the structures and function of the central and/or peripheral nervous system. In 
NDs, pathogenic changes in disease-specific brain areas lead to dysfunction 
and/or loss of specific neuronal populations that arise from often unknown or 
insufficiently characterized molecular and cellular risk factors and causes. The 
clinical manifestations depend on the particular brain regions involved during 
disease progression. Neurodegenerative conditions represent distinct disease 
entities; however, their pathogenesis shares many common features including a 
disturbed protein homeostasis, the aggregation and deposition of pathological 
altered proteins, progressive neuroinflammation, and neuronal dysfunction and 
loss (Dugger and Dickson 2017; Ramanan and Saykin 2013; Armstrong, Lantos, 
and Cairns 2005; Rudy J. Castellani, Perry, and Smith 2004).  
Prion diseases are progressive neurodegenerative conditions characterized by a 
rapid neuronal loss in specific areas of the brain corresponding to a high 
heterogeneity in their pathological features and clinical presentation ranging from 
rapidly progressive dementia to cerebellar ataxia (Appleby et al. 2009). The 
changes in the metabolism of the cellular prion protein PrPc and its formation into 
the abnormal isoform PrPsc, spongiform degeneration, neuronal loss and 
neuroinflammation are attributed to the pathogenesis of prion diseases (Colby and 
Prusiner 2011).  
Alzheimer’s disease (AD) is the most common form of neurodegenerative 
dementia characterized by gradual cognitive decline and impaired memory. AD is 
featured by a complex and multifactorial pathogenesis and the disease hallmarks 
include the deposition of protein aggregates consisting of extracellular amyloid 
plaques and intracellular generation of neurofibrillary tangles (NFTs) as well as 
brain atrophy, neuronal loss, vascular damage and neuroinflammation (De 
Strooper and Karran 2016; Wadsworth and Collinge 2011) 
The pathogenesis of prion diseases and AD shares the impairment of fundamental 
cellular machineries associated to an abnormal processing and aggregation of 
proteins, impaired lysosomal function and clearance mechanisms, proteopathic 
stress on different brain cells of disease-specific brain regions, impaired 
metabolisms, mitochondrial dysfunction as well as uncontrolled glial activation, 
which lead to an irreversible dys-homeostasis of the brain (De Strooper and 
Karran 2016; Puoti et al. 2012a; Castellani, Perry, and Smith 2004). The protein 
aggregation into amyloid conformations is proposed to play a causative role in the 
initiation of neurodegenerative cascades leading to disease pathology in prion 
disease as well as in AD (Selkoe and Hardy 2016; Colby and Prusiner 2011).  
However, the underlying pathogenic mechanisms and triggering factors, which 
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favour the development and progression of these neurodegenerative conditions, 
remain unclear.  
NDs, including prion disease and AD, are thought to develop over a clinically silent 
phase followed by a progressive worsening of clinical symptoms over time 
associated to a cumulative loss of neurons. The lack of knowledge on the ND-
specific molecular and cellular events, as well as key molecules driving disease 
progression hampers the development of therapeutic and diagnostic strategies. 
Studying a broad spectrum of fundamental cellular machineries in ND affected 
brain regions and cells during critical disease stages is essential for understanding 
the complex pathogenic mechanisms in a spatial, temporal and cellular dependent 
manner. 
Recently, straightforward links have been established between NDs and miRNA 
deregulated patterns suggesting miRNAs as contributing factor in 
neurodegeneration (Abe and Bonini 2013a; Hébert and De Strooper 2009a). 
miRNAs are a class of short, non-conding RNAs that represent a complex layer of 
gene expression regulation involved in cellular function and survival (Bartel 2009). 
miRNAs control protein expression on transcriptional level through the binding of 
mRNA targets, which is leading to translation repression and/or mRNA 
degradation dependent on sequence complementarity (Jonas and Izaurralde 
2015b). With their ability to regulate complex networks of genes, dysregulated 
miRNA networks have the potential to be involved in virtually all pathophysiological 
mechanism in NDs (Goodall et al. 2013). Thereby, deregulated miRNA networks 
can be involved in early molecular alterations in initial disease affected brain 
regions before manifestation of clinical signs, as well as throughout clinical 
disease progression in NDs.  
The present work provides comprehensive characterizations of miRNA signatures 
in the brain of patients afflicted with sporadic Creutzfeldt-Jakob disease (sCJD), 
the most common human prion disease, and AD, revealing crucial insights in the 
role of miRNA deregulation during critical stages of NDs.  
Our studies revealed marked alterations of the miRNA network and strong 
indications for complex impairments of the miRNA machinery with sCJD disease 
progression. A miRNA expression time course analysis from a sCJD mouse model 
provided a link between regional pathology and stage of disease and validated 
main observations from human tissue regarding miRNA expression changes. 
Functional miRNA explorations in sCJD were revealed by a selective cell death 
induction through the transfection of sCJD associated miRNAs in cell cultures. 
Using the expertise of characterizing miRNA signatures in sCJD by the usage of 
different analytical techniques and methodologies, the studies were extended to 
expression profiling of selected miRNAs reported to be involved in AD pathology. 
The analyses of miRNA expression in the locus coeruleus (LC), entorhinal cortex 
(EC) and hippocampus at early and mid-stages of AD revealed alterations of 
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disease-associated miRNAs during early AD. Moreover, a neuronal cellular 
environment has been identified for the altered miRNAs in early AD affected brain 
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4.1    Human Prion Disease 
 
Prion diseases, also known as transmissible spongiform encephalopathies, are a 
group of rapidly progressive neurodegenerative conditions present in human and 
in a wide range of animal species. The key neuropathological findings shared by 
prion diseases are widespread neuronal loss, spongiform vacuolation, gliosis, as 
well as the accumulation of the disease-associated isoform of the prion protein in 
the brain, sometimes accompanied by the formation of amyloid plaques (Fig 1A) 
(C. Soto and Satani 2011a; Appleby et al. 2009; Prusiner 1998).  
The main causative pathogenic event in prion diseases is attributed to the 
changes in the structural conformation of the cellular prion protein PrPc, and its 
formation into the abnormal, insoluble, pathogenic isoform, PrPsc, in a self-
propagating manner (Prusiner 1998). 
PrPc is an evolutionarily conserved protein predominantly expressed in the brain, 
and particularly enriched in neurons (Stahl et al. 1987). A large body of knowledge 
supports that PrPc expression and its misfolding into the pathological form PrPsc 
are necessary for the development of prion disease (Prusiner 1998; Aguzzi 2006). 
In this regard, it is suggested that loss of PrPc signaling and/or gain of PrPsc-
mediated toxic signaling can be involved in neuronal dysfunction and death 
(Winklhofer, Tatzelt, and Haass 2008). 
During its biosynthesis in the endoplasmic reticulum (ER) and Golgi apparatus, 
PrPc undergoes a range of post-translational modification, including glycosylation 
that result in di-, mono-, or unglycosylated forms (Ermonval et al. 2003). 
Whereby most PrPc is exposed on the cell surface as a membrane-bound, 
glycosylphosphatidyl inositol (GPI) –anchored glycoprotein, there are also 
transmembrane PrPc forms that traffic in the endosomal system (S. J. Kim 2002). 
PrPc has been supposed to cycle continuously between the plasma membrane 
and endocytic compartments, and thereby, likely involved in complex cellular 
mechanisms (Prado et al. 2004). Multiple biological functions have been proposed 
for PrPc including roles in neuroprotection, protection against oxidative stress, 
circadian rhythm, memory and cognition, metal homeostasis, controlling 
proliferation and differentiation of neural cells (De Mario et al. 2017; Castle and Gill 
2017; Wulf, Senatore, and Aguzzi 2017; Steele et al. 2006). As an extracellular 
scaffolding protein, PrPsc is suggested to be involved in transmembrane signaling 
and to serve as a platform for different signaling molecules (Linden 2017). 
It is hypothesized that PrPc may spontaneously misfold into a pathogenic prion 
protein form, PrPsc, which can occur as a stochastic event or be favored by a 
somatic mutation. A failure in protein clearance mechanisms associated to cellular 
senescence might lead to an accumulation of pathological PrPsc species resulting 
in an irreversible cellular dysfunction. Thereby, PrPsc is proposed to act as an 
infectious agent that recruits endogenous PrPc to replicate itself in a self-
propagating manner, which leads to neuronal injury and death (Gabor G. Kovacs 
and Budka 2008; Colby and Prusiner 2011; Prusiner 1998). 
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The abnormally conformed PrPsc possess several distinct attributes that include 
the propensity to form from α-helical- into a ß-sheet-rich configuration, which is 
associated to the formation of amyloidogenic structures developing various 
degrees of protease-resistance, and tendency to polymerize and aggregate into 
insoluble deposits (Fig 1B, C, D). Moreover, PrPsc is featured by distinct 
conformational protein structure arrangements, which result in specific protease 
cleavage sites and subsequently distinct sizes of protease-resistant PrPsc core 
fragments (Fig 1D). It has been observed that oligomeric PrPsc species represent 
the main toxic and infective agent in prion disease models (Puoti et al. 2012; 




Figure 1: Prion disease hallmarks and PrPsc characteristic: A) Main neuropathological 
findings in prion disease brain are PrPsc deposition, synaptic and dendrite loss, 
spongiform degeneration, neuroinflammation and neuronal loss. B) Physiological PrPc 
structure with high α-helical content. C) Pathological PrPsc structure with high ß-sheet. D) 
Physiological PrPc (variable glycolysated) is sensitive towards proteinase K (PK) 
digestion, whereas distinct pathological PrPsc structure arrangements lead to specific 
protease cleavage sites and subsequently distinct sizes of PK-resistant PrPsc core 
fragments. 
Modified after Soto and Satani, 2011. Trends in Molecular Medicine. 
 
Prion diseases appear in three principal forms: 1) as sporadic forms manifesting 
as sCJD, 2) as inherited forms manifesting as genetic CJD (gCJD), fatal familial 
insomnia (FFI) and Gerstmann-Sträussler-Scheinker syndrome (GSS), and 3) as 
forms acquired by infection including iatrogenic CJD, kuru and variant CJD. 
Human prion diseases represent a wide-ranging clinical heterogeneity including 
rapidly progressive dementia, motor dysfunction, cerebral ataxia, myoclonus and 
insomnia (Geschwind 2015; Imran and Mahmood 2011; Sikorska and Liberski 
2012). 
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The high variability in the clinical presentations and neuropathological patterns are 
associated to disease-causing mutations and polymorphisms in the prion protein 
gene (PRNP), as well as, different conformational protein arrangements of the 
pathological PrPsc (Parchi et al. 2012; Hill et al. 2003; Gambetti et al. 2003). 
Several polymorphisms in the prion protein gene have been described, with 
particular importance of the methionine (M) /valine (V) polymorphism at the codon 
129 of PRNP, which appears to modify disease phenotype and influence 
neuropathological signatures (Jeong and Kim 2014). 
The majority of human prion disease occurs sporadic, whereas the cases of prion 
diseases that are inherited or acquired by infection are comparatively rare. The 
inherited forms account for around 15% of human prion diseases, which are 
associated to autosomal, dominant mutations of the PRNP gene. The most 
prevalent genetic prion disease are those associated to P102L mutation 
(manifesting as GSS), D178N mutation and methionine on the mutated allele at 
codon 129 of the PRNP gene (manifesting as fatal familial insomnia) and E200K, 
(manifesting as familial or genetic CJD (f/gCJD)). In those cases, somatic 
mutations in the PRNP gene favour the spontaneous formation of PrPsc 
(Mastrianni 2010; Takada et al. 2017; Wadsworth and Collinge 2011). 
The very rare cases of acquired human prion disease are caused by exposure to 
exogenous PrPsc through: the consumption of bovine spongiform encephalopathy 
(BSE) contaminated food, cannibalism (kuru), use of contaminated surgical 
instruments or intra-cerebral electroencephalogram (EEG) electrodes, dura mater 
and corneal grafts and hormone administration (Will 2003; Collinge et al. 2006). 
 
4.1.1    Sporadic human prion diseases: sCJD 
 
sCJD is the most prevalent sporadic prion disease, accounting for the majority 
(85%) of all human prion diseases. The disease presents as a rapidly progressive 
dementia and neurologic signs leading to death in a rapid, progressive course, 
usually, in less than 1 years of disease onset. In fact, the clinical manifestation of 
sCJD is highly variable and might present as purely cognitive deficits, including 
commonly rapid progressive dementia, behavioural and personality changes, 
cerebellar symptoms, vision changes or any combination of these symptoms 
(Johnson 2005; Kovács et al. 2005; Heinemann et al. 2007). 
The variable phenotypes in sCJD can be distinguished by the usage of the 
polymorphism at the codon 129 in the PRNP gene encoding either for M or V (MM, 
MV, and VV) in combination with the occurrence of two PrPsc types (type 1 or 2), 
which differ in their conformational protein structure arrangements resulting in 
different protease cleavage sites, and subsequently, different sizes of protease-
resistant PrPsc core fragment. The resulting six phenotypes are used to classify 
molecular disease subtypes (MM1, MM2, MV1, MV2, VV1, VV2), which 
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differentiate clearly in clinical and neuropathological features such early 
symptoms, disease duration and distribution of lesion in the brain including 
spongiform degeneration, neuroinflammation, neuronal loss and amyloid plaque 
depositions (Gambetti et al. 2003; Parchi et al. 2012; Hill et al. 2003; Puoti et al. 
2012).  
Several cerebrospinal fluid (CSF)–based proteins have been demonstrated to 
mirror neuropathological processes in the brain of sCJD. Among them, the 14-3-3 
protein, Tau, ratio phosphor-Tau/Tau, α-synuclein and the detection of PrPsc via 
real-time quaking-induced conversion (RT-QuIC) assay achieve the highest 
diagnostic accuracy in the differential diagnose of sCJD (Atarashi et al. 2011; 
Llorens et al. 2018; 2016; Sanchez-Juan et al. 2006; Collins et al. 2006). However, 
the clinical–pathological variations among the sCJD subtypes have a strong 
influence on the sensitivity of various diagnostic tests (Llorens et al. 2016; 
Castellani et al. 2004; Collins et al. 2006). 
The clinical overlap of sCJD with potentially treatable disorders manifesting as 
rapid progressive dementia, highlights the need for reliable tools for early 
differential diagnosis of sCJD (Rosenbloom and Atri 2011; Geschwind et al. 2008). 
Indeed, a definitive diagnosis of sCJD is currently only obtained by histopathologic 
diagnosis via brain biopsy or autopsy (Paterson et al. 2012). 
 
4.1.1.1    sCJD subtypes MM1 and VV2 
 
sCJD MM1 and VV2 are the most prevalent disease subtypes which occur in 
patients with a methionine or valine homozygosity at codon 129 of the PRNP gene 
and PrPsc type 1 or 2, respectively. Both subtypes are characterized by rapidly 
progressive neurological syndromes with marked brain damage and 
neurodegeneration especially with severe affection of the frontal cortex and 
cerebellum. However, the subtypes show distinct differences in their clinical 
course, early symptoms and neuropathological features with a more prominent 
cortical involvement in MM1 and a more cerebellar involvement in VV2 patients 
(Fig 2) (Parchi et al. 1999; Parchi et al. 2009; Llorens et al. 2013; Gambetti et al. 
2003). 
The most common sCJD subtype MM1 (70%), also termed as “classical” CJD 
type, presents predominately a rapid progressive decline occasionally 
accompanied by cortical visual symptoms, usually followed by ataxia, myoclonus 
and pyramidal signs at disease progression. The peak age of onset in sCJD MM1 
is 65 years with a range of 42-91 years. The MM1 subtype is featured by a short 
clinical duration of 4 months ranging between 1-18 months representing, in 
compare to the other subtypes, the shortest disease duration (Appleby et al. 2009; 
Snowden, Mann, and Neary 2002; Parchi et al. 1999; Gambetti et al. 2003). 
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The second most common form after MM1 is the sCJD subtype VV2 (20%), also 
termed ataxic type. sCJD VV2 presents as predominant early symptoms rapid 
progressive ataxia, whereas cognitive decline usually follows later during disease 
progression, followed by myoclonus and extrapyramidal signs (Parchi et al. 1999). 
In sCJD VV2 patients show a mean age of onset of about 60 years with a range of 
41-81 years and a mean survival of 6 months ranging between 3-18 months 
(Baiardi et al. 2017).  
 
4.1.1.1.1   Neuropathological features of the sCJD subtypes MM1 and VV2 
 
The principal neuropathological features in prion diseases are rapid and massive 
neuronal loss leading to spongiform degeneration, the presence of PrPsc 
deposition and intense microglial and astrocytic activation. However, the 
histopathological findings in sCJD including severity and distribution of neuronal 
loss, the morphology and distribution of spongiform changes, the presence or 
absence of amyloid plaques and microglial activation vary among molecular sCJD 
subtype and brain region (Gambetti et al. 2003; Parchi et al. 1999; Parchi et al. 
2009; Puoti et al. 2012; Franceschini et al. 2018). 
In the brain of sCJD MM1 patients, PrPsc is found as synaptic-like depositions in 
the cerebellar cortex, cerebellum and as perivascular PrPsc depositions in brain 
regions containing spongiform change (Fig 2). Whereas in sCJD VV2, PrPsc 
deposition occur as synaptic-like pattern along with occasional small plaques and 
perineuronal PrPsc deposits in the cerebral cortex (Fig 2). In contrast to MM1, the 
cerebellum of sCJD VV2 shows additionally to synaptic-like depositions, 
widespread plaque-like PrPsc depositions involving the molecular and granular 
layers, as well as in the white matter (Fig 2) (Kovács, Kalev, and Budka 2004; 
Budka 2003; Gambetti et al. 2003; Llorens et al. 2013). 
 




Figure 2: Regional and subtype dependent histopathological changes in the brain of 
sCJD: A) Immunohistochemical analyses of PrPsc revealed differential PrPsc depositions 
in frontal cortex and cerebellum in sCJD MM1 and sCJD VV2 cases. In sCJD MM1, PrPsc 
is found as synaptic-like depositions in the frontal cortex and molecular layer of the 
cerebellum. In sCJD VV2, PrPsc occurred additionally to synaptic-like depositions also as 
plaque-like depositions, severely in the cerebellum. B) Differential morphology and 
distribution of spongiform degeneration in sCJD MM1 and sCJD VV2 observed via 
haematoxylin and eosin staining. 
Modified after Llorens et al., 2013. Prion. 
 
sCJD MM1 exhibits a widespread, microvascular spongiform degeneration 
accompanied by extensive neuronal loss in the cerebral cortex (Fig 2, table 1). 
The basal ganglia, thalamus, hippocampus and cerebellum are involved less 
severely with preserved Purkinje and granule cell layers, whereas the brain stem 
and hippocampus appear relatively spared. The cerebral cortex in sCJD VV2 
appears relatively spared and microvacuolar spongiform change occurs in a 
laminar distribution that usually affects deep layers, particularly more severe in the 
frontal and temporal cortex. The spongiform degeneration is often more severe in 
the basal ganglia, thalamus and hippocampus. The cerebellum of sCJD VV2 is 
often affected severely with spongiform degeneration in the molecular and 
granular layer with marked loss of Purkinje cells (Fig 2,table 1) (Yang et al. 1999; 
Llorens et al. 2013; Gambetti et al. 2003). Specific neuronal populations appear to 
be vulnerable in prion disease and gamma-aminobutyric acid-ergic (GABAergic) 
neurons seem to be the main target of neuronal loss in sCJD and prion disease 
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models (Guentchev et al. 1997; Kovács, Kalev, and Budka 2004; Sikorska and 
Liberski 2012).  
 
 
Table 1: Overview of regional and subtype dependent neuropathology in sCJD: 
Parameters were scored as 0 = absent, 1 = mild, 2 = moderate, and 3 = severe.  
Modified after Llorens et al., 2013. Prion. 
 
The sCJD brain is characterized by subtype- and regional-specific 
neuroinflammation (Franc Llorens et al. 2014; Parchi et al. 1999) (Fig 3). In this 
context, the extent of microglia activation and its regional distribution have been 
shown to relate significantly to sCJD subtypes (Llorens et al. 2014; Franceschini et 
al. 2018; Puoti et al. 2005). sCJD MM1 and VV2 exhibit distinct regional profiles of 
activated microglia, which is resembled by microglial morphology changes and 
expression of activation markers, such as the ionized calcium binding adaptor 
molecule 1 (IBA1) (Fig 3A) (Llorens et al. 2014; Franceschini et al. 2018). In MM1 
brains, activated microglia is mainly dominating in the cerebral cortices, the 
thalamus and cerebellum, whereas in VV2 brains, activated microglia are found 
prominently in the subcortical areas (Franceschini et al. 2018). Similar, a 
widespread activation of astrocytes can be observed in the sCJD brain showing 
subtype-specific and region-specific changes, which is resembled by a reactive 
protoplasmic and fibrillary phenotype, as well as the expression of astrocytic 
activation markers, such as the Chitinase 3-like protein 1 (YKL-40) or the glial 
fibrillary acidic protein (GFAP) (Fig 3B) (Llorens et al. 2014; 2017; Parchi et al. 
1999). 
As activated inflammatory-mediating cell signaling pathways in sCJD have been 
the “janus kinase/signal transducer and activator of transcription” (JAK-STAT) and 
the “NF-κB kinase/nuclear factor kappa-light-chain-enhancer of activated B cells” 
(IKK-NF-κB) identified (Llorens et al. 2014). 




Figure 3: Subtype dependent molecular neuropathology of glial changes in sCJD: 
Gene expression analyses of glial activation marker in the frontal cortex and cerebellum of 
age-matched control brains, and sCJD subtype MM1 and VV2 was performed via qPCR-
analysis. The gene expression of A) IBA1 and B) GFAP resemble microglial activation and 
astrocytic gliosis in sCJD, respectively. 
Modified after Llorens et al., 2014. Front Aging Neuroscience 
 
Whether aggregates of PrPsc in the brain reflect neurotoxicity in prion disease is 
not clear. Observations on the relationship between PrPsc deposition and 
neuronal damage in sCJD revealed no strong associations between PrPsc load 
and spongiform degeneration (Llorens et al. 2013; Piccardo et al. 2007) with 
exception of the cerebellum in sCJD VV2 (Llorens et al. 2013; Faucheux et al. 
2009). Moreover, it has been suggested that the synaptic-like deposition of PrPsc 
is associated to neuronal loss and activation as well as proliferation of astrocytes 
and microglia, whereas large plaque-like PrPsc deposition might represent a 
neuroprotective mechanisms through the sequestering of neurotoxic PrP species 
(Faucheux et al. 2009). In this context, soluble PrP oligomers have been proposed 
as highly neurotoxic and infectious PrP species in prion disease (Simoneau et al. 
2007; Huang et al. 2013). 
The regional- and subtype-specific neuropathological patterns in sCJD have been 
linked with progressive cellular and molecular alterations with disease progression, 
which include neuronal dysfunction and death (Gabor G. Kovacs and Budka 
2010), changes in gene expression networks and RNA editing profiles (Erini 
Kanata et al. 2018), progressive neuroinflammatory and oxidative stress 
responses (Llorens et al. 2014;  2017; Tahir et al. 2016), cellular alterations in the 
Ca2+ homeostasis and activation of Calpain-Cathepsin axis with disease 
progression (Llorens, Thüne, Sikorska et al. 2017), changes in PrP metabolism 
(Llorens et al. 2013).  
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4.1.1.1.2    sCJD biomarkers   
 
The clinical diagnosis of sCJD is based on the symptomatic presentation, 
characteristic abnormalities on EEG and/or magnetic resonance imaging, and CSF 
testing for the presence of protein prion biomarkers (I. Zerr et al. 2009).   
CSF biomarkers have been demonstrated to reflect the neuropathological 
processes in the sCJD brain in a subtype specific manner, potentially enabling the 
identification of sCJD subtypes in differential diagnostic context (Llorens et al. 
2015; Lattanzio et al. 2017; Castellani et al. 2004; Gmitterová et al. 2016; Hamlin 
et al. 2012; Sanchez-Juan et al. 2006). In particular, brain-derived CSF proteins, 
which serve as biomarkers for neuronal damage, display sCJD subtype dependent 
differences (Zerr et al. 1998). In sCJD MM1 and VV2, 14-3-3 has been found to be 
elevated in the CSF, whereas 14-3-3 levels were higher in the CSF of VV2 
patients in compare MM1 cases (Llorens et al. 2015). Similarly, total (t)-Tau and 
phosphorylated (p)-Tau are found to be elevated in the CSF of sCJD, whereas 
homozygous patients (MM/VV) show higher CSF Tau levels than heterozygous 
cases (MV) (Fig 4) (Llorens et al. 2015; Abu-Rumeileh et al. 2018). Moreover, VV2 
shows higher CSF Tau and p-Tau levels than MM1 (Lattanzio et al. 2017). 
Equally, the concentration of CSF neurofilament light (NfL), a general marker for 
white matter damage, has been demonstrated to display higher levels in VV2 in 
compare to MM1 followed by heterozygous cases, which has been proposed to 
reflect subtype dependent degree of white matter damage (Fig 4) (Franc Llorens 




Figure 4: sCJD subtype dependent clinical progression and pathology is associated 
to heterogeneity in CSF biomarker levels. CSF NfL and total (t)-tau protein levels 
reflect rate of clinical progression, degree of neuropathological affection and subcortical 
involvement. 
Modified after Abu-Rumeileh et al., 2018. Alzheimer’s Research and Therapy. 
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4.1.2    Genetic human prion disease: Fatal familial Insomnia 
 
More than 20 disease-causing mutations in the PRNP gene have been described 
(Castilla, Hetz, and Soto 2004; Kovács et al. 2002). Along with the E200K 
mutation in the PRNP gene, which develops in a clinico-neuropathological manner 
as sCJD, the most prevalent genetic prion disease is FFI.  
FFI is caused by a single point mutation, D178N, in the PRNP gene accompanied 
by the presence of methionine at codon 129 on the mutated allele of the same 
gene (Goldfarb et al. 1992). Clinically, FFI manifest predominantly as progressive 
insomnia, autonomic and neuroendocrine dysfunction, usually followed by apathy, 
cognitive and motor problems with disease progression. The mean age at onset is 
51 years of age, and clinical duration is typically 8–72 months (Krasnianski et al. 
2008; Cortelli et al. 1999; Gallassi et al. 1996). 
Neuropathological alterations include predominantly marked astrocytic gliosis and 
neuronal loss of the mediodorsal and anterior thalamic nuclei, whereas temporal 
cortex, hippocampal CA1 region, cingulate cortex and other cortical areas are also 
affected often. Although severely damaged, the thalamus shows no PrPsc 
deposits or spongiosis. Moreover, limited microglia activation is evident in the FFI 
brain (Llorens, Thüne, et al. 2016; Llorens, Zarranz, Fischer, et al. 2017; Cracco, 
Appleby, and Gambetti 2018).  
A diagnosis of FFI requires the presence of a probable sCJD diagnosis in 
combination with the disease-specific gene mutation (Llorens, Zarranz, Fischer, et 
al. 2017). CSF biomarkers used for the clinical diagnostic of sCJD, provide less 
clinical value for FFI (Ladogana et al. 2009). Marker for neuronal damage, such as 
14-3-γ and α-synuclein, show less or no sensitivity, whereby CSF tau is significant 
higher in FFI, but lower when compared to sCJD (Frau-Méndez et al. 2017;  
Llorens, Schmitz, et al. 2016). 
Structural analysis of the mutated PrP D178N revealed that no major alterations 
affect the overall protein structure, however, slight alterations occur in the 
intermolecular contacts between PrP molecules that might be responsible for 
structural instability and increased aggregation propensity (S. Lee et al. 2010; 
Swietnicki et al. 1998). The reason for the spontaneous misfolding of PrP D178N 
and the mechanisms underlying the selective vulnerability of specific brain regions 
during FFI progression are unknown. The impairment of fundamental cellular 
processes including translational and mitochondrial dysfunction and increased 
oxidative stress has been implicated in the pathophysiology of FFI (Llorens, 
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4.2    Tauopathies  
 
Tauopathies are a heterogeneous group of incurable neurodegenerative 
conditions that are pathologically characterized by intracellular accumulation of 
abnormal tau in the brain. Clinically, tauopathies manifest highly diverse and can 
contain both cognitive/behavioral- and movement-disorders including, but  not 
limited to AD, primary age-related tauopathy (PART), progressive supranuclear 
palsy, corticobasal degeneration, Pick’s disease, some frontotemporal dementias, 
chronic traumatic encephalopathy and parkinsonism linked to chromosome 17 
(Irwin 2016; Orr, Sullivan, and Frost 2017; Gabor G. Kovacs 2017; Williams 2006; 
Ferrer et al. 2014). 
The most well described role of tau is that as a microtubule-associated protein 
involved in microtubule assembly and stabilization, particularly of neuronal axons 
(Holtzman et al. 2016). In disease states, pathological tau forms are featured by 
aberrant phosphorylation, truncation and aggregation into neurotoxic oligomers 
and insoluble filaments (Arendt, Stieler, and Holzer 2016; Mair et al. 2016; Y. 
Wang and Mandelkow 2016; Orr, Sullivan, and Frost 2017). The cellular 
mechanisms and drivers involved in pathogenic tau-induced neuronal dysfunction 
and death are still illusive. The development of therapeutic approaches faces 
significant challenges due to the inability to diagnose early and to discriminate 
clearly between distinct tauopathy entities. It is supposed that pathophysiological 
changes in tauopathies occur decades before earliest observed cognitive and 
behavioral impairments (Arendt, Stieler, and Holzer β016; Orr, Sullivan, and Frost 
β017). 
 
4.2.1    Alzheimer’s disease 
 
AD is a progressive, neurodegenerative disorder and the most common form of 
senile dementia affecting more than 20% of the population over 80 years of age 
(Prince et al. 2015). Clinically, AD manifests as gradual cognitive decline and 
impaired memory. The neuropathological hallmarks in AD are extracellular 
deposition of amyloid beta peptides (A ) within senile plaques and the intracellular 
generation of NFTs. These neuropathological changes are accompanied by a 
multifaceted disease pathology including accelerated synaptic and neuronal loss, 
vascular lesions (angiopathy), atrophy and neuroinflammation in specific AD 
associated brain region (De Strooper and Karran 2016). The majority of AD cases 
occurs sporadically in an age-dependent manner with disease onset of usually 
older than 65 years and mean disease duration of 8 years (Mucke 2009; 
Zetterberg and Mattsson 2014). However, due to a wide pathological and clinical 
heterogeneity, AD is featured by the occurrence of subphenotypes (Lam et al. 
2013). 
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Rapidly progressive AD (rpAD), a variant of the disease, is characterized by rapid 
decline in cognition and short disease duration of less than 2 years (Sona, Ellis, 
and Ames 2013; M. E. Soto et al. 2008; Schmidt et al. 2011; 2012). rpAD can 
mimic the clinical signs of other diseases with rapidly progressive neurological 
syndromes, such as sCJD. Furthermore, up to now, classical CSF biomarker used 
for AD diagnosis reflecting pathophysiological processes in the brain, associated 
to A  plaques and NTFs pathology, are not able to discriminate between AD and 
rpAD (Tapiola et al. 1997; 2009; Llorens, Schmitz, Knipper, et al. 2017). 
The mechanisms which contribute to AD heterogeneity in clinical and pathological 
signs are still illusive. Moreover, factors underlying the selective vulnerability of 
specific brain regions during disease progression are unclear. Elucidating the 
molecular drivers that initiate AD at its earliest stages is essential for the 
understanding of triggering factors leading to the development and progression of 
this multifactorial disease.  
The progressive build up and deposition of the A  peptide in the brain 
parenchyma, with plaques first appearing in cortical regions, is considered as a 
key event in the AD pathology (Hardy and Higgins 1992; Karran, Mercken, and 
Strooper 2011). According to the A  cascade hypothesis an imbalance between 
A  production and clearance is an early event in AD initiating a neurotoxic 
cascade that ultimately leads to the development of pathological hallmarks of AD, 
including neurodegeneration and NFT formation, as downstream effects (Selkoe 
and Hardy 2016). A  peptides are derived from the amyloid precursor protein 
(APP) which is a transmembrane protein that is predominantly located at the 
synapses and constitutively cleaved into peptides during cell metabolism. Through 
an amyloidogenic processing of APP aggregation prone A  peptides are 
generated via enzymatic cleavage ( -secretases and -secretases). The presence 
of excessive A  amounts promoting its aggregation into extracellular oligomers, 
fibrils, and eventually into senile and neuritic plaques. Especially soluble oligomers 
of A  have been suggested as early neurotoxic species triggering 
neurodegeneration in AD (Ferreira et al. 2015; Viola and Klein 2015). Less than 
5% of AD cases are associated with autosomal-dominant mutations in genes 
involved in the A  metabolism causing early-onset familial AD (fAD), which 
includes mutations occurring either in the APP, presenting the substrate of A , or 
in the protease presenilin (PSEN1 and PSEN2) that generates A  (L. Wu et al. 
2012). 
However, the causative role of A  aggregation and its importance in the 
pathogenesis of AD is not clear and still under debated (Reitz 2012; H. G. Lee et 
al. 2004; Zetterberg and Mattsson 2014). No strong associations between the 
amount of A  neuritic plaque pathology and the degree of atrophy as well as 
clinical dementia have been observed in AD (Josephs et al. 2008; Serrano-Pozo et 
al. 2011). Frequently, A  deposits are present in the brain of cognitively healthy 
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older people (Rodrigue et al. 2012). AD-associated neurodegeneration has been 
observed to occur independently of A  pathology (Fjell and Walhovd 2012). 
 
4.2.1.1 Neuropathological alterations in early AD 
 
One critical pathological event in early AD is the aggregation of the microtubule 
protein tau into neurofibrillary tangles (NFT) in neurons (Iqbal et al. 2005; Serrano-
Pozo et al. 2011). Tau is the main microtubule associated protein in mature 
neurons that regulates and stabiles microtubule assembly essential for the 
maintenance of neuronal structure, axonal transport, and neuronal plasticity. 
Various regulatory mechanisms, such as phosphatases and kinases, are 
responsible for the associating and dissociating of tau from microtubules (T. Guo, 
Noble, and Hanger 2017). In AD, the abnormal hyperphosphorylation of tau results 
in its dysfunction and mislocalization followed by tau polymerization and its 
aggregation into NFTs in the cell body of neurons, which is associated to neuronal 
dysfunction and death (Iqbal, Liu, and Gong 2016). In fact, it has been shown that 
the density of hyperphosphorylated tau correlates closely with the presence of 
neurodegeneration, brain atrophy and cognitive deficit in AD (Bejanin et al. 2017). 
The NFT pathology preferentially affects specific brain regions and spreads along 
distinct neural pathways in a hierarchical manner, whereas other brain regions 
remain relatively spared. Based on the stepwise progression of neuropathological 
alterations in the AD brain, the NFT pathology is categorized in six stages (Fig 5) 
(H. Braak and Braak 1991; Murayama and Saito 2004). During AD progression, 
NFT pathology first appears in parts of the brainstem, especially the LC, as well as 
entorhinal regions (stages I-II), followed by hippocampal input regions and 
projection zones including region CA1 and subiculum as well as the outer 
molecular layer of dentate gyrus and advancing to temporal regions (stages III-IV) 
and finally followed by large parts of the neocortex (stages V-VI) (H. Braak and 
Braak 1991; Goedert 2015) (Fig 5). The clinical status of AD has been linked to 
Braak stages: during preclinical and early clinical stages of AD, the brain 
pathology has been advanced to Braak stages II and III, while Braak stages V and 
VI are associated to a fully developed AD dementia. During AD, the development 
of tau pathology often occurs before A  accumulation or may also occur in the 
absence of A  pathology (Heiko Braak et al. 2011; H. Braak and Braak 1997; 
Heiko Braak and Del Tredici 2015). The development of A  accumulation is 
considerable different from NFT pathology spreading, with plaques initially 
appearing in cortical regions (Thal et al. 2002). 
 




Figure 5: Staging of NFT pathology in AD: Tau pathology initially develops in the locus 
coeruleus, as well as transentorhinal and entorhinal regions (stages I-II), followed by the 
hippocampal formation and partially also the neocortex (stages III-IV), and finally followed 
by large parts of the neocortex (stages V-VI). 
Modified after Goedert, 2015. Science. 
 
The LC is a brain stem nucleus which serves as a main source of noradrenergic 
innervation projecting widespread throughout the whole forebrain, including the 
EC, hippocampus, amygdala, and cerebral cortex, which are AD pathology 
associated regions (Šimić et al. β017; Nagai et al. 1981). Through its wide 
projections, the LC modulates a variety of functions such as sleep-waking cycles, 
cognition, learning and memory, neuroinflammation, and neuronal survival 
(Kayama and Koyama 2003; M. T. Heneka et al. 2010; Szabadi 2013; Counts and 
Mufson 2012; Sara 2009; Weinshenker 2008). 
The LC is one of the earliest regions affected by consistent and severe neuronal 
dysfunction and loss during early AD stages, which has been linked to 
noradrenalin depletion of the projection areas in the forebrain region (Adolfsson et 
al. 1979; Mravec, Lejavova, and Cubinkova 2014). During large-scale screens in 
non-selected brains, the formation of aberrant tau species within the LC has been 
observed in the absence of Tau-related pathology in the trans-entorhinal region, 
suggesting the LC as an initial site of tau pathology (Heiko Braak et al. 2011; 
Giorgi et al. 2017).  It has been demonstrated that the degeneration of LC neurons 
correlates with AD pathology including the presence of A  plaques and NFT 
pathology as well as cognitive impairment (Andrés-Benito et al. 2017; Giorgi et al. 
2017; Weinshenker 2008). Therefore, the LC degeneration is proposed to play a 
significant role in the AD pathogenesis influencing multiple facets of disease 
progression, including aberrant neuronal metabolism, synaptic dysfunction and 
progressive neuroinflammation. (M. T. Heneka et al. 2010; Weinshenker 2008).  
Strong evidences suggest that aberrant tau species accumulate in LC neurons for 
decades before LC degeneration occurs in AD which might present a potential 
window for early diagnostic and therapeutic intervention (Chalermpalanupap, 
Weinshenker, and Rorabaugh 2017). However, if the buildup of aberrant tau itself 
mediates neurotoxicity is not yet clear and the pathological mechanisms ultimately 
leading to LC dysfunction and degeneration are still elusive. Identifying intrinsic 
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factors and cell-specific, molecular properties of LC neurons during early AD 
pathogenesis are crucial for the understanding of early disease mechanisms. One 
of the main objectives to understand tau pathology associated to AD is to identify 
molecular drivers that could favor the aberrant tau phosphorylation.  
 
4.2.2    Primary age-related tauopathy 
 
PART is common pathologic entity almost universally observed in the brain of 
aged individuals. Neuropathologically, PART is featured by AD-type neurofibrillary 
changes corresponding to Braak stages I-IV, with minimal or without A  
depositions (Reas 2017; Crary et al. 2014). Symptoms in individuals with PART 
range from normal to mild cognitive changes, whereas profound impairment 
occurs rarely (Jefferson-George et al. 2017; Besser et al. 2017). 
Upon neuropathological assessment, brains with PART often appear 
indistinguishable from those with early AD pathology during the absence of A  
plaques (Reas 2017; Crary et al. 2014). Due to these common pathological 
features, PART has been suggested to be a subset or an early stage of AD (Heiko 
Braak and Del Tredici 2011). On the hand, there might be distinct clinical and 
pathological features that differ between PART and AD. In comparison to AD, 
PART shows often limited impact on cognition and progress without development 
of A  deposits (Santa-Maria et al. 2012), whereas neuropathological AD diagnosis 
requires the significant presence of A  depositions (Murayama and Saito 2004; 
Hyman et al. 2016). At present time, PART or/and early AD evolution cannot be 
reliable identified and differentiate premortem, and thus, clear systematic 
characterizations for the clinical-pathological spectrum of these pathological 
entities are needed. Improved biomarkers and imagine techniques might help to 
detect and to prognosticate early NFT-associated pathological changes (Reas 
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4.3   Neurodegeneration disease models: Mice model for studying 
prion diseases of human 
 
Reliable model systems are crucial to examine prion induced neurodegenerative 
mechanisms and to gain clues for relevant therapy and biomarker approaches 
(Watts and Prusiner 2014; Brandner and Jaunmuktane 2017; Delay and Hébert 
2011). By taking advantage of the infectious nature of prions, the intracerebral 
inoculation of mice with prions represents an essential prion bioassay to induce 
the formation and propagation of prions in the host (Brandner and Jaunmuktane 
2017; Watts and Prusiner 2014). Prion isolates, as infectious agent, are known to 
induce highly diverse clinical and pathological outcomes which are supposed to be 
determined and encoded in the biochemical and conformational features of the 
infectious particle PrPsc. This effect is also termed as prion strain phenomenon, 
whereby distinct “prion strains” are hypothesized to propagate their biochemical 
properties in the host by the induction of strain-specific conformational changes in 
the endogenous PrPc resulting in distinct disease phenotypes (Schoch et al. 2005; 
Morales 2017; Moira E. Bruce 2003; M. E. Bruce 1993). Biochemical characteristic 
of PrPsc used to identify distinct strains include protease resistance, glycosylation 
profile and electrophoretic mobility. In vivo, prion bioassays in mice enable the 
analysis of prion strain specific induction of distinct disease phenotypes including 
incubation time, clinical signs and types and patterns of brain lesions (Morales 
2017; Morales, Abid, and Soto 2007; Watts and Prusiner 2014). 
In the last decades the main animal model for prion biology is a mouse model 
infected with scrapie, a prion disease mostly affecting sheep and goats (Watts and 
Prusiner 2014; M. E. Bruce 1993). Classical scrapie strains often used in murine 
bioassays, such as RML, 22A, 139A, Me7, S15, are relevant tools to study 
differences among prion strains in vivo (Di Bari, Nonno, and Agrimi 2012). 
However, mice model for scrapie represent a suboptimal model for prion diseases 
affecting humans (Watts and Prusiner 2014).  
In order to use a disease model highly relevant to human prion pathology, the 
investigations in the present thesis are based on a humanized mice model 
inoculated with sCJD prions (Padilla et al. 2011; Llorens et al. 2014). By 
expressing human PrP on the background of murine Prnp0/0, this transgenic mice 
model is susceptible to prions relevant to humans, particularly those causing 
sCJD, and thereby enabling an efficient transmission and propagation of human 
PrPsc in the host without the interference by the presence of the endogenous 
murine PrP homolog (Watts and Prusiner 2014; Padilla et al. 2011; Telling 2011). 
Importantly, the transgenic human PRNP gene carries the polygenic genotype (M 
or V) at codon 129 which is associated to the susceptibly to distinct human prion 
diseases. The inoculation of humanized mice model with sCJD brain isolate leads 
to a faithful recapitulation of the distinct sCJD subtype specific neuropathological 
patterns and biochemical changes observed in human brain (Padilla et al. 2011; 
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Bishop, Will, and Manson 2010; Giles et al. 2010; Asante et al. 2002). In fact, 
through their reliable resembling of prion disease hallmarks in human brain, these 
mice models are superior to those of major NDs, such as AD (Watts and Prusiner 
2014; Brandner and Jaunmuktane 2017). To date, AD mouse models reflect a 
range of AD-related pathologies. However, none of those models resembles fully 
the complexity of the human disease (Elder, Gama Sosa, and De Gasperi 2010). 
Tau-based disease models associated to mutations in tau are not leading to the 
development of AD, but mimics features of human tauopathies. Transgenic mouse 
models carrying human tau with a P301L mutation, which is causing familial 
frontotemporal dementia, develop motor and behavior deficits and NFT pathology 
in an age-dependent manner (Lewis et al. 2000). On the other hand, amyloid-
based animal models combine genetic mutations associated to an impaired A  
metabolism leading to early-onset fAD and develop cerebral amyloid plaque 
depositions, neuronal loss and cognitive decline, but do not show tangle pathology 
seen in the human AD brain (Oakley et al. 2006). 
The CJD mouse model Tg340-PRNP(129MM), on which investigations are 
focused in the present thesis, is expressing 4-fold human PrP with a methionine 
homozygosity at the codon 129 in the PRNP gene on a Prnp0/0 mouse background 
(Padilla et al. 2011). Transgenic mice that overexpress PrP display an accelerated 
disease process with the development of clinical signs of prion disease upon a 
comparatively short and stable incubation time. Inoculated with human brain 
isolates of sCJD subtype MM1, the mice model resembles the human pathology in 
a brain regional and disease subtype specific manner. In particular, the mice 
model recapitulates the patterns of neuropathological affections observed in the 
brain of sCJD MM1 patients including neuronal loss and spongiform change, 
progressive neuroinflammation as well as accumulation of pathogenic PrPsc in the 
brain with disease progression (Padilla et al. 2011; Llorens, Thüne, Sikorska, et al. 
2017; 2014). Moreover, alterations in molecular mechanisms and cellular 
pathways have been described to be resembled in the sCJD MM1 mouse model 
involving changes in gene expression networks and RNA editing profiles (Erini 
Kanata et al. 2018), as well as calcium dyshomeostasis and activation of Calpain-
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4.4    Function and biogenesis of miRNAs in the brain 
 
miRNAs are a class of small regulatory RNA molecules, which constitute 
fundamental regulators of gene expression through the binding of mRNA targets, 
which is leading to translation repression and/or mRNA degradation dependent on 
sequence complementarity (Jonas and Izaurralde 2015b). Through their flexible, 
rapid and reversible functions, miRNAs enable a precise, temporal and spatial 
gene expression regulation, which is essential for correct function and integrity of 
the brain (Davis, Haas, and Pocock 2015). Moreover, the human brain contains on 
average the longest mRNAs in compare to other human tissues, suggesting a high 
density of regulatory motifs, including miRNA seed sequences, which underlie 
complex temporal and spatial translational programs of the neural cells (Miura et 
al. 2013; L. Wang and Yi 2014). 
miRNAs are ubiquitously and highly cell-type specifically expressed in the CNS 
and thereby involved in a broad range of biological processes including brain 
development, function as well as in the majority of cellular activities such as 
metabolism, proliferation, differentiation, cell fate, survival, synapse formation and 
plasticity (O’Carroll and Schaefer β01γa; Jovičić et al. β01γ). Mature miRNAs are 
localized in the cytoplasm and also in multiple subcellular compartments 
associated to various physiological functions such as local miRNA-mediated 
control of gene expression, miRNA storage or degradation (Fig 6) (Anthony K.L. 
Leung 2015). For instance, processing bodies and stress granules are dynamic 
cytoplasmic sites that contain distinct subsets of proteins and other regulatory 
factors involved in translational regulation including miRNAs. Thereby, processing 
bodies are linked to mRNA turnover and storage, whereas stress granules are 
described to inhibit translation initiation under various stress conditions 
(Chantarachot and Bailey-Serres 2017). Especially in neuronal cells, miRNAs 
have been proposed to be involved in local, autonomously regulated protein 
translation occurring in dendrites, axons and at active synapses (Ye et al. 2016; 
Schratt β009; O’Carroll and Schaefer β01γa; Hu and Li β017; Sambandan et al. 
2017). 
 




Figure 6: Schematic overview of subcellular location-specific miRNA functions. 
Subcellular miRNA localization affects miRNA function.  
Leung, 2015. Trends in Cell Biology. 
 
miRNAs have the ability to regulate several genes involved in one pathway or 
multiple cross-talking pathways through complex miRNA-mRNA interactions, in 
which each miRNA can regulate the translation of hundreds of distinct mRNA 
targets and each mRNA transcript can possess multiple miRNA targeting sites 
(Fig7) (Davis, Haas, and Pocock 2015; Jonas and Izaurralde 2015b). 
miRNA networks modulate gene expression by different mechanisms that are 
associated to specific biological outcomes of miRNA-mRNA interactions. One way 
of miRNA-mediated gene expression modulation is through ‘expression tuning’, by 
which miRNAs tune or reset the mean of the expression level of their target genes 
often in a rapid and flexible way associated to genetic switches (Tsang, Zhu, and 
van Oudenaarden 2007; Wu, Shen, and Tang 2009). For instance, specific 
miRNAs play a role in neuroinflammatory regulation, whereby pro-inflammatory 
(miR-155, miR-27b, miR-326) and anti-inflammatory (miR-124, miR-146a, miR-21, 
miR-223) miRNAs inhibit the translation of corresponding proteins and thereby 
frame neuroinflammatory responses in a coordinated and dynamic manner 
(Gaudet et al. 2017). Uncontrolled neuroinflammation is associated to pathological 
conditions especially during neurodegeneration (Michael T. Heneka et al. 2015; 
Dorothée 2018). 
Another way how miRNA networks mediate gene expression regulation is through 
‘gene expression buffering’, by which miRNAs reduce target gene variances by 
establishing thresholds, which helps to maintain a dynamic homeostasis and 
stabilization for the transcriptome against input noises (Tsang, Zhu, and van 
Oudenaarden 2007; C. I. Wu, Shen, and Tang 2009). For instance, the constant 
  Introduction 
32 
 
expression of specific miRNAs contributes to the maintenance of the cellular 
identity of various cell types. In this regard, specific neuronal-enriched miRNAs 
(miR-124, miR-9) have been demonstrated to maintain the neuronal phenotype by 
suppressing non-neuronal genes, which is necessary for neuronal function and 
survival (Jovičić et al. β01γ; Neo et al. β014; Yoo et al. β011). 
 
  
Figure 7: Model of miRNA-mediated gene regulatory networks: miRNAs modulate 
gene expression through complex miRNA-mRNA network interactions, leading to mRNA 
cleavage and/or translational inhibition, and thereby miRNA networks exert regulatory 
effects on protein expression and biological pathways.   
 
The miRNA biogenesis pathway consists of various processing steps that take 
place inside the nucleus and the cytoplasm involving multiple miRNA maturating 
proteins, which represents a plethora of regulatory options affecting miRNA 
processing efficiency and activity (Fig 8) (O’Carroll and Schaefer β01γa; M. Ha 
and Kim 2014). 
miRNA genes are encoded within various genomic contexts. In human, the 
majority of miRNAs are located in introns of coding or non-coding transcripts, 
whereas some miRNAs are encoded in exonic regions. Often, miRNA genes are 
found to be clustered and organized into a polycistronic transcription unit enabling 
a co-transcription of miRNAs located in the same cluster (Schanen and Li 2011a). 
Some miRNAs genes appear to be embedded in the introns of protein-coding 
genes and, thus, share the promotor of the host gene, often presenting complex, 
regulatory feedback loops between miRNAs and its host genes (Boivin, 
Deschamps-Francoeur, and Scott 2017). However, various regulatory 
mechanisms including multiple miRNA gene transcription start sites, alternative 
promoters or epigenetic mechanisms, such as DNA methylation and histone 
modifications contribute to miRNA expression regulation (O’Carroll and Schaefer 
2013a; M. Ha and Kim 2014). 
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Figure 8: miRNA biogenesis and gene expression control: miRNAs are usually 
transcribed by the RNA polymerase II as long, primary miRNA transcripts following a 
series of cleavage events. In the nucleus, primary miRNAs are processed by the nuclear 
microprocessor complex containing the ribonuclease Drosha. The processed precursor 
miRNAs are exported into cytoplasm by Exportin-5 and further cleaved by the 
ribonuclease Dicer into mature miRNAs, which interact with Argonaute proteins to form 
the miRNA-induced silencing complex. This complex mediates translational inhibition or 
mRNA cleavage according to miRNA-mRNA sequence complementarity. A plethora of 
regulatory mechanisms affect miRNAs processing efficiency and activity. 
Modified after  Barca-Mayo and Lu, 2012. Frontiers in Neuroscience. 
 
In the nucleus, the majority of miRNAs are transcribed by the RNA polymerase II 
as long, primary-(pri)miRNAs transcripts forming hairpin structures that undergo 
5’-capping, polyadenylation at the γ’-end as well as editing and splicing processing 
(Schanen and Li 2011b; Barca-Mayo and Richard Lu 2012). The pri-miRNA is next 
processed by the nuclear microprocessor complex composed of Drosha, an 
nuclear ribonuclease III (Rnase III) enzyme, and its cofactor DGCR8 (DiGeorge 
Critical Region 8) protein. By its double-stranded RNA binding domains, DGCR8 
mediates the site-specific binding of microprocessor complex, while Drosha 
cleaves the stem-loop pri-miRNA structure by its endonuclease activity releasing a 
small hairpin-shaped precursor-(pre)miRNA of ~70-100 nucleotides in length 
(Conrad et al. 2014). The nuclear processed pre-miRNA presents a defined γ’-
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overhang, allowing a specific recognition and export of the pre-miRNA into the 
cytoplasm by Exportin-5 (XPO5) via a guanosine triphosphate-depended 
mechanism (Jonas and Izaurralde β015a; O’Carroll and Schaefer β01γb).  
Alternatively, several classes of miRNAs have been identified to be generated 
using a microprocessor complex independent route through bypassing Drosha-
mediated processing (Y.-K. Kim, Kim, and Kim 2016). The sources for alternative 
precursor miRNAs can be short spliced-out RNA transcripts originated from introns 
of protein-coding genes (Curtis, Sibley, and Wood 2012), small nucleolar RNAs 
(Falaleeva and Stamm 2013), or transfer RNAs-derived RNA fragments 
(Shigematsu, Honda, and Kirino 2014; Keam and Hutvagner 2015).  
In the cytoplasm, pre-miRNAs are recognized and cleaved by an Rnase III-type 
endonuclease termed Dicer producing small, intermediate RNA duplexes with a 
very precise size of 21-24 nucleotides. Dicer is a large (~200 kDa) multi-domain 
enzyme interacting with various proteins and cofactors, which can influence the 
specificity of its action (Song and Rossi 2017). The Dicer-processed small RNA 
duplexes are later separated, whereby one of those strands is determined by 
various strand selection mechanisms and loaded onto an Argonaute (Ago1 to 4 
isofoms) protein. Ago proteins represent the core components of the miRNA 
silencing complex (RISC) that form associated with miRNAs the active functional 
unit of the miRNA-induced silencing complex (Meister 2013a; Jonas and 
Izaurralde 2015a).  
Ago proteins, as RISC effector components, mediate the mRNA degradation, 
destabilization or translational inhibition according to the base-pairing of the Ago-
incorporated miRNA with its complementary site in the γ’ untranslated regions 
(γ’UTR) of mRNA-target. Perfectly complementary mRNA targets are cleaved by 
catalytically active Ago proteins, whereas in human only Ago2 possess 
catalytically activity (Meister 2013a; Jonas and Izaurralde 2015a). However, in 
animals the majority of miRNA-mediated gene silencing takes place by partially 
complementary miRNA binding with the mRNA target, leading to translation 
repression and/or mRNA destabilization by Ago-mediated recruitment of additional 
protein partners (Ipsaro and Joshua-Tor 2015). One of those critical Ago-partners 
are GW182 proteins that function as flexible scaffolds to bridge the interaction 
between Ago and downstream gene silencing effector complexes, such as 
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4.4.1    The role of miRNAs in neurodegeneration 
 
In the past decade, increasing links have been established between NDs and 
dysregulated miRNA expression patterns. Experimental evidences suggest that 
miRNA dysregulation is implicated in the etiology of several ND, including AD, 
Parkinson’s disease (PD), amyotrophic lateral scleroses (ALS), Huntington’s 
disease and prion diseases (Abe and Bonini 2013b; Hébert and De Strooper 
2009b). Even though these diseases represent distinct entities, their pathogenesis 
shares the impairment of fundamental cellular pathways leading to disturbed 
protein homeostasis, an overload of protein clearance pathways, the aggregation 
of pathological altered proteins, and the dysfunction and/or loss of specific 
neuronal populations. With their ability to regulate complex networks of genes, 
dysregulated miRNA networks have the potential to be involved in virtually all 
pathophysiological mechanism in ND (Goodall et al. 2013; Delay, Mandemakers, 
and Hébert 2012; Abe and Bonini 2013a; Femminella, Ferrara, and Rengo 2015; 
Tan, Yu, and Tan 2015; Walter J. Lukiw et al. 2013) 
 
4.4.1.1    miRNAs in prion disease 
 
To date, evaluation of miRNA alterations in human prion diseases are restricted to 
targeted studies in the brain of sCJD (Montag et al. 2012; Lukiw et al. 2011) and 
GSS patients (Lukiw et al. 2011). By performing targeted miRNA screens, the 
upregulation of miR-146a-5p (n=5) and miR-342-2p (n=2) has been observed in 
the brain of prion disease patients (Montag et al. 2012; Lukiw et al. 2011). 
However, no data about the global miRNA expression patterns in the brain of 
human prion disease are available so far. Alterations of miRNA expression in prion 
disease have been investigated in animal and cell culture models. miRNA analysis 
in animal models  focus on murine models intracerebrally inoculated with various 
scrapie strains (Saba et al. 2008; Montag et al. 2012; Majer et al. 2012; Boese et 
al. 2016; Gao et al. 2016) and BSE-infected macaques (Montag et al. 2009). In 
cell culture models, the expression of miRNAs was analyzed in mouse cell lines 
infected with different prion strains (Gao et al. 2016; Bellingham, Coleman, and Hill 
2012; Bellingham and Hill 2017; Montag et al. 2012).These miRNA analyses 
revealed temporally distinct and dynamic miRNA alterations during preclinical and 
clinical prion disease stages. 
Significant altered miRNA profiles were observed in the brain of prion disease 
animal models after the onset of clinical symptoms including few common miRNA 
alterations reported in different disease models including the upregulation of miR-
146a-5p (Gao et al. 2016a; Lukiw et al. 2011; Saba et al. 2008), the upregulation 
miR-26a-5p (Montag et al. 2009), the upregulation of 342-3p (Saba et al. 2008), 
wich was also found to be upregulated in the brain sCJD patients (Montag et al. 
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2009). Majer et al. performed temporal miRNA expression analysis in 
microdissected hippocampal CA1 neurons of prion infected mice revealing 
dynamic miRNA alteration patterns of miR-124-3p, miR-16-5p, miR-26a-5p, miR-
29a-3p, miR-132-3p, miR-140-5p and miR-146a-5p suggesting a potential 
disease-related miRNA mediated effect during early prion disease response. 
Interestingly, all analysed miRNAs showed similar, temporally distinct expression 
patterns during disease progression. While the neuronal miRNAs appear to be 
upregulated during pre-clinical disease stages, their expression profiles returned to 
basal level during disease progression and were found to be downregulated in 
clinical disease stage. Whereas the expression of miR-146a-5p was found to be 
upregulated throughout disease progression, with highest levels during preclinical 
stages displaying distinct miR-146a-5p expression profiles during prion disease 
progression (Majer et al. 2012).  
Boese et al. revealed changes in the abundance of miRNAs in 
synaptoneurosomes from the brain of scrapie infected mice with a small number of 
miRNAs which were found to be changed during preclinical prion disease including 
increased levels of miR-124a-3p, miR-136-5p, miR-376a-3p, miR-345-3p, miR-
361-5p and miR-212-3p, while miR-141-3p, miR-183-5p and miR-200c-3p were 
reduced. The miRNA abundance in the synaptoneurosomes has been observed to 
change with disease progression and increases of miRNAs which have been 
associated to prion diseases in previous studies (Majer et al. 2012; Saba et al. 
2008; Montag et al. 2009; 2012) were detected during clinical disease stages 
including miR-146a-5p, miR-142-3p, miR-143-3p, miR-145a-5p, miR-451a, let-7b-




Figure 9: Molecular alterations during prion disease response in neurons: Majer et 
al. proposed the induction of a bi-phasic gene expression program upon prion infection 
(inoculation point) in neurons. During preclinical disease, genes involved in 
neuroprotective pathways are upregulated, while after an unknown switch, genes involved 
in cell death and apoptosis. Especially, a set of profiled miRNAs showed a dynamic and 
disease-stage specific expression patterns during prion disease progression. 
Modified after Majer et al., 2012. PLOS Pathogens. 
 
  Introduction 
37 
 
Whether the altered miRNAs are part of compensatory mechanisms in order to 
help restore homeostasis upon early prion propagation or if these miRNAs might 
be involved in early prion-meditated neuropathology for instance impaired dendrite 
and synapse formation deserves further investigation. However, Majer et al. 
evidenced a bi-phasic gene expression program in which neuroprotective 
mechanism are upregulated as an early prion disease response while these 
protective mechanisms are diminished during late disease stages (Fig 9) (Majer et 
al. 2012). 
It needs to be stressed that beside analyses in prion disease models, there are no 
preclinical insights into miRNA alterations in human prion disease available. 
Therefore, there is an urgent need for the analyses of potential disease-associated 
miRNA expression patterns in human prion disease and their validation in relevant 
model system reflecting in vivo disease processes, in order to gain crucial insights 
into preclinical molecular alterations. 
 
4.4.1.2    miRNAs in Alzheimer’s disease 
 
In the past years, a growing number of studies report dysregulated miRNA 
expression in the brain of AD patients suggesting miRNA dysregulation as a 
contributing factor in pathophysiological signaling in AD (Maoz, Garfinkel, and 
Soreq 2017; Putteeraj, Yahaya, and Teoh 2017). Transcriptome-wide studies 
uncovering global miRNA expression profiles in disease-context are from great 
importance for the understanding of the role of miRNA dysregulation in AD. 
Several groups performed high-throughput assays to identify miRNA signatures in 
the brain of AD patients revealing altered miRNA networks which are associated to 
brain regional and disease stage-dependent features of AD pathology (Lau et al. 
2013; Cogswell et al. 2008; Hébert and De Strooper 2009a; Müller et al. 2014; 
Delay, Mandemakers, and Hébert 2012). The most comprehensive study was 
performed so far from Lau et al. in which temporal miRNA expression analyses 
were conducted in three different AD brain areas including hippocampus by a 
combination of different methodology for RNA quantification in a cellular- and 
tissue-specific context. The study demonstrated regional and Braak stage specific 
deregulated miRNA expression patterns reflecting miRNA associated disease 
related processes (Lau et al. 2013). 
Experimental evidences have linked specific miRNA changes to multiply 
pathological aspects of AD including misregulated protein homeostasis and the 
occurrence of pathological forms of A  peptides and tau protein, aberrant lipid 
metabolism and neuroinflammation (Femminella, Ferrara, and Rengo 2015; Lukiw 
et al. 2013; Basavaraju and De Lencastre 2016).   
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4.4.1.2.1    miRNAs involved in the regulation of tau metabolism 
 
In regard to tau pathology, miRNA dysregulation in AD could be potentially 
involved in various impaired processes regulating tau metabolism, including tau 
expression, transcriptional- and posttranscriptional modifications and/or cellular 
localization. In particular, the abnormal tau hyperphosphorylation in AD could be 
associated to misregulated tau kinases, phosphatases and/or other aberrant tau 
protein modifications in which miRNA dysfunction might play a role (Ballatore, Lee, 
and Trojanowski 2007; Schonrock and Götz 2012).  
Indeed, several studies have identified disease-specific miRNA changes 
associated to tau pathology in AD. The miR-132-3p has been found 
downregulated in several brain areas in AD (Lau et al. 2013; Cogswell et al. 2008; 
Wong et al. 2013; Hebert et al. 2008; Salta et al. 2016) including the hippocampus 
in which the miRNA was constantly diminished already in early Braak stages (Lau 
et al. 2013). The chronic miR-132-3p downregulation in AD has been linked to the 
dysregulation of tau which is directly targeted by the miRNA as well as through 
miR-132-3p-regulated kinases which are involved in aberrant tau phosphorylation 
(Salta and De Strooper 2017) and impaired APP metabolism (Smith et al. 2011). 
Smith et al. demonstrated that a deletion of miR-132-3p in a transgenic AD mice 
model is leading to increased tau expression, phosphorylation, and aggregation 
accompanied with an enhanced tau and A  pathology (Smith et al. 2015). On the 
other hand, miR-132-3p overexpressing restored tau pathology and cognitive 
function in AD mice (Hernandez-Rapp et al. 2016). Further miRNA dysregulation 
suggested to be involved in tau hyperphosphorylation are altered levels of miR-15, 
miR-26a, miR-125b in AD brain since these miRNAs were identified to target tau 
kinases (Hébert et al. 2010; Cai, Zhao, and Zhao 2012; Banzhaf-Strathmann et al. 
2014). Another example for a tau pathology associated miRNA deregulation is 
miR-219 which has been found downregulated in AD brain. Santa-Maria et al. 
showed that miR-219 directly regulate tau as the reduction of this miRNA in a 
Drosophila model expressing human tau enhanced tau toxicity, whereas miR-219 
overexpression diminished neurotoxic effects (Santa-Maria et al. 2015). 
Alternative splicing of the primary tau mRNA transcripts results in tau isoforms and 
the occurrence of unbalanced ratios of tau isoforms have been causally linked to 
neurodegeneration (Liu and Gong 2008). Smith et al. 2011 identified several 
miRNAs including miR-132, miR-124 and miR-9 which are involved in the 
regulation of tau isoform levels by targeting regulatory and splicing factors 
suggesting that the dysregulation of those miRNAs could be a contributing factor 
in the presence of aberrant tau isoforms in AD (Smith et al. 2011). 
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4.4.1.2.2    miRNAs involved in the regulation of neuroinflammation 
 
Neuroinflammation is a central event in the AD pathophysiology (Michael T. 
Heneka et al. 2015) and miRNAs dysregulation has been proposed to be 
implicated in neuroinflammatory mechanism in AD (Gaudet et al. 2017). Some 
miRNA alterations have been suggested to play an immune-mediating role in AD 
including the upregulation of miR-7, miR-9, miR-34a, miR-125b, miR-146a and 
miR-155. In vitro studies revealed that these miRNAs can be induced by a wide 
variety of inflammation-linked stressors and environmental stimuli such us pro-
inflammatory cytokines and chemokines, or A  peptides (Zhao, Pogue, and Lukiw 
2015). Further, the expression of all miRNAs can be triggered by the inflammation-
inducing NF-kB signaling pathway (Devier, Lovera, and Lukiw 2015; Lukiw et al. 
2011; 2012) and the putative gene targets of these miRNAs seem to be involved in 
underlying AD pathomechanisms. In this regard, Zhao et al. demonstrated that 
miR-34a is upregulated in the hippocampal C1 region in AD brain which was 
linked to impaired microglia responses in AD. In vitro studies in murine microglia 
cell cultures revealed that miR-34a modulates the microglia receptor TREM2, a 
critical player in the phagocytic A  peptide clearance which was found to be 
downregulated in AD (Zhao et al. 2013; Bhattacharjee et al. 2016). 
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5.1    Statement on original contribution 
 
Publication I 
The study was conceived, directed and coordinated by Dr. Franc Llorens, Prof. 
Isidre Ferrer and Prof. Inga Zerr and, as working supervisor and principle 
instructors, they provided conceptual and technical guidance in all aspects of the 
project.  
With the guidance of my working supervisor Dr. Llorens, I acquainted myself with 
the project and became an integral part of the study. After a short initial training, I 
was able to learn all processes, techniques and methods and I took part in the 
continuously development and optimization of the project (table 2). I was able to 
develop the project significantly and to assess the results critically. I participated in 
writing, reviewing and editing of the original draft. 
 
Experimental work: Contributions: 
Fig. 1: small  RNAseq analysis and miRNA 
expression levels in the frontal cortex and 
cerebellum of sCJD 
The small RNAseq was perfomed by the 
collaborating partner Prof. Isidre Ferrer and Dr. Franc 
Llorens. 
RNAseq data analyses: Franc Llorens, Ana 
Vivancos, Orr Shomroni and Eulàlia Martí. 
Figures were done by Franc Llorens and me.  
 
(A) Relative quantitation of regulated miRNAs in the 
brain of sCJD compared to age and gender matched 
controls by small RNA-Seq 
 
(B) Venn diagram of subtype-dependent altered 
miRNA in the brain of sCJD by small RNA-Seq 
Fig. 2: Validation of small RNAseq signature Experimental design and setup was done by me 
upon consultation with Dr. Llorens 
my contribution: 
 brain sample collection, RNA isolation and tissue 
lysate preparation, selection of relevant miRNAs  
 carrying out experiments (qPCR, Ago-
Immunoprecipitation, Western Blot) 
 analyses (densitometric analyses of Western blot, 
delta CT analysis of qPCR + application of 
statistical tests 
 evaluation + technical validation of results  
 data interpretation  
 creating figures 
(A) Of selected miRNAs in the frontal cortex and 
cerebellum of controls, sCJD MM1 and VV2 brains  
 
(B) Detection of sCJD-related miRNAs in Argonaut-
protein (Ago) immunoprecipitates from the frontal 
cortex of controls and sCJD MM1 brain homogenates  
 
(C) Western blot analyses of Ago-2 in the frontal 
cortex and cerebellum 
Fig. 3: Alterations in the levels and distribution of 
the miRNA silencing machinery in sCJD. 
Experimental design and setup was done by Dr. 
Llorens and me 
my contribution: 
 carrying out experiments (brain tissue 
preparations, gel filtration chromatography, 
Western Blot) 
 analyses + application of statistical test 
 evaluation + technical validation of results  
 data interpretation 
 creating figures 
(A) Western-blot analysis for Ago-2 immunodetection 
(upper panel) and densitometry (lower panels) of the 
chromatography gel filtration fractions from the frontal 
cortex of control and sCJD MM1 cases.  
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(B) Representative fluorescence photomicrographs 
of Ago immunoreactivity in the frontal cortex of 
control and sCJD cases  
 
(D) Representative fluorescence photomicrographs 
of eIF3, Tia-1, p54/rck and dcp1a in the frontal cortex 
of control, sCJD cases.  
The protein analyses in sCJD were performed during 
a research stay in the Dept. of Neuropathology, 
IDIBELL, Barcelona, which provided expertise and 
human brain samples. 
my contribution: 
 successfully application of research grants 
(granted by Boehringer-Ingelheim-Fonds) 
 carrying out experiments during research (brain 
tissue sectioning, immunohistochemistry staining) 
 imaging + analyses 
 data interpretation 
 creating figures 
(C) RT-QuIC analysis of Ago-2 immunoprecipitates 
obtained from brain homogenates of control and 
sCJD cases.  
Experimental design, setup and figures were done by 
Dr. Llorens. 
 
(E) Western-blot analyses of eIF3, p54/rck and dcp1a 
in the frontal cortex of control and sCJD cases. 
Experimental design and setup was done by me 
upon consultation with Dr. Llorens 
my contribution:  
 carrying out experiments (Western Blot analyses) 
 densitometry analyses + application of statistical 
test 
 creating figures 
Fig. 4: Altered expression levels of miRNA 
biogenesis components in sCJD.  
Experimental design and setup was done by me and 
Dr. Llorens.  
my contribution: 
 carrying out experiments (brain sample collection, 
RNA isolation and tissue lysate preparation, 
Western Blot)  
 analyses (densitometry analyses of Western blot, 
delta CT analysis of qPCR) + application of 
statistical tests 
 technical validation of results 
 data interpretation  
 creating figures 
(A) Gene expression levels of Drosha, DGCR8 and 
Dicer in the frontal cortex and cerebellum of controls, 
sCJD cases by qPCR. 
  
(B) Protein levels of Drosha, DGCR8, Dicer in the 
frontal cortex and cerebellum of controls, sCJD 
cases.  
Fig. 5: Neural-type miRNA profiling. miRNA profiling data analysis + figures was done by 
Dr. Llorens.  (A) Heat map analysis of the neurons, microglia and 
astrocyte enriched miRNAs, whose levels were found 
to be changed in the brain of sCJD cases.  
(B) In situ hybridization of miRNAs: 124-3p, 26a-5p 
and 146a-5p  in  control and sCJD brain tissue. 
 
(C) Quantification of miRNA-124-3p intensity in 
neurons  of control and sCJD brain tissue.  
The miRNA in situ hybridization assays in human 
brains were performed during a second research stay 
in the Dept. of Neuropathology, IDIBELL, Barcelona, 
in which the in situ hybridization technic was 
implemented and optimized by me under the 
supervision of Prof. Ferrer.  
my contribution: 
 successfully application of research grants 
(granted by Felgenhauer Stiftung) 
 carrying out experiments (brain tissue sectioning, 
miRNA in situ hybridization) 
 imaging + analyses 
 creating figures 
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Fig. 6: Analysis of common altered miRNAs in 
sCJD, AD, DLB and FFI. 
Experimental design and setup was done by me and 
Dr. Llorens.  
The relevant miRNAs for the cross-disease analyses 
were selected by me and Dr. Llorens. The Venn 
diagram was designed by Dr. Llorens. 
my contribution: 
 carrying out experiments (brain sample collection, 
RNA isolation, qPCR)  
 analyses (delta CT) + application of statistical tests 
 creating figures 
 
 
(A) Venn diagrams of the comparison between 
altered miRNAs in AD and sCJD.  
(B) qPCR analysis for miRNA: 146a-5p, 195-5p, 342-
5p, 877-5p, 323a-5p, 5701 in the frontal cortex of 
controls, AD and rpAD  
(C) qPCR analysis for miRNA: 146a-5p, 195-5p, 342-
5p, 877-5p, 323a-5p, 5701 in the frontal cortex of 
controls and DLB  
(D) qPCR analysis for miRNA: 342-5p, 146a-5p, 195-
5p, 5701 in the frontal cortex and cerebellum of 
controls and FFI  
Fig. 7: Regional and temporal-dependent 
neuropathological characteristics and miRNA 
signatures in sCJD MM1 mouse model tg340-
PRNP129MM.  
The miRNA expression analyses were expanded on 
a sCJD mice model. A detailed and comprehensive 
characterization of the neuropathological hallmarks of 
the tg340 mouse model was designed and 
coordinated by Dr. Llorens and me.  
 
The tg340 mice model was developed and inoculated 
with human brain homogenates by Prof. Olivier 
Andréoletti, INRA, Toulouse, France. 
(A) tg340 mice inoculated with control or sCJD MM1 
brain homogenates. 
(B) PET-blot analysis for the detection of PrPSC in the 
cortex and cerebellum of sCJD MM1 inoculated 
tg340 mice. 
 
The PET-blot analyses of the mice brain section were 
done by Prof. Olivier Andréoletti, INRA, Toulouse. 
(C) Densitometric analysis of western blots 
developed for PSD-95 and synaptophysin in the 
cortex and cerebellum of tg340 mice samples at 
different disease stages. 
Western blot analyses were done by Dr. Llorens.  
my contribution: Densitometry analysis + figures 
were done by me. 
 
(D) Heat map analysis of key inflammatory mediators 
and cytokines measured by qPCR analysis in the 
cortex and cerebellum of control and tg340 mice at 
different disease stages. 
my contribution: 
The qPCR and double delta CT analyses + figure 
were done by me. 
(E) Hematoxylin-eosin staining in the cortex and 
cerebellum of control and sCJD MM1 infected tg340 
animals. 
The histochemistry analysis + figures of mice brain 
tissue were performed during my first research stay 
in the neuropathological laboratory of Prof. Ferrer, 
IDIBELL, Barcelona. 
(F) qPCR analysis of the miRNAs validated in human 
sCJD tissue in the cortex and cerebellum of control 
and tg340 mice at different disease stage  
my contribution: 
The qPCR and double delta CT analyses + figures 
were done by me. 
Fig. 8: miRNA profiling in the CSF of control and 
sCJD cases 
Experimental design and setup was done by me and 
Dr. Llorens.  
my contribution: 
 CSF sample collection, isolation of RNA from CSF, 
miRNA profiling in the CSF via qPCR analyses  
 creating figures + statistical analyses 
 
(A) RT-qPCR analysis of the housekeeping U6 and 
 
(B) miRNA-378a-3p, miRNA-26a-5p and miRNA-204-
5p in the CSF of control and sCJD cases 
Supplementary Fig 1: 
MA plots from small RNAseq in the frontal cortex and 
cerebellum of control, sCJD MM1 and VV2 cases 
miRNA data analyses and plots were done by Dr. 
Eulàlia Martí. 
Supplementary Fig 2: 
Distribution of the different types of isomiRs in control 
and sCJD 
miRNA data analyses and plots were done by Prof. 
Eulàlia Martí, Centre of Genomic Regulation, 
Barcelona. 
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Supplementary Fig 3: 
Expression of GW182 in sCJD brain tissue 
my contribution: qPCR, delta CT analyses + figures 
were done by me. 
Immunohistochemistry + phase contrast microscopy 
and imagine were done by Dr. Daniela Diaz-Lucena. 
Supplementary Fig 4: 
Analysis of gel filtration chromatography fractions 
from sCJD cases  
my contribution: Western Blot (A, D), RT-QuIC (B), 
Dot Blot (C) + figures. 
Supplementary Fig 5: 
Subcellular localization of Ago-2 in sCJD brain tissue 
Immunohistochemistry + phase contrast microscopy 
and imagine were done by Dr. Daniela Diaz-Lucena. 
Supplementary Fig 6: 
Expression of Exportin 5 in sCJD brain tissue 
my contribution: Analyses of Exportin 5 via qPCR 
and Western blot + figures were done by me. 
Supplementary Fig 7: 
Synaptic loss in the sCJD MM1 mouse model tg340-
PRNP129MM 
my contribution: western blot analyses were done 
by me 
Supplementary Fig 8: 
Temporal-dependent expression of validated 
miRNAs in the sCJD MM1 mouse model tg340-
PRNP129MM 
my contribution: qPCR analyses + figures were 
done by me 
Supplementary Fig 9: 
Selective cell death induction by sCJD miRNAs 
transfection in cell cultures 
Functional miRNA experiment was designed by me 
upon feedback from Dr. Llorens. 
my contribution: RNA isolation from human brain, 
gel purification of miRNA from total RNA, miRNA 
transfection of two different cell cultures, qPCR 
analyses + technical validation + figures 




















The study was conceived, directed and coordinated by Prof. Isidre Ferrer, Dr. 
Franc Llorens and Prof. Inga Zerr and, as working supervisor and principle 
instructors, they provided conceptual and technical guidance in all aspects of the 
project.  
I acquainted myself with the project and became an integral part of the study (table 
3). By analyzing the cellular environment of mRNAs during early AD brain 
pathology, I provided key experimental work through which the project developed 
significantly. The main body of experimental work in this study was done by me, 
whereas experiments were supplemented and enhanced by Dr. Belén Ansoleaga 
and Pol Andrés-Benito. The manuscript was written by Prof. Ferrer and Dr. 
Llorens, whereas I contributed partially in writing: 
 chapter: In Situ Hybridization (Material and Methods), page 209 
 chapter: Discussion, page 211-212, literature research + partially written by 
me 
 
Experimental work: Contributions: 
Fig. 1: miRNA expression analysis in early AD: The qPCR analyses of miRNAs and figures were 
done by Pol Andrés-Benito and Dr. Belén Ansoleaga 
und supervision of Dr. Franc Llorens. 
miRNAs: 27a-3p, 124-3p, 132-3p, and 143-3p 
expression levels in the locus coeruleus, entorhinal 
cortex, CA1 region, and dentate gyrus in middle-aged 
and stages I-II and III-IV of NFT pathology as 
revealed by RT-qPCR. 
Fig. 2: Validation of small RNAseq signature:  Experimental design and setup was done by me 
upon consultation with Prof. Ferrer and Dr. Llorens. 
 
my contribution: 
 carrying out experiments (brain sample collection 
and tissue sectioning, miRNA in situ hybridization) 
 imaging + analyses 
 creating figures 
(a, d, g) Localization of miRNA-27a-3p, miRNA-124-
3p, and miRNA-143-3p in the dentate gyrus in cases 
with NFT pathology at stage I-II revealed by in situ 
hybridization 
 
(b, e, h) Localization of miRNA-27a-3p, miRNA-124-
3p, andmiRNA-143-3p in CA1 region of the 
hippocampus in cases with NFT pathology at stage I-
II  revealed by in situ hybridization. 
 
(c, f, i) Localization of miRNA-27a-3p, miRNA-124-
3p, and miRNA-143-3p in entorhinal cortex in cases 
with NFT pathology at stage I-II revealed by in situ 
hybridization. 
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Abstract
Increasing evidence indicates that microRNAs (miRNAs) are contributing factors to neuro-
degeneration. Alterations in miRNA signatures have been reported in several neurodegen-
erative dementias, but data in prion diseases are restricted to ex vivo and animal models.
The present study identified significant miRNA expression pattern alterations in the frontal
cortex and cerebellum of sporadic Creutzfeldt-Jakob disease (sCJD) patients. These
changes display a highly regional and disease subtype-dependent regulation that correlates
with brain pathology. We demonstrate that selected miRNAs are enriched in sCJD isolated
Argonaute(Ago)-binding complexes in disease, indicating their incorporation into RNA-
induced silencing complexes, and further suggesting their contribution to disease-associ-
ated gene expression changes. Alterations in the miRNA-mRNA regulatory machinery and
perturbed levels of miRNA biogenesis key components in sCJD brain samples reported
here further implicate miRNAs in sCJD gene expression (de)regulation. We also show that a
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subset of sCJD-altered miRNAs are commonly changed in Alzheimer’s disease, dementia
with Lewy bodies and fatal familial insomnia, suggesting potential common mechanisms
underlying these neurodegenerative processes. Additionally, we report no correlation
between brain and cerebrospinal fluid (CSF) miRNA-profiles in sCJD, indicating that CSF-
miRNA profiles do not faithfully mirror miRNA alterations detected in brain tissue of human
prion diseases. Finally, utilizing a sCJDMM1mouse model, we analyzed the miRNA dereg-
ulation patterns observed in sCJD in a temporal manner. While fourteen sCJD-related miR-
NAs were validated at clinical stages, only two of those were changed at early symptomatic
phase, suggesting that the miRNAs altered in sCJD may contribute to later pathogenic pro-
cesses. Altogether, the present work identifies alterations in the miRNA network, biogenesis
and miRNA-mRNA silencing machinery in sCJD, whereby contributions to disease mecha-
nisms deserve further investigation.
Author summary
miRNAs are small non-coding RNAs that regulate gene expression through complemen-
tary binding to their mRNA targets. Specific miRNA signatures have been proposed for
several neurodegenerative diseases supporting the idea that miRNA deregulation is a com-
mon disease hallmark. Here we present the comprehensive miRNA signature in sporadic
Creutzfeldt-Jakob disease (sCJD). Our study unravels the complex network of regional
and disease-subtype miRNA alterations, and the presence of a disturbed miRNA biogene-
sis pathway and miRNA-mRNA silencing machinery. We also highlight the existence of
time-dependent miRNA profiles and identify commonly regulated miRNAs between sev-
eral dementias with cortical pathology sharing a partial clinical overlap and pathological
involvement with sCJD. The present data shed light on the potential role of miRNAs as a
contributing factor of pathogenic molecular traits associated with sCJD.
Introduction
Creutzfeldt-Jakob disease (CJD) is a human transmissible spongiform encephalopathy charac-
terized by behavior changes, progressive dementia, loss of coordination and myoclonus. At the
molecular level, CJD is associated with the conversion of the normal, cellular prion protein
(PrPC) to an abnormal conformation (PrPSc) and further accumulation of PrPSc in the brain
in the form of protein aggregates [1]. Despite the established role of PrPC in several neuronal
functions such as synaptic plasticity, neurotransmission and neuronal development, the
molecular mechanisms triggering the PrPC to PrPSc conversion and the cellular pathways
unchained by prion infection leading to neuronal damage and cell death remain elusive.
Sporadic CJD (sCJD) is the most common human prion disease, presenting a high degree
of heterogeneity. sCJD is classified into six subtypes, based on variations at codon 129 of the
prion protein gene (PRNPMet or Val) and on the size of protease resistant PrPSc (type 1 or 2).
Among these subtypes MM1 and VV2 are the most prevalent [2,3] and give rise to unique clin-
ical and neuropathological features, such as specific gliosis, neuroinflammation, spongiosis
and synaptic loss signatures [2,4–7]. A widespread regional and subtype-specific mRNA and
protein deregulation leading to the alteration of multiple biological functions and signaling
pathways is also associated with sCJD [5,8–10].
microRNAs in Creutzfeldt-Jakob disease
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Transcriptomic and proteomic patterns are regulated by several factors including miRNAs;
these have been recognized as key regulators of gene expression. miRNAs are small (21–25
nucleotides long), non-coding RNAs, that regulate gene expression through partial comple-
mentary binding to their mRNA targets in the RNA-induced silencing complex (RISC). This
miRNA-mRNA interaction usually leads to gene silencing through a variety of forms, includ-
ing mRNA cleavage, translational repression and de-adenylation [11,12].
Several miRNAs are selectively expressed in the central nervous system (CNS) and have
been reported to be involved in CNS development, function and pathogenesis [13,14]. In addi-
tion, specific miRNA signatures have been proposed for Alzheimer’s (AD), Parkinson’s (PD)
and Huntington’s (HD) disease, as well as for Fronto-temporal dementia (FTD) [15–20], sup-
porting the idea that miRNA deregulation is a common hallmark of neurodegenerative dis-
eases. While the study of miRNAs in relation to prion pathogenesis has gained experimental
momentum since several miRNAs were found to be altered in in vivo and ex vivomodels of
prion diseases [21–25], the miRNA signature in sCJD has not been reported so far.
A potential link between miRNAs and prion diseases has been suggested based on the co-
localization of PrPC within RISC components in endosomes and multivesicular bodies. Bind-
ing of PrPC to the type III RNase Dicer (Dicer) and Argonaute (Ago) proteins, which repre-
sent essential components of the RISC loading complex, has been proposed as a requirement
for effective repression of several miRNA targets [26]. Hence, miRNA deregulation could be
triggered by many aspects of sCJD pathology, including replacement of the physiological PrP
forms with pathological ones. Simultaneously, miRNA deregulation may have drastic conse-
quences in sCJD gene expression patterns and may act as a contributing factor in the cascade
of events leading to fast disease progression.
In order to increase our understanding of the miRNA contribution to sCJD pathogenesis,
we performed small RNA-Sequencing (small RNA-Seq) in the two most affected brain regions
in sCJD, frontal cortex (FC) and cerebellum (CB), in the two most prevalent sCJD subtypes
(MM1 and VV2), which are linked to region specific clinical and pathological outcomes [2,27].
We demonstrate a strong regional and subtype-specific alteration of miRNA expression in
sCJD and molecular alterations in miRNA biogenesis and silencing machinery; we further
show that a subset of sCJD enriched miRNAs are actively incorporated in the RISC complex.
Additionally, we detected the presence of commonly changed miRNAs in other neurodegener-
ative dementias such as AD, dementia with Lewy bodies (DLB) and fatal familial insomnia
(FFI). Further, sCJD-related miRNA alterations were studied in a temporal manner, utilizing a
sCJD mouse model; sCJD miRNA profiles were validated in the utilized animal model at clini-
cal disease stages, whereas most of those miRNAs were not found to be regulated at earlier dis-
ease points suggesting diverse and dynamic miRNA expression programs during disease
progression. Finally, we profiled selected miRNAs in the CSF of sCJD cases, which ruled out
the presence of a major correlation between miRNA levels in CSF and brain tissue.
Altogether, our results show a significant deregulation of miRNA expression, activity and
biogenesis in sCJD and they highlight the potential role of miRNAs in the pathology of prion
diseases and alternative neurodegenerative conditions.
Results
Altered miRNA signatures in the FC and CB of sCJDMM1 and VV2 cases
miRNA expression signatures were determined by small RNA sequencing in the frontal cortex
(FC) and in the cerebellum (CB) of sCJDMM1 and VV2 and in age and gender matched con-
trols. We selected these brain regions, because they are strongly affected in sCJD and display
differential neuropathological patterns between MM1 and VV2 subtypes [2, 27]. Obtained
microRNAs in Creutzfeldt-Jakob disease
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sequences were annotated based on the overlap with publicly available genome annotations,
including miRNAs, tRNAs, rRNAs, other small RNAs and genomic repeats. miRNAs repre-
sented an average of 27% of total counts (S1 Table). Total number of reads on the FC and CB
mapping onto miRNAs with at least 2 counts in a given sample are shown (S2 Table). Two
independent pipelines were used for the analysis of the differential miRNA expression, Seqbus-
ter [28] and OASIS [29]. Both pipelines showed a high level of agreement in the detection of
differentially expressed miRNAs (89%). Seqbuster analysis revealed the presence of 70 miR-
NAs with altered expression in the FC of sCJDMM1 and 27 in sCJD VV2 compared to con-
trols (Fig 1A, S3 Table). In the CB, 22 miRNAs were changed in sCJDMM1 and 69 in sCJD
VV2 compared to controls (Fig 1A, S3 Table). The majority of the differentially altered miR-
NAs were expressed in both tissues, suggesting that the changes on their levels are tissue spe-
cific (S2 and S3 Tables).
The miRNA signature in sCJD was highly dependent on the brain region and sCJD subtype
(Fig 1B and S3 Table). Regarding sCJD subtype alterations, a high percentage of miRNAs were
commonly regulated between both subtypes in the FC (31%) (Fig 1B). In the CB, the percent-
age of commonly altered miRNAs between subtypes was lower (10%) (Fig 1B).
miRNA variability is ubiquitous in the brain of control and sCJD cases
Isoforms of a mature miRNA have been referred as isomiRs [30]. They are functionally active
and highly abundant in brain tissue, both in control and in neurodegenerative diseases
[15,31,32]. In the present study, 2883 and 4075 different isomiRs were found in the CB and
FC, respectively (S4 Table). Furthermore, most of the sequences mapping onto miRNA data-
base (reference miRNAs and IsomiRs) showed 3–50 counts. No major differences were
detected between control and sCJD subtype cases regarding their isomiRs profiles (S2 Fig),
suggesting that isomiR processing is not significantly altered in sCJD.
sCJD-related miRNA validation and enrichment in RISC complexes
A subset of miRNAs found to display altered expression in sCJD based on small RNA-Seq
analysis was further validated by qPCR analysis. miRNAs were selected according to number
of counts and fold change alterations in the RNA-seq analysis and/or their previous association
with prion disease pathogenesis and/or other neurodegenerative diseases [21,23,33,34]. A total
of 18 miRNAs were analyzed in both regions. The alterations in the levels of 15 and 10 miR-
NAs were validated in a regional specific manner in the FC and CB, respectively (Fig 2A). In
sCJD FC, miRNAs 29b-3p, 342-3p, 146a-5p, 154-5p, 195-5p, 26a-5p, 16-5p, 449a, 142-3p,
let7i-5p and 135a-5p were increased, while miRNAs 124-3p, 331-3p, 877-5p and 125a-5p were
decreased compared to controls, in agreement with RNA-seq data. miRNAs 378a-3p and
5701, which expression was only altered in CB did not present changes in the FC. In CB, miR-
NAs 146a-5p, 154-5p, 26a-5p, 378a-3p, 449a, 142-3p, let7i-3p and 5701 were increased, and
miRNAs 124-3p and 877-5p were decreased in sCJD, in agreement with RNA-seq data. The
rest of miRNAs, which expression was only altered in FC did not present changes in the CB.
Finally, miRNA-204-5p, a miRNA presenting no alterations in the FC and CB of sCJD by
RNA-seq analysis, was used as negative control showing no changes among groups at qPCR
level. Therefore, while most of the qPCR validated miRNAs were altered in both disease sub-
types, a subset of them presented subtype-specific changes, which were in agreement with
small RNA-Seq data (S3 Table).
To confirm that upregulated miRNAs in sCJD brain tissue were functionally active, we
performed RISC immunoprecipitations in the FC of control and sCJDMM1 cases using two
different Argonaute (Ago) antibodies detecting Ago-2 (11A9) and Ago1-4 family members
microRNAs in Creutzfeldt-Jakob disease
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Fig 1. Small RNA-Seq analysis and miRNA expression levels in the FC and CB of sCJD. (A) Relative quantitation of
regulated miRNAs in the FC and CB of sCJDMM1 and VV2 subtypes compared to age and gender matched controls
microRNAs in Creutzfeldt-Jakob disease
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(H-300). These antibodies were able to immunoprecipitate Ago-containing miRNA complexes
from brain tissue (Fig 2B). RNA extraction from immunoprecipitates and further qPCR
by small RNA-Seq. For FC 13 controls, 11 sCJDMM1 and 13 sCJD VV2 were analyzed. For CB: 12 controls, 12 sCJD
MM1 and 9 sCJD VV2 were analyzed. Differential expression in miRNA sequencing data was evaluated with the
DESeq2 tool and significantly differently expressed miRNAs were detected according to an adjusted p value of<0.05.
Data represent log2 fold change for each comparison. log2 fold change was>0.5 for upregulated miRNAs and<-0.5
for downregulated miRNAs. MA plots are also supplied for data visualization (S1 Fig). (B) Venn diagram of subtype-
dependent altered miRNA in the FC and CB of sCJD by small RNA-Seq. Percentage of maximal coincidence
(percentage of maximal number of miRNAs that can be coincident between groups) is indicated.
https://doi.org/10.1371/journal.ppat.1006802.g001
Fig 2. Regional and subtype-dependent miRNA expression confirmation and representative miRNA incorporation into functional complexes. (A)
Validation of the small RNA-Seq signature in selected miRNAs by RT-qPCR analysis in the FC (upper panel) and CB (lower panel) of controls, sCJDMM1
and VV2. Results were normalized to the housekeeping genes U6 snRNA (figure) and RNU5 expression, which showed similar results in the expression
analysis of deregulated miRNAs between control and sCJD cases. Housekeeping gene levels remained unaltered between groups. Normalization was
performed relative to controls. Error bars indicate SD. (B) Detection of sCJD-related miRNAs by RT-qPCR in Ago immunoprecipitates from the FC of
controls (n = 3) and sCJDMM1 brain homogenates (n = 3). The two Ago antibodies used (11A9 and H-300) were able to immunoprecipitate Ago-2 from
brain tissue (left panel) and reported similar results in the specific enrichment of sCJD-related miRNAs (146a-5p, 26a-5p, 195-5p, 154-5p, 204-5p and 5701)
in the FC of sCJDMM1 cases (right panels). miRNA-204-5p was selected as negative control, since no changes were detected between control and sCJD
cases with small RNA-Seq and RT-qPCR analysis. Non-specific immunoglobulins (NS) were used as control antibody for the immunoprecipitation. Error
bars indicate SD. (C) Upper panel: western blot analysis of Ago-2 (11A9 antibody) in the FC and CB control, sCJDMM1 and VV2 cases. Four
representative cases per diagnostic group and brain region are shown in the western blot. Quantifications derived from densitometry analysis were
performed in 15 cases per diagnostic group (n = 15/group). -actin was used as loading control. Densitometries of the western blots are shown.
Normalization was performed relative to controls. Error bars indicate SD. Bottom panel: Gene expression levels of Ago-2 in the FC and CB of controls,
sCJDMM1 and VV2 cases by RT-qPCR. Results were normalized to housekeeping genes GAPDH (figure) and GUSB with similar results. Housekeeping
levels remained unaltered between groups. 10 cases per diagnostic group (n = 10/group) were analyzed. In all cases, statistical significance (compared to
controls) was set at p<0.05.
https://doi.org/10.1371/journal.ppat.1006802.g002
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analysis allowed us to detect miRNA enrichment for a subset of miRNAs with increased
expression in sCJD MM1 brain tissue according to qPCR analysis (miRNA-146a-5p, miRNA-
26a-5p, miRNA-195-5p and miRNA-154-5p). As negative controls, miRNA-204-5p and
miRNA-5701 were tested. According to RNA-seq and qPCR data, miRNA-204-5p was regu-
lated neither in the FC nor in the CB of sCJD, while miRNA-5701 was upregulated only in the
CB of sCJD cases. In agreement with this, miRNA-204-5p and miRNA-5701 levels were
unchanged in RISC immunoprecipitates between control and sCJD cases (Fig 2B). To rule out
the possibility that the differences in RISC-miRNA enrichment were due to alterations in Ago-
2 expression between controls and sCJD, Ago-2 levels were analyzed by qPCR and western
blot. No alterations were found in Ago-2 protein and mRNA levels between controls and sCJD
cases, either in the FC or in the CB (Fig 2C). Similarly, no changes on the expression levels of
GW182, an Ago binding protein essential for miRNA-mediated gene silencing [35] were
detected between control and sCJD cases (S3A and S3B Fig).
Alterations in miRNA-mRNA silencing complexes in sCJD
Next, we investigated potential alterations in the miRNA-mRNA silencing complexes that
could explain the alterations in sCJD miRNA signatures previously detected. As a first step, we
performed gel filtration chromatographic assays of control and sCJD brain homogenates. Ten
fractions containing different proteomic patterns according to their molecular weight were
obtained. PrP levels were homogeneously distributed along the chromatographic fractions as
described before [36,37] (S4A and S4B Fig). Western blot analysis revealed the presence of
Ago-2 in higher molecular weight fractions in sCJD compared to control samples, suggesting
that Ago-2 in sCJD is interacting with a different subset of partners (Fig 3A). This is in agree-
ment with a different subcellular localization of Ago in sCJD brain tissue as revealed by immu-
nohistochemistry analysis. Indeed, using two different antibodies, we detected an increased
nuclear localization of Ago in the FC of sCJDMM1 and VV2 cases, in contrast to controls,
where staining was mainly detected in the cytoplasmic compartment (Fig 3B and S5A and S5B
Fig). While Ago-2 expression was mainly detected in neurons, both in controls and sCJD
cases, double immunofluorescence analysis revealed the presence of Ago-2 positive microglial
cells (S5 Fig). In contrast, no differences on subcellular localization were detected for GW182
between control and sCJD cases (S3 Fig).
PrP and Ago-2 are interacting proteins in physiological conditions [26], but nothing is
known about the potential role of PrPSc in the RISC complex. Since the endosomal compart-
ment, in which RISC assembly and turnover occurs, has been proposed as a site of prion con-
version [38] we aimed to investigate the presence of PrPSc in Ago-2 complexes, which could
be one of the contributors to their altered chromatographic Ago-2 patterns in sCJD. To this
end, Ago-2 immunoprecipitates from the FC of controls and sCJD MM1 were subjected to
RT-QuIC analysis. Positive signal was detected in immunoprecipitates from sCJD samples,
but not from controls (Fig 3C), indicating the presence of pathogenic PrP in Ago-2 complexes,
in agreement with the presence of RT-QuIC signal and protein oligomers in Ago-2 containing
chromatographic fractions (S4C and S4D Fig).
The alteration of RISC components in sCJD and the well-known presence of reticulum
stress in models of prion disease [39–41] raised the possibility that stress granules (SG), which
are normally transient structures, form stable complexes in sCJD. Immunohistochemical and
immunoblot analysis of the SG markers eukaryotic initiation factor 3 (eIF3) and T-cell-
restricted intracellular antigen-1 (Tia-1) revealed that, in sCJD, neither their subcellular locali-
zation nor their expression levels were altered (Fig 3D and 3E). In agreement with this, we did
not detect hyper-phosphorylation of the SG activator eIF2 in sCJD (Fig 3D). Similarly, levels
microRNAs in Creutzfeldt-Jakob disease
PLOS Pathogens | https://doi.org/10.1371/journal.ppat.1006802 January 22, 2018 7 / 33
Fig 3. Alterations in the levels and distribution of the miRNA silencing machinery in sCJD. (A) Western blot analysis for Ago-2
immunodetection (upper panel) and densitometry (lower panel) of the chromatography gel filtration fractions from the FC of control (n = 3)
and sCJDMM1 (n = 3) cases. Western blot analysis shows a representative image of a control and a sCJD case, while densitometry shows
microRNAs in Creutzfeldt-Jakob disease
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of the SG and p-bodies marker DEAD-Box Helicase 6 (p54/rck) showed no alterations
between controls and sCJD. However, increased expression levels of the specific p-bodies
marker decapping mRNA 1a (dcp1a) was detected in sCJDMM1 and VV2 (Fig 3E). Alto-
gether, our findings suggest the presence of alterations in the p-bodies-dependent mRNA
decay mechanisms without the activation of stress granule responses.
Altered miRNA biogenesis machinery in sCJD
Disruption of the miRNA biogenesis pathway components might cause alteration of miRNA
homeostasis and neurodegeneration [42,43]. miRNA alterations in sCJD prompted us to con-
sider possible alterations in the miRNA biogenesis pathway. The expression levels of three key
components of miRNA biogenesis, the ribonucleases Dicer and Drosha and the microproces-
sor complex DGCR8, a cofactor of Drosha, were studied in sCJD brain samples. mRNA
expression analysis revealed decreased DGCR8 levels in the CB of sCJD cases (Fig 4A). At the
protein level, Drosha levels were significantly lower in the FC of sCJD MM1 and in the CB of
sCJD VV2, resembling the regional and subtype pathological involvement of the disease.
Decreased Dicer levels were detected in the FC of sCJDMM1, while reduced levels of DGCR8
were found in the CB of sCJD VV2 (Fig 4B). The absence of direct regional and/or subtype-
specific alterations among the main components of the miRNA biogenesis pathway suggests
the presence of a complex impairment of the miRNA biogenesis machinery in sCJD. Addition-
ally, we investigated the expression levels of Exportin 5, a RanGTP-dependent dsRNA-binding
protein mediating pre-miRNAs nuclear export [44,45], which expression is deregulated in AD,
but not in PD or Down’s syndrome dementia [46]. Exportin 5 levels in sCJD were altered nei-
ther at mRNA nor at protein levels compared to controls (S6 Fig).
Neural-type miRNA expression profiling in sCJD
A prominent hallmark in sCJD pathogenesis is the concomitant increase of neuronal loss and
gliosis [2,47]. Since cell-type specific miRNA signatures have been described in neural popula-
tions [34,48,49], we aimed to investigate the neural-type miRNA expression profiling in sCJD.
First, sCJD-regulated miRNAs were compared to those reported to be enriched in neurons,
microglia and astrocytes [34]. The expression of neuron-enriched miRNAs was not signifi-
cantly altered in sCJD (Fig 5A), indicating that the sCJD-related miRNA signature is not a
mere consequence of neuronal death. On the other hand, most microglia and astrocyte-
enriched miRNAs presented deregulated levels in sCJD, most likely as a result of glial prolifera-
tion and activation. To gain insight into subcellular and neural-type localization of sCJD-asso-
ciated miRNAs in human brain tissue, in situ hybridizations were performed for the following
miRNAs: miRNA-124-3p, miRNA-26-5p and miRNA-146a-5p (Fig 5B and 5C). The three
miRNAs were localized in the cytoplasm of neurons. Additionally, miRNA-146a-5p labeling
was also detected in capillary walls and in some small cells compatible with glial morphology.
mean values and SD of all cases studied. (B) Representative fluorescence photomicrographs of Ago immunoreactivity in the FC of control
and sCJDMM1 cases. The two antibodies used (11A9 and H-300) showed similar Ago distribution between control and sCJDMM1 cases.
Scale bar = 25μm (C) RT-QuIC analysis of Ago-2 immunoprecipitates (11A9) obtained from the FC of brain homogenates of control (n = 3)
and sCJDMM1 (n = 3) cases. RT-QuIC assays were run in triplicate for each sample. A representative curve for each condition is shown. (D)
Representative fluorescence photomicrographs of eIF3, Tia-1 and p-eIF2 (Ser51) immunoreactivity in the FC of control and sCJDMM1
cases. Scale bar for eIF3 = 10 μm and Tia-1 = 20μm, for p-eIF2 (Ser51) = 10μm (E)Western blot analysis of eIF3, Tia-1, p54/rck and dcp1a in
the FC of control, sCJDMM1 and VV2 cases. Three representative cases per diagnostic group and brain region are shown in the western
blot. Quantifications derived from densitometry analysis were performed in 15 cases per diagnostic group (n = 15/group). GAPDHwas used
as a loading control. Densitometries of the western blots are shown. Normalization was performed relative to controls. Error bars indicate
SD. In all cases, statistical significance (compared to controls) was set at p<0.05.
https://doi.org/10.1371/journal.ppat.1006802.g003
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Fig 4. Altered expression levels of miRNA biogenesis components in sCJD. (A) Gene expression levels of Drosha (n = 10),
DGCR8 (n = 10) and Dicer (n = 10) in the FC and CB of controls, sCJDMM1 and VV2 cases by RT-qPCR. Results were
normalized to housekeeping genes GAPDH (figure) and GUSB with similar results. Housekeeping levels remained unaltered
between groups. (B) Protein levels of Drosha, DGCR8, Dicer in the FC and CB of controls, sCJDMM1 and VV2 cases, by
western blot analysis. Three representative cases per diagnostic group and brain region are shown in the western blot.
Quantifications derived from densitometry analysis were performed in 15 cases per diagnostic group (n = 15/group). -actin
was used as a loading control. Densitometries of the western blots are shown. Normalization was performed relative to controls.
Error bars indicate SD. In all cases, statistical significance (compared to controls) was set at p<0.05.
https://doi.org/10.1371/journal.ppat.1006802.g004
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Fig 5. Neural-type miRNA profiling in sCJD. (A) Heat map analysis of the neuron, microglia and astrocyte enriched miRNAs, whose levels
were changed in the FC and CB of sCJDMM1 and VV2 cases by RNA-seq analysis. Neural-type enriched miRNAs were reported in the
bibliography based on neural-type enrichment analysis (49). (B) In situ hybridization of miRNA-124-3p in the FC and CB of control and
sCJDMM1 brain tissue, and of miRNAs 26a-5p and 146a-5p in the FC of sCJDMM1 brain tissue. (C) Quantification of miRNA-124-3p
intensity in the FC and CB of control and sCJDMM1 neurons.>100 neurons in total were quantified for each group. Normalization was
performed relative to controls. AU/neuron indicates arbitrary units quantified in the densitometry analysis for each neuron. Error bars
indicate SD. Scale bar in FC = 30μm and in CB = 50μm. In all cases, statistical significance (compared to controls) was set at p<0.05.
https://doi.org/10.1371/journal.ppat.1006802.g005
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Decreased miRNA-124-3p staining detectable in sCJD was associated with a reduced number
of neurons. However, we also detected less signal intensity in surviving sCJD neurons, both in
the FC and in the CB (Purkinje and granular cells) regions (Fig 5B and 5C), in agreement with
the idea that lower expression of neuronal-related miRNAs in sCJD is not exclusively associ-
ated with neuronal loss.
Cross-validation of sCJD-miRNA signature in alternative
neurodegenerative diseases
Several neurodegenerative disorders share pathological hallmarks such as accumulation of
protein aggregates and self-propagation, and common pathways seem to contribute to the
neurodegenerative mechanisms in different diseases [50–52]. Thus, we speculated that an
overlap between miRNA sCJD profiling and other dementia-related conditions could exist. In
order to select the most appropriate miRNAs we compared the miRNA signatures in the FC of
sCJD obtained from the small RNA-seq analysis from this study with the one reported in the
pre-frontal cortex (PFC) of AD cases by Lau et al. [20]. Eight (22.8% max. coincidence) and
seven miRNAs (14% max. coincidence) were commonly increased and decreased respectively
in both datasets (Fig 6A). Among these, miRNA-195-5p, 877-5p and 323a-5p were previously
validated in sCJD from our small RNA-Seq dataset and miRNA-195-5p and 877-5p were vali-
dated by qPCR (Fig 2A).
To perform a cross-validation study with the corresponding sCJD brain regions and meth-
odologies we extracted RNA from the FC of AD and DLB cases and age-matched controls. Six
miRNAs were selected: i) miRNA-195-5p, 877-5p and 323a-5p, commonly regulated in the FC
of sCJD and in the PFC of AD, ii) miRNA-146a-5p and miRNA-342-3p, reported to be altered
in AD and prion disease models [22,23,53,54] and iii) miRNA-5701. The latter was used as a
negative control due to its exclusive enrichment in the CB of sCJD. In AD samples, we
detected coincident gene expression regulations with sCJD for miRNA-195-5p (increased) and
for miRNA-877-5p and 323a-5p (decreased) (Fig 6B). Rapid progressive forms of AD (rpAD)
mimicking the disease progression and cognitive decline of sCJD [55,56] were included in our
study. No significant differences in the expression levels of the six analyzed miRNAs were
detected between AD and rpAD (Fig 6B). In DLB, we detected coincident gene expression reg-
ulations with sCJD for miRNA-877-5p and miRNA-323a-5p (both with decreased expression
levels) (Fig 6C).
Finally, we extended our analysis to cases of fatal familial insomnia (FFI), a genetic prion
disease presenting mild cortical and cerebellar affection [57,58]. A subset of four sCJD-regu-
lated miRNAs in the FC and CB were tested. Only miRNA-195-5p showed common expres-
sion profiles in sCJD and FFI, with increased expression in both brain regions compared to
age-matched control (Fig 6D) indicating a lack of complete specificity of miRNA patterns
between neurodegenerative diseases from same etiology.
Temporal dependent sCJD miRNA profiling
To gain insights into the temporal-dependent sCJD miRNA profiles we took advantage of the
sCJDMM1 mouse model tg340-PRNP129MM (tg340) inoculated with sCJD MM1 brain
homogenate. Mice were sacrificed at pre-clinical (120 dpi), early clinical (160 dpi) and clinical
(180 dpi and 210 dpi) disease stages. Survival time was 199 ± 7.5 days (Fig 7A). To confirm the
disease-specific regional and subtype neuropathological and biochemical alterations in the
tg340 mice, several prion hallmarks were assessed. Increased PrPSc deposition (Fig 7B), synap-
tic damage (Fig 7C and S7 Fig), neuroinflammation (Fig 7D) and spongiform degeneration
(Fig 7E) were detected in the cortex compared to the CB of the tg340 infected mice. These data
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Fig 6. Analysis of commonly altered miRNAs in sCJD, AD, DLB and FFI. (A) Venn diagrams of the comparison between altered
miRNAs in AD and sCJD. Commonly deregulated miRNAs in the PFC of AD cases obtained from small RNA-seq analysis (20) (blue
circles) and in the FC of sCJD cases obtained from small RNA-seq analysis in the present work (yellow circles). Common elements and
percentage of maximal coincidence between groups are shown. Among these, the deregulated expression levels of miRNA-195-5p,
miRNA-877-5p and miRNA-323a-5p (marked in red) were previously validated by qPCR in the FC of sCJD cases (Fig 2). (B) RT-qPCR
analysis for miRNA-146a-5p, miRNA-195-5p, miRNA-342-5p, miRNA-877-5p, miRNA-323a-5p and miRNA-5701 in the FC of
controls (n = 5), AD (n = 8) and rpAD (n = 6) cases. (C) RT-qPCR analysis for miRNA-146a-5p, miRNA-195-5p, miRNA-342-5p,
miRNA-877-5p, miRNA-323a-5p and miRNA-5701 in the FC of controls (n = 5) and DLB (n = 5) cases. (D) RT-qPCR analysis for
miRNA-342-5p, miRNA-146a-5p, miRNA-195-5p and miRNA-5701 in the FC and CB of controls (n = 3) and FFI cases (n = 3). Results
were normalized to the housekeeping U6 snRNA expression, which remained unaltered between groups. Normalization was performed
relative to controls. Error bars indicate SD. In all cases, statistical significance (compared to controls) was set at p<0.05.
https://doi.org/10.1371/journal.ppat.1006802.g006
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Fig 7. Regional and temporal-dependent neuropathological characteristics and miRNA signatures in the sCJDMM1mouse model
tg340-PRNP129MM. (A) tg340 mice were inoculated with control or sCJDMM1 homogenates; cortex and CB samples were collected at
different time points: 120 dpi for pre-symptomatic phase and 160 dpi, 180 dpi and 210 dpi for symptomatic phase (n = 4–5 per group). Animals
sacrificed at 210 dpi were inoculated with a 10–1 inoculum dilution. (B) PET-blot analysis for the detection of PrPSc in the cortex and CB of sCJD
MM1 inoculated tg340 mice at clinical disease stage. (C) Densitometric analysis of western blots developed for PSD-95 and synaptophysin in the
cortex and CB of tg340 samples at different disease stages. Significant alterations on PSD-95 and synaptophysin levels between control and sCJD
inoculated animals is indicated. Statistical significance was set at p<0.05, (n = 4–5 per group). (D) Heat map analysis of key inflammatory
mediators and cytokines measured with RT-qPCR analysis in the cortex and CB of control and sCJDMM1 inoculated tg340 mice at different
stages of the disease. Fold change between sCJDMM1 infected and control animals is shown. (E) Hematoxylin-eosin staining in the cortex and
CB of control and sCJDMM1 infected tg340 animals. (F) RT-qPCR analysis of the miRNAs validated in human sCJD tissue in the cortex and CB
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confirmed the region specific alterations of sCJD MM1 subtype in the tg340, resembling the
most prominent cortical pathology in human sCJDMM1 [5,59]. Next, the expression levels of
the qPCR-validated miRNAs in sCJD were analyzed in a temporal manner (Fig 7F). Ten and
eleven miRNAs were validated in the cortex and in the CB at one of the clinical stages (180
and/or 210 dpi), respectively. Among these, seven were commonly changed in both regions, in
agreement with data from sCJDMM1. An interesting observation from our qPCR panel was
the temporal specific alterations of the sCJD-related miRNAs, since only miRNA-16a-5p
(increased) and miRNA-124-3p (decreased) showed altered levels at early clinical stages of the
disease in the cortex (Fig 7F and S8 Fig). This indicates that qPCR validated miRNAs are
reflecting late pathogenic alterations, while miRNA-16a-5p and miRNA-124-3p may also par-
ticipate in early pathogenic mechanisms. In agreement with this, functional enrichment analy-
sis from small RNA-Seq indicates that the main common functions related to the sCJD-
regulated miRNAs are cell death and survival (S5 Table).
These results suggested that diverse deregulated miRNA, rather than a specific miRNA
deregulation, could contribute to the pathological mechanisms in sCJD. Therefore, we highly
purified miRNAs from the FC of control, sCJD MM1 and VV2 brains and transfected them
into neuroglioma (H4) and differentiated neuroblastoma (SH-SY5Y) cells. Five miRNAs were
analyzed with qPCR in both cell lines, resembling the disease subtype profiling in human sCJD
brain (S9A Fig). Overexpression of sCJD-MM1 purified miRNAs lead to an increased cell
death in neuroblastoma, but not in neuroglia cells (S9B Fig), indicating that the overexpression
of the sCJD regulated miRNAs is able to induce subtype specific cell death in neuron-like cells.
Finally, to gain insight into the potential upstream regulators of differential miRNA expression
in sCJD a motif enrichment analysis was performed for data generated from FC of sCJD MM1
sequencing. Among the known sCJD related pathways, our analysis revealed a significant
enrichment of a STAT3-binding motif for miRNAs with increased expression in sCJD (S6
Table). This suggests that the expression of sCJD-specific miRNAs is under STAT3 regulation,
which has been described as activated not only in experimental models of prion diseases
[60,61], but also in sCJD post-mortem tissue [5].
Differential miRNA expression levels of abundant CSF miRNAs in sCJD
CSF miRNAs have been suggested as a source of biomarkers in neurodegenerative disease mir-
roring alterations in the brain tissue [62,63]. Thus, we aimed to investigate whether the
detected miRNA alterations in the brain tissue of sCJD patients could be reflected in the CSF.
CSF RNA was extracted from twelve control and twelve sCJD cases and was subjected to
qPCR analysis for the following miRNAs: 154-5p, 204-5p, 378a-3p, 331-3p, 26a-5p, 195-5p,
124-3p, 7i-3p, 143-3p, 449a and 5701. For normalization we used the non-coding small nuclear
RNA U6, which showed stable levels between control and sCJD cases (Fig 8A). Detectable sig-
nal (35<Cts) was obtained for miRNAs 378a-5p, 26a-5p and 204-5p, with miRNA-204-5p
showing significantly decreased levels in sCJD compared to controls (Fig 8B).
Discussion
In the present study, we report the first systematic analysis of miRNA populations in two brain
areas and two disease subtypes of sCJD cases, utilizing small RNA-seq analysis. We detected
of tg340 mice. Samples from different time points of disease progression were analyzed. Fold change between sCJDMM1 infected and control
animals is shown. Results were normalized to the housekeeping gene U6 snRNA expression. U6 levels remained unaltered between groups.
Normalization was performed relative to controls. Error bars indicate SD. In all cases, statistical significance (compared to controls) was set at
p<0.05.
https://doi.org/10.1371/journal.ppat.1006802.g007
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marked alterations in miRNA patterns with the presence of regional and sCJD-subtype specific
signatures, with highest deregulations in the FC of MM1 and in the CB of VV2 cases, two
brain regions and subtypes showing high pathological affection in sCJD [1]. In this regard, the
low overlap between sCJD subtypes altered miRNAs in CB and FC could be explained by the
singular pathology of sCJD VV2 in CB, where characteristic PrPSc aggregates (synaptic and
plaque-like) and degree of spongiform degeneration, neuronal loss and neuroinflammation
profiling are detected [5–7], following classical well-known sCJD regional and subtype-depen-
dent molecular neuropathology [2,47,64].
Small RNA-seq provides a blind and unbiased approach to the study of the small RNA tran-
scriptome. However, a limitation of this technique is the presence of potentially biased fold
changes when number of counts is low. Therefore, confirmatory analysis by qPCR is indis-
pensable to consistently validate the regulation of selected targets. The enrichment of regulated
miRNAs in Ago-containing complexes, as well as a severe, global reduction of miRNA expres-
sion levels in sCJD compared to controls described herein, supports the idea that alterations in
expression levels are translated into the functional miRNA silencing machinery. Small RNA-
seq also revealed length and sequence heterogeneity for the vast majority of miRNAs. How-
ever, the fact that the proportion of different miRNA variants detected by isomiR profiling was
similar in all cases indicates that the molecular mechanisms involved in isomiR generation are
not altered in sCJD, similarly to the situation previously reported for HD [15].
Data on miRNA alterations in sCJD are limited to two targeted studies, including very small
cohorts of cases. Upregulation of miRNA-146a-5p in the neocortex of sCJD cases (n = 3 sCJD,
n = 3 controls) [65] and upregulation of miRNA-342-3p in sCJD brain tissue (n = 2 sCJD, n = 1
control) [23] are in agreement with our observations. In contrast, several studies have been
devoted to analysing the miRNAome in prion animal models. A lack of major correlation
between regulated miRNAs in sCJD and scrapie-infected mice was detected in high-throughput
studies. However, miRNAs: 146a-5p, 342-3p, 142-3p, 26a-5p, 124a-3p (RNA-seq altered and
qPCR validated in sCJD) and 338-5p, 18a-3p, 455-5p, 182-5p (RNA-seq altered in sCJD) are
commonly altered in at least one of the studies where scrapie miRNA profiles have been investi-
gated [21–23,25,33,66]. Additionally, two miRNAs upregulated in the basis pontis of bovine
spongiform encephalopathy-infected macaques, miRNA-342-3p and miRNA-494-3p [23], were
also enriched in sCJD, but exclusively in the FC region. Although low co-occurrence on
miRNA profiles may be due to different methodologies, the absence of detailed regional studies
in mouse models and the specific prion-related pathology in humans may explain this diver-
gence. Altogether, these data highlight the importance of detailed regional and disease-subtype
studies in prion diseases. Yet, intra-species comparisons are now achievable through the study
of humanized PRNPmouse models, which not only fully recapitulate pathological hallmarks of
human disease [5,59] but also, as reported in the present study, resemble human miRNA profil-
ing. In this regard, alterations in miRNA signatures in tg340 at clinical stages are not detectable
at pre-clinical stages. This finding, along with the presence of enriched miRNA-target genes
related to cell death and survival, indicates that sCJD-regulated miRNAs may play a role in the
molecular mechanisms related to the neurodegenerative process and that a different population
of miRNAs, would be responsible for the primary causative events of the disease.
Relative decreased mature miRNA levels in sCJD are consistent with decreased expression
levels of Dicer, Drosha and DGCR8. The miRNA biogenesis pathway is highly conserved and
Fig 8. miRNA profiling in the CSF of control and sCJD cases. RT-qPCR analysis of the housekeeping U6 snRNA (A)
and miRNA-378a-3p, miRNA-26a-5p and miRNA-204-5p (B) in the CSF of control (n = 12) and sCJD cases (n = 12).
Samples were normalized by the relative expression of the housekeeping small nuclear RNAU6, which showed stable
Ct values between the studied groups. Statistical significance was set at p<0.05.
https://doi.org/10.1371/journal.ppat.1006802.g008
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its disruption is a well-reported cause of neurodegeneration. Loss of Dicer levels provokes neu-
ronal dysfunction in Purkinje cells [67], dopaminergic neurons [68] and motor neurons [69],
and increased excitability of CA1 pyramidal neurons [70] while compromising axonal integ-
rity in Schwan cells [71]. In addition, Dicer protein levels have been found to be decreased in
temporal lobe epilepsy patients with hippocampal cell loss, with about half of the miRNAs in
the tissue displaying reduced levels [72]. Finally, similar to our observations, impaired miRNA
biogenesis at Dicer level associated with downregulation of miRNA levels and reorganization
of Dicer and Ago-2 complexes has recently been described in amyotrophic lateral sclerosis
[73] suggesting that miRNAmalfunction could be a contributor to pathogenesis associated
with protein-misfolding associated diseases. Interestingly, lack of expression changes in Expor-
tin 5 suggests that changes detected in the miRNA expression profiles in sCJD are most likely
not due to alterations in the nuclear export of pre-miRNA.
Whether alterations of miRNA biogenesis and homeostasis in sCJD are primary factors in
the neurodegenerative phenotype of the disease due to dysfunctional miRNA maturation, or
are a consequence of the pathology, deserves further studies.
Besides highlighting alterations in miRNA biogenesis and network, our results also reveal a
remodelling of the miRNA-mRNA silencing complexes in sCJD. This is sustained by partial
re-distribution of Ago-2 to higher molecular weight chromatographic fractions, increased Ago
nuclear reactivity, presence of Ago-2 positive microglial cells and increased expression of
p-body marker dcp1 in sCJD brain tissue. Ago-2 and RISC components have recently been
found in the nucleus of humans and Drosophila and associated in multi-protein complexes
with functional silencing activity over nuclear targets [74,75], as well as with additional func-
tions in pre-mRNA splicing and transcriptional repression [75]. The role of Ago proteins,
especially Ago-2, in prion pathology deserves attention not only due to its differential localiza-
tion in sCJD, potentially altering its physiological functions, but also because PrPC has been
described as an Ago-2 interacting partner, promoting the accumulation of miRNA-RISC effec-
tor complexes [26]. PrPC is internalised into the endocytic recycling pathway and most of the
molecules are recycled intact to the cell surface [76]. Since late endosomes and/or multivesicu-
lar bodies are the main site for intracellular conversion of PrPC to PrPSc, and RISC formation
and/or turnover depends on the endosomal pathway [77,78]; the detection of PrPSc in Ago-2
complexes provides a link between RNA silencing and membrane trafficking in sCJD patho-
genesis. Additionally, a translocation of Ago-2 from cytoplasm to nuclear fractions in sCJD
would alter, and potentially impair, the silencing of cytoplasmic mRNA targets by the RISC
complex.
As additional modifiers of the miRNA-mRNA silencing complexes in sCJD we investigated
the presence of SG, which appear in the cell under stress conditions such as oxidative and
endoplasmic reticulum stress [79,80], two well-known sCJD hallmarks [41,81]. Although both
p-bodies and SG may support overlapping cellular functions and share components, they are
not equivalent and they are spatially distinct. SG are thought to be responsible for mRNA stor-
age as these sites lack the decapping enzyme [82], and their formation is mediated through
phosphorylation of eIF2 and aggregation of Tia-1 [83,84]. Neither increased eIF2 phosphor-
ylation nor altered levels of SG markers were detected, suggesting that SG are not specific
structures in sCJD.
A surprising finding of our study was the absence of massive reduction of neuronal-
enriched miRNAs levels, indicating high miRNA stability in brain after neuronal death. An
exception to this was the decreased levels of miRNA-124-3p, also decreased in experimental
models of prion diseases [21,22,66]. In situ hybridization supports the idea that miRNA-124-
3p is not merely decreased as a consequence of neuronal death, since surviving neurons
express less miRNA-124-3p compared to those from controls, pointing towards a specific role
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for this miRNA in sCJD pathology. miRNA-124-3p is the most abundant miRNA in the brain
and promotes neuronal differentiation and maintenance of neuronal identity [85]. In AD, its
expression is decreased in the anterior temporal cortex [86], decreased in the dentate gyrus,
and upregulated in the locus coeruleus [87]. In an ex vivomodel of PD, miRNA-124-3p is
decreased regulating apoptosis and impaired autophagy [88]. This plethora of evidence
denotes a functional role of miRNA-124-3p in neurodegeneration.
In fact, our study details the existence of common miRNA traits in the cortical region of
AD, DLB and sCJD. There is virtually no information on the functions of the two commonly
regulated miRNAs in the brain of the three dementias (miRNA-877-5p and miRNA-323a-5p).
On the contrary, miRNA-195-5p, elevated in AD and sCJD, downregulates A production by
targeting APP and BACE1, and protects against chronic brain hypoperfusion-mediated
dementia [89]. Its overexpression also led to reduced BACE1 and decreased A levels in an
independent study [90]. Although the precise role of miRNA-195-5p in prion diseases is
unknown, we also detected increased levels in the FC of fatal familial insomnia (FFI), a genetic
prion disease with moderate cortical involvement [91].
Based on the conception that one miRNA can target multiple mRNAs and one mRNA can
be targeted by multiple miRNAs, our results support multiple lines of evidence indicating that
the result of the intricate alterations in miRNA networks and clusters, rather than representing
a change in the expression of a single miRNA, are responsible for pathological phenotypes
[92–94]. Thus, the precise miRNA homeostasis in sCJD brain would underlie the spectrum of
molecular and phenotypic cues, in agreement with the acquisition of a disease-related pheno-
type by a neuronal-like cell line upon transfection with the sCJD-associated miRNA
transcriptome.
CSF miRNAs may reflect alterations in brain pathology of neurodegenerative diseases.
Indeed, miRNA profiling in AD and PD correlates with disease status and pathological fea-
tures [63,95] but less is known about the levels of brain-regulated miRNAs in the CSF. Our tar-
geted study revealed that only miRNAs with reported high CSF expression levels were
detectable [96]. Of these, only miRNA-204-5p displayed decreased levels in sCJD cases. Inter-
estingly, this miRNA was not statistically regulated in sCJD brain. Our findings are in line
with those reported in AD, where no obvious relationship between altered miRNAs in CSF
and pathologically affected brain regions was found [17,95]. As the reason for this lack of cor-
relation is unknown, it is tempting to speculate that different disease stages between CSF and
brain sample collection (time of diagnosis for CSF versus post-mortem for brain tissue) may
contribute to these differences. Additionally, as the origin of CSF miRNAs is not well under-
stood, CSF miRNAs may originate not only from brain, but also from extracraneal tissues.
In summary, our study presents, for the first time, comprehensive miRNA signatures in
human prion diseases and unravels the complex network of regional and disease-subtype
miRNA alterations in sCJD, as well as revealing the presence of a disturbed miRNA biogenesis
pathway and miRNA-mRNA silencing machinery. It also highlights the existence of time-
dependent miRNA profiles along disease duration and identifies commonly altered miRNAs
between several dementias sharing a partial clinical overlap. Taken together, the present data
shed light on the potential role of miRNAs as a contributing factor and/or transmitters of path-
ogenic molecular traits in sCJD.
Materials andmethods
Reagents
List of Taqman probes assays, Exiqon primer sets and antibodies is given in S7 Table. Lipofec-
tamine 2000 was from Thermo Fisher Scientific. Thioflavin and Propidium Iodide were from
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Sigma. WST-1 was from Roche. TruSeq Small RNA Sample Preparation Kit was from Illu-
mina. CHROMA SPIN-200 spin columns were from Clontech and Protein G magnetic beads
were from Invitrogen.
Cases and general processing
Brain tissue processing has been described before [5–7,97]. Mean ages and gender for studied
control and sCJD cases, for RNA-seq, qPCR and western blot analysis are detailed in S8 Table.
Information on the mean ages and gender for the AD, DLB and FFI samples that were ana-
lysed with RT-qPCR in the present study are as below: For AD analysis: Control = 75 (3M/2F),
AD = 76 (4M/4F) and rapid progression AD (rpAD) = 77 (3M/3F). rpAD cases were AD cases
with disease duration shorter than 2 years. For DLB analysis: Control = 71 (3M/2F), DLB = 75
(3M/2F). For FFI analysis: Control = 58 (2M/1F), FFI = 52 (2M/1F). Biochemical studies
including sCJD and FFI cases were performed in biosafety rooms (S3 level). mRNA and
miRNA levels were associated neither to RNA integrity number (RIN) values nor to post-mor-
tem time. Protein levels were not associated to post-mortem time.
CSF samples were obtained from an unrelated series of patients with sCJD and from con-
trols. sCJD patients diagnosed with probable or definite sCJD according to established criteria
were considered for the sCJD group [98]. The control group was composed of patients suffer-
ing from neurological conditions (S9 Table). The presence of neurodegenerative diseases in
the control cohort was excluded in the follow-up clinical diagnostic, and CSF neurodegenera-
tive biomarkers (14-3-3, tau, p-tau and A 42) were negative at the time of diagnosis.
CJD subtype characterization
PRNP codon 129 genotyping (Met or Val) was performed after genomic DNA isolation from
blood samples according to standard methods [99]. Western blot PrPSc profile was classified
as type 1 (un-glycosylated PrPSc at 20 kDa) or type 2 (un-glycosylated PrPSc at 19 kDa), based
on electrophoretic mobility after proteinase K (PK) digestion [4,64].
RNA extraction and sequencing
The purification of RNA from FC and CB of CJD and age-matched controls was performed
using the mirVana isolation kit (Ambion, US) according to the manufacturer’s instructions.
After purification, samples were treated with the RNase-free DNase set (Ambion, US) for 30
min to avoid carry over and subsequent amplification of genomic DNA. The concentration of
each sample was determined using the NanoDrop 2000 spectrophotometer (Thermo Scien-
tific, US). RNA integrity number (RIN) was verified with the Agilent 2100 Bioanalyzer (Agi-
lent, US). The threshold for further sample selection was set to RIN value equal to or greater
than 5.5. Starting from 1 μg of total RNA, libraries were prepared following the TruSeq Small
RNASample Preparation Guide protocol from Illumina (Part # 15004197 Rev. E). Library
quality was assessed on the Agilent Technologies 2100 Bioanalyzer. DNA was loaded into a
lane of a single-read flow cell at a concentration of 3–3.5 pM for cluster generation using a sin-
gle-read cluster generation kit (Illumina). From 13 to 15 barcoded samples were sequenced
per lane. The sequencing primer (50-CGACAGGTTCAGAGTTCTACAGTCC GACGATC-30)
was annealed to the clusters and the flow cell was then mounted on a Hiseq 2000 instrument
(Illumina) for sequencing, and 36–41 sequencing cycles were performed. A PhiX control lane
loaded at a concentration of 2 pM was used to monitor run quality. Image processing and base
calling was performed using Illumina sequencing analysis pipelines v0.3.0 or v1.3.2. A total of
72 samples were analyzed by small RNA-seq: For FC 13 controls, 13 sCJDMM1 and 13 sCJD
VV2 were analyzed for CB: 12 controls, 12 sCJD MM1 and 9 sCJD VV2.
microRNAs in Creutzfeldt-Jakob disease
PLOS Pathogens | https://doi.org/10.1371/journal.ppat.1006802 January 22, 2018 20 / 33
Small RNA data processing and mapping
Reads were trimmed to 36 nt and ligation adapters were removed using the adrec.jar program
from the seqBuster suite (http://github.com/lpantano/seqbuster) [28] with the following
options: java -jar adrec.jar 1 8 0.3. Sequences were mapped to the hg19 genome with the com-
mand line: bowtie -f -v 1 –a–best–strata. For summing up miRNA read counts we mapped the
reads against miRBase version 21 hairpins with the miraligner.jar tool with these options:
java–jar miraligner.jar 1 3 3.
Out of a total of several million reads, we discarded any reads without a minimum of 10-nt
linker subsequence directly adjoining the insert, showing two or less mismatches. Then
sequences were mapped to human pre-miRNA and mature miRNA databases provided in the
miRBase (http://miRNA.sanger.ac.uk/sequences/, Release 14), as well as mRNA, ncRNA,
repeats and genome databases available at (http://hgdownload.cse.ucsc.edu/goldenPath/hg18/
bogZips/), using Mega BLAST.
For motif discovery, deregulated miRNAs were searched for the genomic coordinates of
their primary miRNAs. Upstream regions of 1kb size from each miRNA were extracted and
exported to BED files and the script findMotifsGenome.pl in HOMER suite was used to find
transcription factor binding motifs within promoter regions using genome assembly hg38 [100].
For differential expression analysis we used DESeq2 analysis and log2 transformation of the
count data. Padj value was<0.15 and nominal p values were in all cases<0.05. We used the
count matrix generated by Seqbuster. Only miRNAs consistently expressed (counts> 10) in at
least 10 samples out of the 21–26 were included in each analysis (controls versus MM1 or VV2
cases).
Analysis of miRNA variability (IsomiRs)
IsomiRs were annotated and analyzed using the SeqBuster tool [28]. For miRNA annotation
the following parameters were configured: one mismatch, 3 nts in the 3’ or 5’-trimming vari-
ants, 3 nts in the 3’-addition variants. These options permitted annotations of the following
types of alignment: (i) perfect match, where the sequence is completely identical to the refer-
ence sequence; (ii) trimming at the 3’-end of the reference miRNA sequence, which is an
miRNA variant several nucleotides shorter or longer that matches to the mature or precursor
reference sequence, respectively; (iii) trimming at the 5’-end of the sequence, an analogous
case as to (ii) but focused on the 5’-end of the miRNA; (iv) nucleotide additions at the 3’-end
of the sequence and (v) nucleotide substitutions, showing nucleotide changes with respect to
the reference sequence. The parameters for the alignment to the mRNA and genome databases
allowed up to one mismatch and up to three nucleotide additions in the 3’-terminus.
For deep characterization of IsomiRs we applied several filters. First, the sequences consid-
ered in the analysis presented a frequency above 3. Second, 10 was chosen as the ‘Contribution
Cut-Off’ parameter, meaning that every isomiR considered in the analysis contributes by more
than 10% to the total number of variants annotated in the same miRNA locus. Third, we
applied the Z-score option to exclude sequencing errors as the possible cause of the nucleotide
changes observed in some variants.
miRNA purification for transfection experiments
RNA samples extracted with the mirVANA isolation kit (Ambion) using the specific protocol
for small RNA isolation were run on a 6% Urea–PAGE. The bands containing miRNAs (15–
30 nt) were excised from the gel and incubated for 1 hour with 250 mMNaCl and 1 mM
EDTA. miRNAs were then precipitated with 2.5 volumes of 100% ethanol (v/v) over night at
−80˚C, washed twice with 70% ethanol and re-suspended in nuclease-free water.
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Cell cultures and transfection
H4 and SH-SY5Y cells (American Type Culture Collection) were cultured at 37˚C in a 95%/
5% Air/CO2 water-saturated atmosphere in Dulbecco’s modified Eagle’s medium (DMEM,
Thermo Fisher Scientific) containing 10% heat inactivated fetal bovine serum (FBS, Thermo
Fisher Scientific), 2 mM L-glutamine and 100U/ml Penicillin/streptomycin (Gibco). SH-SY5Y
cells were differentiated with DMEM containing 3% FBS and 10 μM all-trans retinoic acid
(RA, Sigma) for 72 hours. Differentiation medium was replenished after 48 hours. Cells were
transfected with 250 ng of highly purified miRNAs with Lipofectamine 2000 (Invitrogen) fol-
lowing the manufacturer’s instructions.
Gel filtration
Analysis of protein fractions according to their molecular weight was performed as described
before [36] using CHROMA SPIN-200 (Clontech, USA) spin columns. Columns were pre-
spun at 200xg for 3 min to remove storage buffer. Buffer exchange was made by the addition
of 500 μl lysis buffer followed by centrifugation at 200 xg for 3 min. This step was then
repeated. 75 μl of 1% brain homogenates were applied to the gel bed. After spinning at 120 xg
for 2 min elution fractions were collected, and 40 μl of extraction buffer was added after each
centrifugation step.
sCJDMM1mice–tg340 PRNP129MM
The tg340 mouse line expressing about 4-fold level of the human PrP M129 on a mouse PrP
null background was generated as described elsewhere [59]. Control and sCJDMM1 brain tis-
sues (10% (w/v) homogenates) were used as inocula. Individually identified 6–10 week-old
mice were anesthetized and inoculated in the right parietal lobe using a 25-gauge disposable
hypodermic needle. Additionally, MM1 inoculum dilutions were performed to study pro-
longed disease times; animals were sacrificed at 210 dpi (10–1 dilution). Mice were observed
daily and their neurological status was assessed weekly. The animals were euthanized at pre-
symptomatic (pre-clinical: 120 dpi) and symptomatic (early clinical: 160 dpi and clinical: 180
dpi) stages and the brain was removed. A part of the brain was fixed by immersion in 10%
buffered formalin, to quantify spongiform degeneration and perform immunohistological
analysis. The other part was frozen at −80˚C, for extraction of protein and RNA. Paraffin-
embedded tissue blots from tg340 mice samples was carried out as described previously [5].
For each tissue sample, serial sections, 4 mm thick for PET blot, were collected on membranes.
Serial sections were stained with hematoxylin and eosin. SHa31 antibody was used for PrP
immunodetection.
RT-qPCR
In order to confirm the direction of the miRNA alterations detected by RNA-seq in sCJD cases
(increased or decreased levels compared to controls) by an independent methodology qPCR
analysis of selected miRNAs was performed. Quantitative real time PCR for miRNAs was per-
formed using the miRCURY LNAmiRNA PCR System (Exiqon) following Minimum Infor-
mation for Publication of Quantitative Real-Time PCR Experiments guidelines. RNA was
extracted with the mirVana isolation kit (Ambion) following the manufacturer’s instructions.
PCR amplification and detection were performed with the Roche LightCycler 480 detector,
using 2x SYBR GREENMaster Mix. The reaction profile was: Polymerase Activation/Denatur-
ation (95˚C for 10 min) followed by 40 amplification cycles (95˚C-10 sec, 60˚C-20 sec).
miRNA levels were calculated using the LightCycler 480 software. Samples were normalized
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by the relative expression of the housekeeping small nuclear RNAs U6 and U5. Housekeeping
genes showed no variability between analyzed groups. CT values obtained from the miRNA
qPCR analysis ranged from 18 to 31.
Quantitative real time PCR for mRNAs was performed using Taqman probes (Life Tech-
nologies) on total RNA extracted with mirVana’s isolation kit (Ambion) following the manu-
facturer’s instructions. PCR assays were conducted in duplicate using cDNA samples obtained
from the retrotranscription reaction and diluted 1:15 in 384-well optical plates. PCR amplifica-
tion and detection were performed with the Roche LightCycler 480 detector, using Taqman
Universal PCRMaster Mix, following the manufacturer’s instructions. The reaction profile was
as follows: denaturation–activation cycle (95˚C for 10 min) followed by 40 cycles of denatur-
ation–annealing–extension (95˚C, 10 min; 72˚C, 1 min; 98˚C, continuous). mRNA levels were
calculated using the LightCycler 480 software. Samples were normalized based on the relative
expression of a housekeeping gene (glyceraldehyde-3-phosphate dehydrogenase [GAPDH]).
The housekeeping gene showed no variability between analyzed groups.
Western blot
Human tissues were lysed in lysis buffer: 100 mM Tris pH 7, 100 mMNaCl, 10 mM EDTA,
0.5% NP-40 and 0.5% sodium deoxycolate plus protease and phosphatase inhibitors. After cen-
trifugation at 14,000g for 20 min at 4˚C, supernatants were quantified for protein concentra-
tion (BCA, Pierce), mixed with SDS-PAGE sample buffer, boiled, and subjected to 8–15%
SDS-PAGE. Gels were transferred onto nitrocellulose membranes and processed for specific
immunodetection by chemiluminescence (ECL Amersham, US) using the indicated antibod-
ies. Densitometries were carried out with the ImageJ software and values were normalized
using -actin levels.
RISC immunoprecipitation
Protein G magnetic beads were pre-equilibrated in lysis buffer (150 mMNaCl, 50 mM Tris,
0.5% NP40, protease and phosphatase inhibitors) and mixed with 1 mg of human FC brain
homogenate from either control or sCJD MM1 cases and with 4 μg of Ago antibodies 11A9 or
H-300. As a control, 4 μg of an unspecific IgG antibody was used. Complexes were incubated
overnight at 4˚C with gentle end-to-end shaking. To extract the immunoprecipitated RNA,
beads were washed three times in lysis buffer and resuspended in phenol-chloroform. The
RNA in the aqueous phase was precipitated for 1 h at -80˚C after addition of 2.5-fold volume
ethanol and 0.1-fold volume NaAc (3mol/l); precipitated RNA was pelleted by centrifugation
for 25 min at 4˚C at 20,000xg. After washing in cold 70% ethanol, centrifugation and air dry-
ing, RNA was re-suspended in 10 μl of RNase-free water. The miRCURY LNA Universal RT
miRNA PCR kit (Exiqon) was used for miRNA reverse transcription. For this, 6.5 μl of re-sus-
pended RNA was applied in a total RT reaction volume of 10 μl (2μl 5x reaction buffer, 1μl
enzyme mix, 0.5μl nuclease free water). cDNA was synthesized as described before for miRNA
RT. A 1:80 cDNA dilution was used for miRNA quantification via real-time PCR amplification
and miRNA LNA primer sets.
miRNA in situ hybridization
For miRNA recognition locked nucleic acid (LNA) modified probes combined with signal
amplification technology using enzyme-labeled immunoassay were obtained from Exiqon
(Vedbaek, Denmark). The following double digoxigenin (DIG)-labelled sequences of the LNA
probes were used: hsa-miRNA-124: 5’-DIG/ggcattcaccgcgtgcctta/DIG-3’, hsa-miRNA-146a 5’-
DIG/aacccatggaattcagttctca/DIG-3’, has-miRNA-26a 5’-DIG/agcctatcctggattacttgaa/DIG-3’.
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The sequence of the U6 snRNA positive control probe was: 5’-DIG/cacgaatttgcgtgtcatcctt/-3’.
6 μM-thick brain tissue sections were deparaffinised, deproteinized with Proteinase K (15μg/
ml) at 37˚C for 10 min, washed in PBS and dehydrated in increasing concentrations of ethanol.
Probe hybridization was performed over night at 55˚C with 100 nM (hsa-miRNA-146a, hsa-
miRNA-26a), 40 nM (miRNA-124), or 1 nM (U6 snRNA) of LNA probe diluted in hybridiza-
tion mix. After stringent washing in salt sodium citrate (SSC) buffer and blocking with 2%
sheep serum/1% bovine serum albumin, probe-target complex was visualized immunologically
with anti-DIG antibody (Roche, 1:800) conjugated to alkaline phosphatase acting on the chro-
mogen NBT/BCIP. In some cases, slides were counterstained with nuclear fast red (Vector
laboraties). For quantification of miRNA-124-3p, 3 controls and 2 sCJD MM1 cases were
used.
Immunofluorescence
For immunofluorescence analysis in brain tissues, de-waxed sections, 4 microns thick, were
stained with a saturated solution of Sudan black B (Merck, DE) for 15 min, to block the auto-
fluorescence of lipofuscin granules present in cell bodies, and then rinsed in 70% ethanol and
washed in distilled water. The sections were boiled in citrate buffer to enhance antigenicity
and blocked for 30 min at room temperature with 10% fetal bovine serum diluted in PBS.
Then, the sections were incubated at 4˚C overnight with primary antibodies. After washing,
the sections were incubated with Alexa488 or Alexa546 (1:400, Molecular Probes, US) fluores-
cence secondary antibodies against the corresponding host species. The sections were
mounted in Immuno-Fluore mounting medium (ICN Biomedicals, US), sealed, and dried
overnight. Sections were examined with a Leica TCS-SL confocal microscope.
Real time quaking induced conversion (RT-QuIC)
RT-QuIC was performed as previously described [101] with minor modifications. Briefly,
recombinant PrP (10 μg) was seeded with 15 μl of Ago-2-Immunoprecipitates in 85 μl of reac-
tion buffer. Reaction was set in a final volume of 100 μl and placed in a 96-well black optical
bottom plate (Fisher Scientific). Each sample was run in duplicate. Prepared plates were sealed
and incubated in a FLUO Star OPTIMA plate reader (BMG Labtech Ortenberg, GE) at 42˚C
for 80 h, with intermittent shaking cycles consisting of 1 min double orbital shaking at the
highest speed (600 rpm) followed by a 1 min break.
CSF analysis
Lumbar punctures were performed for diagnostic purposes at the time point of the first diag-
nostic work-up and samples were stored at −80˚C until analysis. 14-3-3 protein was analyzed
as described previously [102] and total tau was quantitatively measured using the enzyme-
linked immunosorbent assay kits INNOTEST-hTAU-Ag from Fujirebio according to the
manufacturer’s instructions. RT-QuIC analysis was performed as described before [101]. RNA
purifications from CSF were performed using miRCURY RNA Isolation Kit–Biofluids (Exi-
qon) following manufacturer-provided protocol with minor modifications. 200 μl CSF input
volume was used and treated with 2 μg/μl Proteinase K in order to optimize the RNA yield. As
an inert RNA carrier 2 μg Glycogen per CSF sample was added. The miRCURY LNA Univer-
sal RT miRNA PCR kit (Exiqon) was used for miRNA reverse transcription. For this, 4 μl of
re-suspended RNA was applied as input in a total RT reaction volume of 10 μl (2 μl 5x reaction
buffer, 1 μl enzyme mix, 3 μl nuclease free water) and cDNA was synthesized as described
before for miRNA RT. A 1:80 cDNA dilution was used for miRNA quantification via real-time
PCR amplification and miRNA LNA primer sets. The small RNA U6 revealed to be stable
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in CSF samples from sCJD and control samples and was used as reference gene for miRNA
quantification.
Statistical analysis
For comparisons of the two groups, the Mann-Whitney test was used. In multiple compari-
sons, the Kruskal-Wallis test was used. Dunn’s multiple comparison test was used for post hoc
analysis. Statistical analyses and calculations were carried out using GraphPad Prism 5 soft-
ware. Statistical significance was set at p<0.05.
Ethics
Brain tissue samples were obtained from the Institute of Neuropathology Brain Bank (HUB-I-
CO-IDIBELL Biobank) and the Biobank of Hospital Clinic-IDIBAPS, following pertinent
guidelines of the Spanish legislation and the local ethics committee. The present study was
conducted according to the revised Declaration of Helsinki and Good Clinical Practice guide-
lines and was approved by the local ethics committees (University of Göttingen -No. 9/6/08,
19/11/09 and 18/8/15). Informed written consent was given by all study participants or their
legal representative. All participants were adults, and samples were anonymized.
For animal investigation, principles of laboratory animal care (NIH publication No. 86–23,
revised 1985) were followed. All animal experiments were performed in compliance with the
French, national guidelines, in accordance with the European Community Council Directive
86/609/EEC. The protocols comply with the Animal Research: Reporting In Vivo Experiments
(ARRIVE) guidelines. The experimental protocol was approved by the INRA Toulouse/ENVT
ethics committee (Permit number: 310955547).
Supporting information
S1 Fig. MA plots from small RNA-Seq in the FC and CB of control, sCJDMM1 and VV2
cases. Plots represent the log2 fold change over the mean expression of mean normalized
counts for each group comparison.
(TIF)
S2 Fig. Distribution of the different types of isomiRs in control and sCJD. IsomiR distribu-
tion in control individuals (red) and MM1 or VV2 samples (blue), in the FC (A-B) and the CB
(C-D). The size of the dots shows the relative abundance of the different types of isomiRs. The
Y-axis shows the fraction of unique sequences affecting specific nucleotides along the miRNAs,
indicated in the X-axis. In the X-axis the nucleotide changes at diverse positions defining the
isomiR are indicated with respect the reference miRNA (the miRbase sequence). For the trim-
ming variants positions with a minus refer positions upstream of the reference miRNA.
(TIF)
S3 Fig. Expression of GW182 in sCJD brain tissue. (A) Gene expression levels of GW182
(n = 10) in the FC and CB of controls, sCJDMM1 and VV2 cases by RT-qPCR. Results were nor-
malized to housekeeping genes GAPDH (figure) and GUSB with similar results. Housekeeping
levels remained unaltered between groups. (B) Protein levels of GW182 in the FC of controls,
sCJDMM1 and VV2 cases, by western blot analysis. Three representative cases per diagnostic
group and brain region are shown in the western blot. Quantifications derived from densitometry
analysis were performed in 15 cases per diagnostic group (n = 15/group). -actin was used as a
loading control. Densitometries of the western blots (n = 15 cases/group) are shown. Normaliza-
tion was performed relative to controls. Error bars indicate SD. In all cases, statistical significance
(compared to controls) was set at p<0.05. (C) Representative fluorescence photomicrographs of
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GW182 immunoreactivity in the FC of control, sCJDMM1 and sCJD VV2 cases. Phase contrast
and merge images are shown. Scale bar = 25μm.
(TIF)
S4 Fig. Analysis of gel filtration chromatography fractions from sCJD cases. (A) Coomas-
sie-blue staining of the chromatographic gel filtration fractions obtained from the FC of a
sCJD brain homogenate. A representative image of three independent experiments is shown.
Molecular weight and fraction numbers are indicated (B) Western blot analysis of the different
gel filtration fractions using the Prion protein SAF70 antibody. A representative control and
sCJD case is shown. (C) RT-QuIC analysis of the input and chromatographic gel filtration
fractions 2 and 7 obtained from the FC of a control and of sCJD brain homogenate. Positive
signal was only detected in sCJD fractions. Higher signal, as detected by shorter lag phase was
detected in the input, fraction 2 and fraction 7, respectively. A representative image of three
independent experiments is shown. (D) Dot-blot analysis developed against the oligomer anti-
body 11A of the input and chromatographic gel filtration fractions 2 and 7 obtained from the
FC of a control and sCJD brain homogenate. Positive signal was only detectable in sCJD frac-
tions. A representative image of three independent experiments is shown.
(TIF)
S5 Fig. Subcellular localization of Ago-2 in sCJD brain tissue. (A) Representative fluores-
cence photomicrographs of Ago-2 immunoreactivity (11A9 antibody) in the FC of control,
sCJDMM1 and sCJD VV2 cases. Phase contrast and merge images are shown. Scale
bar = 25μm. Representative fluorescence photomicrographs of Ago-2 (11A9 antibody, green
channel) and Iba-1 (red channel) immunoreactivity in the FC of control and sCJDMM1 cases.
Arrowheads indicate absence of Ago-2 expression in microglial cells in control cases. In con-
trast, in sCJD cases some microglial cells are double stained with Ago-2 antibody. Merge
images are shown. Scale bar = 25μm (C).
(TIF)
S6 Fig. Expression of Exportin 5 in sCJD brain tissue. (A) Gene expression levels of Exportin
5 (n = 10) in the FC and CB of controls, sCJDMM1 and VV2 cases by RT-qPCR. Results were
normalized to housekeeping genes GAPDH (figure) and GUSB with similar results. House-
keeping levels remained unaltered between groups. (B) Protein levels of Exportin 5 in the FC
of controls, sCJDMM1 and VV2 cases, by western blot analysis. Two representative cases per
diagnostic group and brain region are shown in the western blot. Quantifications derived from
densitometry analysis were performed in 15 cases per diagnostic group (n = 15/group). -actin
was used as a loading control. Densitometries of the western blot (n = 15 cases/group) are
shown. Normalization was performed relative to controls. Error bars indicate SD. In all cases,
statistical significance (compared to controls) was set at p<0.05.
(TIF)
S7 Fig. Synaptic loss in the sCJDMM1mouse model tg340-PRNP129MM.Western blot
analysis of PSD-95 and synaptophysin in the cortex and CB of control and sCJDMM1 inocu-
lated mice at different disease stages. GAPDH was used as a loading control.
(TIF)
S8 Fig. Temporal-dependent expression of validated miRNAs in the sCJDMM1mouse
model tg340-PRNP129MM. Representation of the miRNAs with regulated expression levels
in the cortex (A) and CB (B) of the tg340 mice by RT-qPCR analysis at any of the different
stages of the disease. Data is represented as the fold change between sCJDMM1 and control
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inoculated animals and each colored line represents a miRNA.
(TIF)
S9 Fig. Selective cell death induction by sCJD miRNAs transfection in cell cultures. (A)
miRNAs from Control, sCJDMM1 and sCJD VV2 cases (FC region) were highly purified using
commercial RNA extraction kits followed by in-gel purification and transfection into SH-SY5Y
RA-differentiated cells and glioblastoma H4 cells. RNA was extracted from the cells and selected
sCJD-related miRNAs were quantified by qPCR. NT: non-transfected. Statistical differences
of comparison with non-transfected cells are indicated; p<0.05. (B) Cell toxicity assay, using
Iodide Propidium staining (PI) on H4 and SY-SY5Y cells at 48h post-transfection with highly
purified miRNAs derived from Control, sCJDMM1 and sCJD VV2 cases (FC region). (C) Cell
viability, usingWST-1 on SY-SY5Y cells at 48h post-transfection transfected with highly puri-
fied miRNAs derived from Control, sCJDMM1 and sCJD VV2 cases (FC region). Statistical dif-
ferences are referred to controls. Statistical significance was set at p<0.05.
(TIF)
S1 Table. Excel file including the total RNA-sequence reads in each case (online).
(XLSX)
S2 Table. Excel file including the total number of reads mapping onto miRNAs.miRNAs
with at least 2 counts in a given sample (online).
(XLSX)
S3 Table. Excel file including regulated miRNAs detected in this study (online).
(XLSX)
S4 Table. Excel file displaying isomiRs detected in this study. Base mean> or equal to 10
(online).
(XLSX)
S5 Table. Table providing information on the functional enrichment analysis of miRNAs
identified based on small RNA-Seq in this study.
(TIF)
S6 Table. Top transcription factor binding sites enriched for promoter regions of target
downregulated (A) and upregulated (B) miRNAs in the FC of sCJD MM1 cases.
(TIF)
S7 Table. List of Taqman probes, miRCURY LNA primers and antibodies used in this
study.
(TIF)
S8 Table. Brain samples used in the present study.Diagnostic, sCJD subtype, brain region,
age, sex and the type of experiment for which each case was used (RNA-seq, miRNA qPCR,
mRNA qPCR and western blot) is indicated.
(TIF)
S9 Table. Demographics and biomarker profiling for the CSF samples analyzed in this
study.NA = Non-analyzed, + = positive according to sCJD cut-off, − = negative according to
sCJD cut-off. M = male, F = female.
(TIF)
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S1 Fig. MA plots from small RNA-Seq in the FC and CB of control, sCJD 
MM1 and VV2 cases. 
Plots represent the log2 fold change over the mean expression of mean normalized 





















S2 Fig. Distribution of the 
different types of isomiRs in 
control and sCJD. 
IsomiR distribution in control 
individuals (red) and MM1 or VV2 
samples (blue), in the FC (A-B) and 
the CB (C-D). The size of the dots 
shows the relative abundance of the 
different types of isomiRs. The Y-
axis shows the fraction of unique 
sequences affecting specific 
nucleotides along the miRNAs, 
indicated in the X-axis. In the X-axis 
the nucleotide changes at diverse 
positions defining the isomiR are 
indicated with respect the reference 
miRNA (the miRbase sequence). For 
the trimming variants positions with a 
minus refer positions upstream of 









S3 Fig. Expression of GW182 in sCJD brain tissue. 
(A) Gene expression levels of GW182 (n = 10) in the FC and CB of controls, sCJD 
MM1 and VV2 cases by RT-qPCR. Results were normalized to housekeeping genes 
GAPDH (figure) and GUSB with similar results. Housekeeping levels remained 
unaltered between groups. (B) Protein levels of GW182 in the FC of controls, sCJD 
MM1 and VV2 cases, by western blot analysis. Three representative cases per 
diagnostic group and brain region are shown in the western blot. Quantifications 
derived from densitometry analysis were performed in 15 cases per diagnostic group (n 
= 15/group). β-actin was used as a loading control. Densitometries of the western blots 
(n = 15 cases/group) are shown. Normalization was performed relative to controls. 
Error bars indicate SD. In all cases, statistical significance (compared to controls) was 
set at *p<0.05. (C) Representative fluorescence photomicrographs of GW182 
immunoreactivity in the FC of control, sCJD MM1 and sCJD VV2 cases. Phase contrast 







S4 Fig. Analysis of gel filtration chromatography fractions from sCJD 
cases. 
(A) Coomassie-blue staining of the chromatographic gel filtration fractions obtained 
from the FC of a sCJD brain homogenate. A representative image of three independent 
experiments is shown. Molecular weight and fraction numbers are indicated (B) 
Western blot analysis of the different gel filtration fractions using the Prion protein 
SAF70 antibody. A representative control and sCJD case is shown. (C) RT-QuIC 
analysis of the input and chromatographic gel filtration fractions 2 and 7 obtained from 
the FC of a control and of sCJD brain homogenate. Positive signal was only detected in 
sCJD fractions. Higher signal, as detected by shorter lag phase was detected in the 
input, fraction 2 and fraction 7, respectively. A representative image of three 
independent experiments is shown. (D) Dot-blot analysis developed against the 
oligomer antibody 11A of the input and chromatographic gel filtration fractions 2 and 7 
obtained from the FC of a control and sCJD brain homogenate. Positive signal was 
only detectable in sCJD fractions. A representative image of three independent 







S5 Fig. Subcellular localization of Ago-2 in sCJD brain tissue. 
(A) Representative fluorescence photomicrographs of Ago-2 immunoreactivity (11A9 
antibody) in the FC of control, sCJD MM1 and sCJD VV2 cases. Phase contrast and 
merge images are shown. Scale bar = 25μm. Representative fluorescence 
photomicrographs of Ago-2 (11A9 antibody, green channel) and Iba-1 (red channel) 
immunoreactivity in the FC of control and sCJD MM1 cases. Arrowheads indicate 
absence of Ago-2 expression in microglial cells in control cases. In contrast, in sCJD 
cases some microglial cells are double stained with Ago-2 antibody. Merge images are 







S6 Fig. Expression of Exportin 5 in sCJD brain tissue. 
(A) Gene expression levels of Exportin 5 (n = 10) in the FC and CB of controls, sCJD 
MM1 and VV2 cases by RT-qPCR. Results were normalized to housekeeping genes 
GAPDH (figure) and GUSB with similar results. Housekeeping levels remained 
unaltered between groups. (B) Protein levels of Exportin 5 in the FC of controls, sCJD 
MM1 and VV2 cases, by western blot analysis. Two representative cases per 
diagnostic group and brain region are shown in the western blot. Quantifications 
derived from densitometry analysis were performed in 15 cases per diagnostic group (n 
= 15/group). β-actin was used as a loading control. Densitometries of the western blot 
(n = 15 cases/group) are shown. Normalization was performed relative to controls. 
Error bars indicate SD. In all cases, statistical significance (compared to controls) was 











S7 Fig. Synaptic loss in the sCJD MM1 mouse model tg340-PRNP129MM. 
Western blot analysis of PSD-95 and synaptophysin in the cortex and CB of control and 





















S8 Fig. Temporal-dependent expression of validated miRNAs in the 
sCJD MM1 mouse model tg340-PRNP129MM. 
Representation of the miRNAs with regulated expression levels in the cortex (A) and 
CB (B) of the tg340 mice by RT-qPCR analysis at any of the different stages of the 
disease. Data is represented as the fold change between sCJD MM1 and control 













S9 Fig. Selective cell death induction by sCJD miRNAs transfection in 
cell cultures. 
(A) miRNAs from Control, sCJD MM1 and sCJD VV2 cases (FC region) were highly 
purified using commercial RNA extraction kits followed by in-gel purification and 
transfection into SH-SY5Y RA-differentiated cells and glioblastoma H4 cells. RNA was 
extracted from the cells and selected sCJD-related miRNAs were quantified by qPCR. 
NT: non-transfected. Statistical differences of comparison with non-transfected cells are 
indicated; p<0.05. (B) Cell toxicity assay, using Iodide Propidium staining (PI) on H4 
and SY-SY5Y cells at 48h post-transfection with highly purified miRNAs derived from 
Control, sCJD MM1 and sCJD VV2 cases (FC region). (C) Cell viability, using WST-1 
on SY-SY5Y cells at 48h post-transfection transfected with highly purified miRNAs 
derived from Control, sCJD MM1 and sCJD VV2 cases (FC region). Statistical 









S2 Table. Excel file including the total number of reads mapping onto 
miRNAs. 
miRNAs with at least 2 counts in a given sample (online). 
https://doi.org/10.1371/journal.ppat.1006802.s011 
(XLSX) 




S4 Table. Excel file displaying isomiRs detected in this study. 



















S5 Table. Table providing information on the functional enrichment 




















S6 Table. Top transcription factor binding sites enriched for promoter 
regions of target downregulated (A) and upregulated (B) miRNAs in the 



















S7 Table. List of Taqman probes, miRCURY LNA primers and antibodies 






S8 Table. Brain samples used in the present study. 
Diagnostic, sCJD subtype, brain region, age, sex and the type of experiment for which 





























S9 Table. Demographics and biomarker profiling for the CSF samples 
analyzed in this study. 
NA = Non-analyzed, + = positive according to sCJD cut-off, − = negative according to 
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Abstract The present study analyzes by RT-qPCR the ex-
pression of microRNA (miRNA)-27a-3p, miRNA-124-3p,
miRNA-132-3p, and miRNA-143-3p in the locus coeruleus
(LC), entorhinal cortex (EC), CA1 region of the hippocampus
(CA1), and dentate gyrus (DG) of middle-aged (MA) individ-
uals with no brain lesions and of cases at Braak and Braak
stages I-II and II-IVof neurofibrillary tangle (NFT) pathology.
The most affected region is the LC in which miRNA-27a-3p,
miRNA-124-3p, and miRNA-143-3p show a trend to increase
at stages I-II and are significantly up-regulated at stages III-IV
when compared with MA. Only miRNA-143-3p is up-
regulated in the EC at stages III-IV when compared with
MA and with stages I-II. No modifications in the expression
levels of miRNA-27a-3p, miRNA-124-3p, miRNA-132-3p,
and miRNA-143-3p are found in CA1 at any stage, whereas
miRNA-124-3p is significantly down-regulated in DG at
stages I-II. Accompanying in situ hybridization reveals
miRNA-27a-3p, miRNA-124-3p, and miRNA-143-3 locali-
zation in neurons, indicating that changes in miRNA expres-
sion are not a direct effect of changes in the numbers of neu-
rons and glial cells. Present observations show for the first
time important miRNA de-regulation in the LC at the first
stages of NFT. Since the LC is the main noradrenergic input
to the cerebral cortex, key regulator of mood and depression,
and one of the first nuclei affected in aging and Alzheimer’s
disease (AD), these findings provide insights for additional
study of the LC in aging and AD.
Keywords MicroRNA .Neurofibrillary tangle pathology .
Alzheimer disease . Locus coeruleus . Entorhinal cortex .
Hippocampus
Introduction
MicroRNAs (miRNAs) are genome-encoded small RNAs that
primarily regulate gene expression at the post-transcriptional
level, thus controllingdiverse cellular functions.miRNAgenes
can be located in intergenic regions or within protein-coding
genes; they are transcribed as precursor miRNAs which are
processed into its final ~ 21–23 nucleotide mature forms.
Incorporated in the RNA-induced silencing complex (RISC),
miRNAs imperfectly bind to specific target mRNA and direct
gene expression repression (Meister 2007; Eulalio et al. 2009).
Importantly, a single miRNA can target several mRNAs, and a
single mRNA can be targeted by different miRNAs, thus lead-
ing to complex regulatory mechanisms geared to fine tuning




1 CIBERNED (Network Centre for Biomedical Research of
Neurodegenerative Diseases), Institute Carlos III, Ministry of Health,
Madrid, Spain
2 Department of Neurology, University Medical School,
Göttingen, Germany
3 German Centre for Neurodegenerative Diseases (DZNE),
Göttingen, Germany
4 Institute of Neuropathology, IDIBELL-University Hospital
Bellvitge, Hospitalet de Llobregat, Spain
5 Centre for Genomic Regulation, Barcelona, Spain
6 Department of Pathology and Experimental Therapeutics, Faculty of
Medicine, University of Barcelona, c/Feixa Llarga sn,
08907 Hospitalet de Llobregat, Spain
7 Institute of Neurosciences, University of Barcelona,
Barcelona, Spain
J Mol Neurosci (2017) 63:206–215
DOI 10.1007/s12031-017-0971-4
gene expression (Krek et al. 2005; Friedman et al. 2009).
miRNAs are involved in a broad range of biological processes,
presenting specific expression patterns in the central nervous
system, where they regulate several functions including neuro-
nal differentiation, circadian clock, synaptic plasticity, and
neurite outgrowth (Follert et al. 2014). In this regard, miRNA
levelsdonotnecessarily reflect their expressionefficacy; rather,
these values represent a dynamic equilibrium between the syn-
thesis anddegradation rates,whichmaybedisease-specific and
different in particular brain regions compared to others (Krol
et al. 2010b). For instance, miRNAs with high decay and in-
creased transcription rates, such asmiR-211 (Krol et al. 2010a),
have been recently involved in the pathological mechanisms
associated to several neurological conditions (Fan et al. 2016;
Bekenstein et al. 2017).
Alzheimer’s disease (AD) is a common age-related neuro-
degenerative process characterized neuropathologically by the
presence of neurofibrillary tangles (NFTs) composed of
hyper-phosphorylated tau and β-amyloid diffuse and senile
plaques (Duyckaerts and Dickson 2011). NFT pathology is
categorized into stages I-II with involvement of the entorhinal,
transentorhinal cortex, and part of the hippocampus; stage III-
IV with additional involvement of the limbic system; and
stages V-VI with widespread NFTs in the neocortex. NFTs
are also present in selected nuclei of the brain stem, as the
locus coeruleus (LC), at early stages of the disease (Braak
and Braak 1991; Rub et al. 2001; Simic et al. 2009; Arendt
2012; Ferrer 2012; Arendt et al. 2015; Braak and Del Tredici
2015; Andrés-Benito et al. 2017). It is worth noting that stages
I-II and even stages III-IV are asymptomatic, although some
individuals at stage IV may have cognitive impairment; clas-
sical dementia of AD type appears at stages V-VI. Stages I-IV,
usually, are incidentally encountered in the routine post-
mortem neuropathological examination.
miRNA expression in AD shows high region- and stage-
dependent regulation (Cogswell et al. 2008; Hébert et al.
2008; Delay et al. 2012; Lau et al. 2013; Femminella et al.
2015). In this regard, Lau et al. showed down-regulation of 20
miRNAs and up-regulation of 15 miRNAs in the total hippo-
campus of 41 AD cases when compared to 23 controls.
Temporal analysis was also performed in the pre-frontal cortex
in a second cohort of 49 cases of AD at stages III-IVand V-VI
(Lau et al. 2013). Here, we selected four miRNAs which have
been implicated in pathological aspects of AD such as
miRNA-27a-3p, miRNA-124-3p, and miRNA-132-3p
(Cogswell et al. 2008; Hébert et al. 2008; Smith et al. 2011;
Delay et al. 2012; Fang et al. 2012; Lau et al. 2013; Wong
et al. 2013; Salta et al. 2016), or its expression is altered in
blood as miRNA-143-3p (Cheng et al. 2014). Our focus was
on the early stages of NFT pathology (stages I-II and III-IV)
and in those regions which are first affected byNFT pathology
in aging and AD. Expression levels of selected miRNAs were
assessed by RT-qPCR in LC, entorhinal cortex, CA1 region of
the hippocampus, and dentate gyrus. This was accompanied
by in situ hybridization in tissue sections of a limited number
of cases just to identify cellular localization.
Material and Methods
Human Cases
Human brain tissue was obtained from the Institute of
Neuropathology Brain Bank (HUB-ICO-IDIBELL Biobank,
Barcelona, Spain) following the guidelines of Spanish legis-
lation and the approval of the local ethics committee.
Onehemispherewas immediatelycut into1-cm-thickcoronal
sections, and selected areas of the encephalon were rapidly dis-
sected, frozen on metal plates over dry ice, placed in individual
air-tight plastic bags, numbered with water-resistant ink, and
stored at− 80 °C. The other hemispherewas fixed by immersion
in 4% buffered formalin for 3 weeks for morphologic studies.
Neuropathological categorization was performed according to
the Braak and Braak classification adapted for paraffin sections
(Braak et al. 2006). Early-onset familial AD cases were not in-
cluded. Since first stages of NFT pathology are not associated
with β-amyloid deposits, we cannot exclude the possibility that
several cases in the present series could be classified as primary
age-related tauopathy (PART) (Crary et al. 2014). Cases with
associated neurodegenerative processes (i.e., Lewy body dis-
ease, TDP43 proteinopathy, and other tauopathies such as
argyrophilic grain disease and aging-related tau astrogliopathy
(ARTAG)), vascular diseases, andmetabolic syndromewere not
included. Importantly, cases with systemic inflammatory, auto-
immune, and infectious diseaseswere rejected. Special care was
also taken to not include cases with hypoxia and prolonged ago-
nal state (patients subjected to intensive care). Cases with minor
changes consistent with small blood vessel disease were accept-
able for the present purpose. Middle-aged (MA) cases with no
neurological disease and no lesions at post-mortem neuropatho-
logical examinationwere used as controls. A total of 114 human
samples of four different regions—locus coeruleus (LC), ento-
rhinal cortex (EC), CA1 region of the hippocampus, and dentate
gyrus (DG)—from 75 cases were selected for this study includ-
ing 19 middle-aged (50.5 ± 7.3 years), 31 stage I-II
(69.2 ± 9.1 years), and 25 stage III-IV (78.6 ± 7.1 years) cases.
Not all regions were available in every case. The summary of
cases and samples analyzed is shown in Table 1.
RNA Purification
Purification of RNA from LC, EC, CA1, and DG was carried
out with RNeasy Lipid Tissue Mini Kit (Qiagen GmbH,
Hilden, Germany) following the protocol provided by the
manufacturer. Quality of isolated RNA was first measured
with BioAnalyzer Assay (Agilent Technologies, Palo Alto,
J Mol Neurosci (2017) 63:206–215 207
Table 1 Summary of control
(middle-aged: MA) and cases at
Braak and Braak stages I-II and
III-IV used for RT-qPCR analysis
RIN
Number Braak &Braak Age Sex PM LC EC CA1 DG
1 I-II 61 M 03 h 40 min 6.9
2 I-II 64 F 02 h 15 min 7.3
3 I-II 58 M 08 h 00 min 6.7
4 I-II 79 F 03 h 35 min 7.3
5 I-II 79 F 06 h 25 min 7.1
6 I-II 64 M 04 h 35 min 6.4
7 I-II 66 M 09 h 45 min 6.6
8 I-II 73 M 07 h 05 min 6.4
9 I-II 56 F 08 h 00 min 6.7
10 I-II 67 M 14 h 40 min 6.6
11 I-II 70 M 02 h 00 min 7.9
12 I-II 61 M 04 h 30 min 6.6
13 I-II 65 M 05 h 00 min 6.9
14 I-II 77 F 03 h 15 min 7.2
15 I-II 79 M 04 h 15 min 7.2
16 I-II 83 M 04 h 30 min 8.0
17 I-II 71 M 05 h 15 min 6.6 7.1
18 I-II 86 F 04 h 15 min 7.4
19 I-II 85 M 03 h 45 min 8.2
20 I-II 66 M 05 h 45 min 6.7 6.6
21 I-II 77 M 02 h 55 min 7.0
22 I-II 55 F 09 h 30 min 6.9
23 I-II 66 M 14 h 00 min 6.4
24 I-II 68 F 04 h 30 min 7.6 7.3 7.1
25 I-II 55 M 09 h 45 min 6.5 7.5 6.6
26 I-II 57 M 04 h 30 min 7.6 8.0
27 I-II 69 M 03 h 45 min 7.0 8.0
28 I-II 80 M 03 h 30 min 7.3
29 I-II 78 M 12 h 00 min 6.5 7.2
30 I-II 72 F 04 h 00 min 7.4
31 I-II 60 M 02 h 35 min 5.9
32 III-IV 83 M 18 h 00 min 6.8
33 III-IV 77 F 11 h 30 min 6.7
34 III-IV 81 M 04 h 00 min 6.5
35 III-IV 78 F 06 h 00 min 7.0
36 III-IV 82 M 03 h 45 min 6.8
37 III-IV 77 M 04 h 10 min 6.3 7.3
38 III-IV 65 F 04 h 10 min 6.8 7.2
39 III-IV 69 M 13 h 10 min 7.7
40 III-IV 80 M 04 h 20 min 6.7 7.2 7.8
41 III-IV 67 F 06 h 10 min 6.6
42 III-IV 90 F 04 h 00 min 7,2 6.9 7.1 7.5
43 III-IV 79 F 03 h 35 min 7.7 6.9
44 III-IV 73 M 04 h 15 min 8.1
45 III-IV 77 M 05 h 40 min 6.4
46 III-IV 76 F 03 h 50 min 6.5
47 III-IV 82 F 04 h 50 min 6.4
48 III-IV 79 F 03 h 40 min 6.5 6.9
49 III-IV 82 F 03 h 05 min 6.4 6.8 6.4
50 III-IV 75 M 03 h 25 min 6.3 7.3
51 III-IV 76 M 06 h 00 min 6.0
52 III-IV 74 M 04 h 45 min 6.6
53 III-IV 99 F 05 h 00 min 7.3 7.1
54 III-IV 79 M 04 h 15 min 7.0
55 III-IV 89 M 03 h 20 min 7.5 6.4
56 III-IV 77 M 19 h 00 min 8.1
57 MA 66 F 04 h 15 min 6.9
58 MA 40 M 05 h 10 min 6.3
59 MA 44 M 06 h 40 min 7.0
60 MA 52 M 03 h 00 min 6.50 7.10 7.2
61 MA 50 F 14 h 30 min 6.6
62 MA 50 M 17 h 15 min 6.6
63 MA 48 F 04 h 00 min 6.7 8.1
64 MA 54 F 06 h 45 min 6.3 6.4
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CA). RIN values in human cases are indicated in Table 1. The
concentration of each sample was obtained from A260 mea-
surements with Nanodrop 1000 (Thermo Scientific,
Wilmington, DE). RNA integrity was tested using the
Agilent 2100 BioAnalyzer (Agilent). No association between
post-mortem delay and RNA integrity was found.
Retrotranscription and Quantitative PCR (RT-qPCR)
miRNAs were reverse-transcribed and individually quantified
via miRNA-specific primers using the TaqMan® microRNA
RT kit (Applied Biosystems, USA) and the associated
microRNA-specific stem-loop primers (TaqMan® microRNA
assay kit). Primer IDs were as follows: 001182 (miRNA-124-
3p), 000408 (miRNA-27a-3p), 000457 (miRNA-132-3p), and
002249 (miRNA-143-3p). RT product was mixed with
TaqMan® Universal PCR Master Mix and TaqMan®
microRNA assay and run using an Applied Biosystems
7900HT real-time PCR instrument (Applied Biosystems). PCR
reactions for each sample were run in duplicate, including blank
controls without cDNA. Normalization, which showed no ex-
pression alteration between the analyzed groups of samples,was
performed using RNU44. Shapiro-Wilk normality test was ap-
plied. After evaluation of non-parametric data distribution,
Kruskal-Wallis test was used to evaluate statistical differences
between groups. Dunn’s multiple test comparison was used for
post hoc analysis. Values of p<0.05were considered significant
(*p<0.05;**p<0.01;***p<0.001).Sincealterationsbetween
RNA expression profiles and RNA quality, as well as with the
neuropathological state of the brain tissue/cognitive status, have
been recently reported (Vermeulen et al. 2011; Barbash et al.
2017), correlationanalyseswereperformed inorder todetermine
potential associations between RIN values and post-mortem
timingwithmiRNAexpression levels.However, noassociations
were detected (Spearman rank correlations p > 0.05).
In Situ Hybridization
Fixation lasted for no more than 4 weeks, paraffin embedding
was performed at 57 °C, and tissue sections 6 μm thick were
obtained with a sliding microtome, mounted on glass slices
and stored at 4 °C until use. All these procedures were carried
out in RNase-free medium. Three cases were used for each
one of the groups: MA, stages I-II, and stages III-IV. For
miRNA detection, locked nucleic acid (LNA)-modified
probes, which achieve high sequence specificity, low second-
ary structure, and minimal self-annealing, combined with sig-
nal amplification technology using enzyme-labeled immuno-
assay were obtained from Exiqon (Vedbaek, Denmark). The
following double-digoxigenin (DIG)-labeled sequences of
LNA probes were used: hsa-microRNA-124-3p: 5′-DIG/
ggcattcaccgcgtgcctta/DIG-3′, hsa-microRNA-143-3p: 5′-
DIG/gagctacagtgcttcatctca/DIG-3′, and hsa-microRNA-27a:
5′-DIG/gcggaacttagccactgtgaa/DIG-3′. The sequence for the
U6 snRNA was 5′-DIG/cacgaatttgcgtgtcatcctt/-3′. U6 was
used as positive control of specific nuclear staining. Six-
micrometer-thick human tissue sections were de-waxed, de-
proteinized with 15 μg/ml protease K at 37 °C for 10 min,
washed in PBS, and dehydrated in increasing concentrations
of ethanol. The probe hybridization was performed overnight
at 55 °C (miRNA-143, miRNA-27a-3p, U6 snRNA) or at
59 °C (miRNA-124-3p) with 100 nM for miRNA-143-3p
and miRNA-27a, 40 nM for miRNA-124-3p, and 1 nM for
U6 snRNA of LNA probe diluted in hybridization mix. After
stringent washing in salt sodium citrate (SSC) buffer and
blocking with 2% sheep serum/1% bovine serum albumin,
probe-target complex was visualized immunologically with
anti-DIG antibody (Roche, 1:800) conjugated to alkaline
phosphatase acting on the chromogen NBT/BCIP. In some
cases, slices were counterstained with nuclear fast red
(Vector Laboratories, Burlingame, CA, USA). In situ hybrid-
ization for miRNA-132-3p was unsuccessful in our hands.
Table 1 (continued)
RIN
Number Braak &Braak Age Sex PM LC EC CA1 DG
65 MA 52 M 04 h 40 min 7.0 6.7 7.2
66 MA 52 F 05 h 45 min 6.1 6.6 6.2 6.7
67 MA 57 M 05 h 20 min 7.3 7.2
68 MA 41 M 11 h 35 min 5.9 6.8 6.9
69 MA 60 F 11 h 30 min 6.5
70 MA 47 M 10 h 25 min 6.4
71 MA 35 M 17 h 00 min 6.4
72 MA 59 M 08 h 30 min 6.6 6.2
73 MA 51 F 04 h 00 min 8.1 7.7 8.3
74 MA 54 M 08 h 45 min 6.8 6.8
75 MA 48 F 14 h 30 min 6.0
F female,Mmale, PM post-mortem delay, RIN RNA integrity number, LC locus coeruleus, EC entorhinal cortex,
CA1 region of the hippocampus, DG dentate gyrus
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Results
Analysis of miRNA expression levels obtained by RT-qPCR
using Taqman-specific primers showed marked regional differ-
ences (Fig. 1). Major alterations were observed in the LC, as
miRNA-27a-3p, miRNA-124-3p, and miRNA-143-3p showed
a trend to increase or a significant increase at stages I-II (p=0.07,
p = 0.12, and p = 0.02, respectively) and were significantly up-
regulated at stages III-IV (p = 0.01, p = 0.03, and p = 0.001,
respectively) when compared to MA. miRNA-132-3p showed
a significant increase at stages I-II (p = 0.01).
In contrast, only miRNA-143-3p was up-regulated in the EC
at stages III-IV when compared with MA (p = 0.001) and has a
tendency to increase at stages I-II (p = 0.1). Expression levels of
miRNA-27a-3p, miRNA-124-3p, and miR132-p were not
modified.
Fig. 1 miR-27a-3p, miR-124-3p,
miR-132-3p, and miR-143-3p
expression levels in the locus
coeruleus, entorhinal cortex, CA1
region, and dentate gyrus in
middle-aged (MA) and stages I-II
and III-IVof BFT pathology as
revealed by RT-qPCR.
Expression levels are normalized
with RNU44. Comparisons
between groups are assessed with
the Kruskal-Wallis test followed
by Dunn’s multiple test
comparison for post-hoc analysis;
#trend with no significant
difference. * p < 0.05; **
p < 0.01; *** p < 0.001
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No modifications in the expression levels of miRNA-27a-
3p, miRNA-124-3p, miRNA-132-3p, and miRNA-143-3p
were observed in the CA1 region at any stage.
Finally, miRNA-124-3p was significantly down-regulated
(p = 0.0001) in the DG at stages I-II and showed a trend to
decrease at stages III-IV (p = 0.09). Expression levels of
miRNA-27a-3p, miRNA-132-3p, and miRNA-143-3p were
not modified in the DG at any stage.
No modifications in the expression levels of miRNA-27a-
3p, miRNA-124-3p, miRNA-132-3p, and miRNA-143-3p
were observed in the CA1 region at any stage.
Gender differences have been reported in the prevalence
and cognitive function in AD. After stratification of RT-
qPCR results, absence of gender-dependent differences on
miRNAwas detected (p > 0.05).
In situhybridizationofmiRNA-27a-3p,miRNA-124-3p, and
miRNA-143-3was carried out in a few slices containing theEC,
CA1, and DG (Fig. 2). miRNA-143-3p was expressed in the
cytoplasm of neurons in every case whereas miRNA-27a-3p
staining was in the cytoplasm and nucleus of neurons. U6 small
nuclear RNAwas used as a positive control of specific nuclear
staining (data not shown). miRNA-124-3p was expressed in the
cytoplasm of neurons. In situ hybridization of miRNA-124-3p
and miRNA-143-3p in the LC revealed expression localized in
the cytoplasm of neurons (Fig. 3). Because of the lownumber of
cases in every group, no attemptwasmade to quantify the in situ
hybridization signal in tissue sections.
Discussion
The present findings support the concept that marked dif-
ferences exist among miRNAs, brain regions, and age-
related Braak and Braak stages of NFT pathology. Since
MA cases are younger than those with NFT pathology, it
cannot be established as a working hypothesis that modi-
fications in miRNA expression are partly due to aging. In
this line, it is worth stressing that about 85% of individuals
aged 65 years have at least stages I-II of NFT pathology
(Ferrer 2012). Whether such early stages at this age are
normal aging or first stages of a degenerative process
named AD or PART is not solved. A limitation of the study
is the modest cohort of cases analyzed due to the low
availability of neuropathologically well-characterized AD
samples from the selected brain regions.
miRNA-27a-3p was previously reported up-regulated in
the cerebellum, hippocampus, middle-frontal gyrus, and
pre-frontal cortex in AD (Cogswell et al. 2008; Hébert
et al. 2008; Delay et al. 2012; Lau et al. 2013). The present
findings do not support these data in the EC, CA1, and DG,
at least at stages I-II and III-IV of NFT pathology.
However, miRNA-27a-3p is up-regulated in the LC at
these stages. In situ hybridization shows miRNA-27a-3p
localization in the cytoplasm and nuclei of neurons.
Mature forms of miRNA-92a, miRNA-25, miRNA-27a,
and miRNA-92b have been found in nuclear structures
(Politz et al. 2009) and nuclear-enriched fractions of pri-
mary cultured neurons (Khudayberdiev et al. 2013).
Although the precise function of nuclear miRNAs and oth-
er RISC components is unknown, some studies suggest
roles in post-transcriptional gene silencing/activation,
miRNA storage, alternative splicing, and chromatin struc-
ture (Liang et al. 2013; Roberts 2014).
miRNA-124-3p expression has been reported as unal-
tered in pre-frontal cortex (Lau et al. 2013), moderately
decreased in the anterior temporal cortex (Smith et al.
2011), and decreased in the hippocampus (Lau et al.
2013) in AD. miRNA-124-3p is up-regulated in the LC at
stages I-II and III-IV, not modified in EC and CA1, and
reduced in the DG at stages I-II, in the present series.
miRNA-124-3p is expressed in neurons and regulates a
broad range of genes involved in synaptic plasticity, mem-
ory functions, and neuronal development, among others
(Jovičić et al. 2013; Sun et al. 2015; Gu et al. 2016; Li
and Ling 2017). miR-124 has been reported to play a pro-
tective role in β-amyloid-mediated toxicity by targeting
BACE 1 (Fang et al. 2012). Yet, no relation is found be-
tween lack of β-amyloid deposition in these structures at
early stages of NFT pathology and miRNA-124-3p de-reg-
ulation. miRNA-124 also induces protection after focal is-
chemia and in experimental models of Parkinson’s disease
(Hamzei Taj et al. 2016; Saraiva et al. 2016).
On the other hand, miRNA-132 is a highly conserved and
stress-responding miRNA (Haviv et al. 2017) involved in a
broad range of neuronal functions such as neuronal plasticity
and activity (Magill et al. 2010; Hansen et al. 2010) in agree-
mentwith its specific neuronal localization detected in our in
situ hybridizations. miRNA-132 regulates differentiation of
dopaminergic neurons (Yang et al. 2012), is amajor regulator
of the cholinergic system (Maharshak et al. 2013), and seems
to play a role inADpathogenesis as its decrease augmentsβ-
amyloid deposition in transgenic mice (Hernandez-Rapp
et al. 2016; Salta and De Strooper 2017). miRNA-132-3p
expression is down-regulated in several brain regions, in-
cluding the hippocampus and prefrontal cortex in AD brains
(Cogswell et al. 2008; Smith et al. 2011; Salta et al. 2016).
Down-regulation of miRNA-132-3p in AD brain has been
associated with neuronal tau hyper-phosphorylation (Lau
et al. 2013; Salta et al. 2016) and with β-amyloid (Smith
et al. 2011). Yet, the present findings show no changes in
EC, CA1, and DG but miRNA-132-3p up-regulation in the
LC. In this regard, it is worth noting that tau-hyper-
phosphorylation is present in the LC, EC, and CA1 whereas
no tau pathology is found in the DG; β-amyloid is absent in
the LC and only scarce in the hippocampus at the assessed
stages of NFT pathology. It can be argued that miRNAs may
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have different functions in different settings/regions and
when acting in combination with other miRNAs, but this
suggestion must be sustained by more robust experimental
data.
miRNA-143-3p expression is elevated in blood in AD
(Cheng et al. 2014). Interestingly, miRNA-143-3p is sig-
nificantly up-regulated in the LC and EC in the present
series. In situ hybridization has shown localization in neu-
rons; therefore, it cannot be established that increased
miRNA-143-3p expression in EC is due to increased num-
bers of astrocytes. miRNA-143-3p has been linked to mus-
cle aging and altered muscle regeneration (Soriano-
Arroquia et al. 2016). However, no information is avail-
able, as far as we know, regarding effects of miR-143-p
regulation in brain.
The focus of the present study is on the LC, in which up-
regulation of four miRNAs is found with disease progres-
sion at early stages of NFT pathology. It is important to
stress that the LC is the main source of noradrenergic in-
nervations of the cerebral cortex and that LC is the main
noradrenergic nucleus affected in AD (Zarow et al. 2003).
Moreover, LC is one the first regions of the brain showing
NFTs in the context of AD-related pathology (Rub et al.
2001; Simic et al. 2009; Attems et al. 2012; Andrés-Benito
et al. 2017; Šimić et al. 2017). De-regulation of molecular
pathways in LC has important implications in the control
of arousal, attention, sleep-awake cycles, emotional states,
cognition, memory, and learning, among others, all of
which are altered in AD (Aston-Jones and Cohen 2005;
Szabadi 2013; Šimić et al. 2017).
Fig. 2 Localization of miRNA-
27a-3p, miRNA-124-3p, and
miRNA-143-3p in the dentate
gyrus (a, d, g), CA1 region of the
hippocampus (b, e, h), and
entorhinal cortex (c, f, i) in a case
with NFT pathology at stage I-II
as revealed by in situ
hybridization. miRNA-27a-3p is
localized in the cytoplasm and
nuclei of neurons whereas
miRNA-124-3p and miRNA-
143-3p are localized only in the
cytoplasm of neurons. Paraffin
sections without counterstaining,
bar = 100μm; bar inserts = 10μm
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Conclusion
Our working hypothesis was that similar alterations might be
found in EC (at least) and LC because these structures are first
targets ofNFTpathologywith age. Present findings indicate that
miRNAchanges are independent of tau-phosphorylationandare
likely not related to neuron loss as no neuronal loss is found at
these stages of NFT pathology in LC (Rodríguez et al. 2012;
Arendt et al. 2015). However, involvement of the LC at early
stages of NFT pathology has important functional implications:
loss of synapses in spite of preserved tyrosine hydroxylase (TH)
immunoreactivity is found inNFT-containingneuronsofLC,but
decreased TH and increased α2A adrenergic receptor protein
levelsoccurin thehippocampusandtheamygdalawhichprimary
targets noradrenergic innervations (Andrés-Benito et al. 2017).
These observations shift the focus of the present observations to
the LC and to its participation in non-cognitive symptoms in
agingandADincludingalteredmoodanddepression. In this line,
miRNA-124-3p has been postulated as a putative epigenetic sig-
nature of major depressive disorder (Roy et al. 2016). In short,
they suggest that certain miRNAs may participate in the devel-
opment of non-cognitive symptoms in aging and early stages of
AD bymodulating the function of the LC.
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8.    Discussion 
 
8.1    miRNA research in human prion diseases and Alzheimer’s 
disease 
 
Increasing evidences postulate alterations in miRNA signatures in NDs as critical 
factor in pathogenesis, progression and prognosis of diseases (Abe and Bonini 
2013a; Hébert and De Strooper 2009a; Femminella, Ferrara, and Rengo 2015; 
Bellingham and Hill 2017; Tan, Yu, and Tan 2015). However, different levels of 
progress and insights in miRNA expression patterns and miRNA-regulated gene 
networks have been achieved in the brain of patients afflicted with 
neurodegenerative conditions. The presented publications provided 
comprehensive characterizations of miRNA signatures in sCJD and during early 
AD-type NFT pathology, revealing crucial insights in the role of miRNA 
deregulation in NDs. The studies complement previous research and develop 
significantly the understanding of miRNA dysregulation in ND.  
 
8.1.1    Current status and progress in miRNA research in human prion 
diseases 
 
Evaluation of miRNA alterations in human prion diseases are limited to targeted 
studies in the brain of sCJD (Montag et al. 2009; Lukiw et al. 2011) and GSS 
patients (Lukiw et al. 2011). When identifying miRNA alterations during disease, 
the major issues in these studies are the small number of patients, controls and 
different brain regions analysed. Additionally, the miRNAs screens were performed 
to identify the expression of specific brain miRNAs suggested to be involved in 
prion diseases. Comprehensive and temporally analysis of miRNAs expression in 
human prion diseases are clearly needed to determine global expression 
signatures in disease affected brain regions in order to understand which miRNA-
controlled molecular networks are impaired during disease. In order to capture 
fully miRNA changes, it is necessary to conduct miRNA quantifications in a large 
number of patients by a combination of different analytical techniques and 
methodologies.  
In the presented publication I, we identified for the first time global miRNA 
expression alterations in the frontal cortex and cerebellum of sCJD. We 
demonstrated that the miRNA expression patterns in two sCJD subtypes, MM1 
and VV2, are highly changed in a regional and disease subtype-dependent 
manner correlating with neuropathological affection, which suggests specific 
functional roles of the miRNA network in sCJD pathology as potential driving 
factors in disease etiology. In order to characterize the cellular environment of 
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miRNA dysregulation, a neural-type specificity of altered miRNAs was unveiled by 
in situ assays.  
Potential underlying aberrant mechanisms leading to massive alteration of the 
miRNA patterns in sCJD were investigated. By analyzing the key proteins involved 
in miRNA biogenesis, we observed reduced levels of the miRNA-processing 
RNases Drosha and Dicer as well as the microprocessor complex subunit DGCR8 
in frontal cortex and cerebellum in sCJD, pointing out strong evidences for 
impaired miRNA biogenesis machinery in the late stages of sCJD.   
A sCJD mouse model that recapitulates faithfully sCJD neuropathology in the 
brain (Padilla et al. 2011; Llorens et al. 2014), provided insights into pathological 
processes during preclinical phases of the sCJD progression. The observed 
miRNA signature of the sCJD mouse model resembled the miRNA expression 
patterns in sCJD brain. Temporal miRNA expression analysis in the sCJD mouse 
model revealed a link between regional pathology and miRNA dysregulation 
during disease progression, indicating functional implications of the deregulated 
miRNA network in sCJD pathology. 
In cross-disease validation studies, we detected that specific sCJD-regulated 
miRNAs are commonly altered in alternative NDs such as AD, dementia with Lewy 
bodies (DLB) and FFI, shedding light shedding light into potential common miRNA-
related mechanisms in the neurodegenerative processes. 
It has been demonstrated that miRNA expression levels, biogenesis, cellular 
abundance and miRNA function are differentially regulated in tissue of origin 
(Gulyaeva and Kushlinskiy 2016; Schanen and Li 2011a). Therefore systematic 
characterizations of putative regulators of cellular- and tissue-specific miRNA 
expression and function are essential for the understanding of miRNA function in 
pathophysiological processes during human prion disease. This entails, for 
instance, the context-specific characterisation of miRNA biogenesis machinery, 
formation of silencing complex RISC, P-bodies and stress granules, transcription 
factors, RNA-binding proteins, isomeric miRNA sequences, and the cellular 
environment of miRNAs during disease. Under consideration of context-specific 
factors, different experimantal procedures in relevant tissue or cell types modelling 
disease conditions are essential to investigate how miRNAs regulate complex 
gene networks in disease. Experimental disease models resembling cellular 
environment and gene networks including the expression of disease-associated 
miRNAs patterns and tissue specific target genes are needed to determining what 
genes are regulated by a miRNAs during disease (Akbari Moqadam, Pieters, and 
Den Boer 2013). 
Gaining a complete picture of the global disease-associated miRNA signatures, 
context-specific factors and the neural cell types in which miRNA dysregulation 
occurs will be the first step to open new research lines for identification of miRNA 
targets and complex miRNA-regulated networks during disease. 
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8.1.2    Current status and progress in miRNA research in AD 
 
Global and temporally alterations of miRNA signatures in the brain of AD patients 
have been identified revealing altered miRNA networks which are associated to 
brain regional and disease stage-dependent features of AD pathology (Lau et al. 
2013; Cogswell et al. 2008; Hebert et al. 2008; Müller et al. 2014; Delay, 
Mandemakers, and Hébert 2012). Moreover, experimental evidences have linked 
specific miRNA changes to AD pathogenesis (Delay and Hébert 2011; Cai, Zhao, 
and Zhao 2012; Banzhaf-Strathmann et al. 2014; Smith et al. 2015; Hernandez-
Rapp et al. 2016). However, less information are available about miRNA 
alterations during initial stages of AD. The LC is one of the earliest regions 
affected by consistent and severe neuronal dysfunction and loss during early AD 
stages, which has been linked to noradrenalin depletion of the projection areas in 
the forebrain region (Andrés-Benito et al. 2017; Weinshenker 2008; Giorgi et al. 
2017). 
In the presented publication II, we performed miRNA expression profiling in the 
LC, EC, hippocampal CA1 region and dentate gyrus at early and mid-stages of 
Braak NFT pathology. The profiled miRNAs were selected according to their 
described implications in pathological aspects in AD. Using the expertise of 
characterization miRNA signatures in sCJD by the use of different analytical 
techniques and methodologies, we aimed to extent our studies by analyzing the 
expression of selected miRNAs reported to be involved in Alzheimer's disease 
pathology. 
We provided for the first time insights into crucial miRNA expression alterations in 
the LC during early NFT pathology before AD-associated neuronal death is 
evident. In the LC, the miRNA-27a-3p, miRNA-124-3p, and miRNA-143-3p 
showed a trend to increase their expression at early stages (Braak I-II) and they 
were found significantly upregulated at mid-stages (Braak III-IV) of disease. Only 
miRNA-143-3p has been found upregulated in EC at mid-stages of disease. None 
of the profiled miRNAs revealed expression alterations in the hippocampal CA1 
region, while miRNA-124-3p was downregulated in DG at early stages of NFT 
pathology.  
The characterization of the cellular miRNA environment via in situ hybridization 
assays revealed that the deregulated miRNAs are localized in the cytoplasm of 
neurons during NFT pathology progression. Additionally, miRNA-27a-3p has been 
shown to be localized in the nucleus. 
We provided strong evidences that the observed miRNA alterations are involved in 
the early AD pathology. Weather the altered miRNAs are involved in the selective 
neuronal degeneration in early AD stages, or representing neuroprotective 
compensatory pathways during early disease evolution is not clear.  
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8.2    Profiling disease-associated miRNA signatures in sCJD and 
early AD-type neuropathology 
 
We aimed to identify disease-associated miRNA expression patterns during critical 
disease stages in the brain of sCJD and during early AD-type NFT neuropathology. 
In publication I, we were able to gain a comprehensive picture of global miRNA 
expression changes in the frontal cortex and cerebellum in clinical stages of sCJD. 
In publication II, we successfully performed miRNA expression analyses during the 
first stages of NFT formations in the LC, EC, hippocampal CA1 region and dentate 
gyrus. Thereby, we intended to perform a targeted expression profiling of miRNAs 
that have been suggested to be implicated in AD pathogenesis in brain regions 
vulnerable to early AD-type NFT pathology. 
 
8.2.1    Spatial and cellular miRNA profiling in the brain of sCJD patients 
 
For the first time, we provided comprehensive miRNA expression analysis in 
postmortem human sCJD brains revealing regional- and subtype-specific miRNA 
signatures. We used small RNA sequencing (RNAseq) analysis and quantitative 
polymerase chain reaction (qPCR) validation to profile the miRNA expression 
changes in two brain areas of two sCJD subtypes in a sufficiently large cohort of 
sCJD patients and controls. Our work clearly demonstrates that the miRNA 
expression is altered in sCJD brain, with 70 miRNAs significantly altered in the 
frontal cortex of sCJD MM1 and 27 in sCJD VV2 compared to controls. In the 
cerebellum, 22 miRNAs were found altered in sCJD MM1 and 69 in sCJD VV2 
compared to controls. Through the use of independent pipelines for the differential 
miRNA expression analyses, Seqbuster (Pantano, Estivill, and Martí 2009) and 
OASIS (Capece et al. 2015), we aimed to achieve reproducible and accurate 
representations of the transcriptional miRNA expression changes in sCJD. Indeed 
a high degree of coincidence between both pipelines (~ 89%) in detecting 
differentially expressed miRNAs was achieved. RNAseq provides the opportunity 
of high-throughput small RNA quantification on single-nucleotide level, however, 
the technology can introduce bias, for instance during small RNA library 
preparation method, or while detecting low copy number transcripts resulting in 
less sensitive RNAseq results (S. M. Smith and Murray 2012; Pritchard, Cheng, 
and Tewari 2012). In order to confirm the RNAseq data and to ensure an 
accurately quantification of miRNA transcripts in the brain samples, we 
successfully validated the observed differential expression of a subset of miRNAs 
in sCJD via qPCR analysis.  
Our results revealed miRNA alterations that are highly changed in a regional and 
disease subtype-dependent manner, while the most of the recorded expression 
changes show low overlap in the brain of the sCJD subtypes MM1 and VV2. In 
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particular, the differing degree of pathological severity reported between sCJD 
subtypes in the frontal cortex and cerebellum, appears to be reflected in the 
degree of miRNA alterations in number and fold change. The neuropathological 
patterns in sCJD show in general a more prominent cortical involvement in MM1, 
while a more cerebellar involvement is evident in the brain of VV2 patients (Parchi 
et al. 1999; Parchi et al. 2009; Llorens et al. 2013; Gambetti et al. 2003). The 
underlying molecular mechanisms leading to the selective vulnerability and 
neuropathological phenotypes of different brain regions among sCJD subtypes are 
still elusive (Jackson 2014). The observed miRNA dysregulation in sCJD could be 
a contributing factor in favoring neurodegenerative processes in disease affected 
brain regions. More precisely, the miRNA alterations have the potential to be 
involved in the diverse sCJD pathogenesis at multiply molecular level including 
neuronal dysfunction and death (Gabor G. Kovacs and Budka 2010), changes in 
gene expression networks (Kanata et al. 2018), dysregulation of 
neuroinflammatory response (Franc Llorens et al. 2014; Franc Llorens, Schmitz, 
Knipper, Schmidt, et al. 2017), endoplasmic and oxidative stress (Tahir et al. 
2016), cellular alterations in the Ca2+ homeostasis and activation of Calpain-
Cathepsin axis (Llorens, Thüne, Sikorska, et al. 2017), changes in PrP metabolism 
(Llorens et al. 2013). 
To understand the contribution of miRNA dysregulation to disease, it is essential to 
integrate the reported miRNA alterations into the complex cellular context of the 
brain. It is supposed that different brain cell types including neuronal networks, as 
well as microglia and astrocytes contribute to neurodegenerative processes in a 
cell-type specific and temporal manner (Majer et al. 2012; F. Llorens et al. 2013; 
Aguzzi and Liu 2017; Franceschini et al. 2018). Our miRNA expression profiling 
via RNAseq and qPCR validation in sCJD brain was performed on bulk tissue, 
which implies challenges for the interpretation of miRNA expression signatures in 
unique cells and cell types. The RNAseq data provides limited information, 
weather a miRNA and its putative target is coexpressed in the same cell. 
Moreover, miRNAs that are expressed only in a subgroup of cells or cell 
compartments might be mask during RNAseq analyses of brain tissue due to the 
effect of averaging the number of miRNA transcripts over the entire pool of cells 
(Koshiol et al. 2010; Chugh and Dittmer 2013). Especially, the heterogeneous 
nature of brain cells and their complex cellular reactions in sCJD needs to be 
considered in order to gain insights in the role of miRNA dysregulation in disease.  
In order to gain cellular resolution of reported miRNA expression changes in sCJD, 
we successfully performed miRNA in situ hybridization assays of miR-124-3p, 
miR-26a-5p and miR-146a-5p in human brain tissue of sCJD MM1 and age-
matched control brains. We demonstrated that the miRNAs, which we found 
altered in sCJD, are mainly localized in neuronal cytoplasm. Additionally, miR-
146a-5p was found in small cells compatible to glial cells. While analyzing the 
cellular context of miR-124-3p, we observed that the overall miRNA signal was 
reduced and decreased numbers of neurons were detected in sCJD compared to 
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control brains, which stands in agreement with RNAseq and qPCR data. The 
provided insights into the cellular miRNA context via semiquantitative in situ 
hybridization analysis, represents an important complement to the miRNA 
expression profiling on bulk tissue level.  
The brain-enriched, NF-kB-sensitive miR-146a-5p has been suggested to mediate 
inflammatory microglial responses in prion diseases (W. J. Lukiw et al. 2011; Saba 
et al. 2008). Interestingly, we demonstrated strong evidences for a neuronal miR-
146a-5p expression, additionally to glial cells, in sCJD brain. This observations 
stands in agreement with neuronal miR-146a-5p upregulation in animal prion 
disease models (Majer et al. 2012; Boese et al. 2016), suggesting a miR-146a-5p 
upregulation in neurons induced by potential pathological pro-inflammatory and/or 
neurotoxic stimuli during prion disease progression. miR-146a-5p overexpression 
was also reported in AD brain (Müller et al. 2014; Sethi and Lukiw 2009), 
associated to  different brain cell type context including neurons (Wang et al. 2016) 
and astrocytes (Arena et al. 2017; Cui et al. 2010). In vitro studies suggest that 
variable miR-146a-5p expression in the different brain cell context, contributes to 
cell-type specific behavior during neuroinflammation (Li et al. 2011).  
Beside its role in neurogenesis and neuronal development, the neuron-enriched 
miR-124-3p has been described to be constitutively expressed in differentiated 
neurons. In this context, miR-124-3p is proposed to target non-neuronal 
transcripts, and thereby, maintaining neuronal integrity and function (Lim et al. 
2005; Neo et al. 2014). Thus, overall miR-124-3p downregulation could reflect 
neuronal loss in sCJD. Additionally, the observation of less miR-124-3p signal 
detectable in surviving neurons, suggest a physiopathological roll of the miRNA in 
sCJD pathology.  
 
8.2.1.1    Comparison of sCJD-associated miRNA signatures with miRNA 
alterations in prion disease 
 
While comparing our observed miRNA signatures in sCJD with studies on miRNA 
alterations in human prion disease and animal models, few miRNA candidates 
appear to be commonly changed in prion disease (Table 4), reviewed in (Kanata, 
Thüne et al. 2018). The upregulation of miR-146a-5p that was reported in sCJD by 
us, was also demonstrated in sCJD and GSS (Lukiw et al. 2011), in mice infected 
with scrapie prion strains: 139A (Gao et al. 2016; Lukiw et al. 2011), Me7, S15 
(Gao et al. 2016), and 22A (Saba et al. 2008), as well as in CA1 neurons (Majer et 
al. 2012) and forebrain synaptoneurosomes (Boese et al. 2016) from scrapie RML 
infected mice. Additionally, miR-146a-5p showed a trend towards upregulation in a 
scrapie infected neuroblastoma cell linen (Montag et al. 2012). 
The downregulation of miR-124-3p in sCJD observed by us, was also reported in 
mircodissected CA1 neurons from scrapie RML strain infected mice during clinical 
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stages of disease (Majer et al. 2012). Interestingly, during pre-clinical disease 
stages, miR-124-3p appeared to be upregulated in neurons and 
synaptoneurosomes of scrapie infected mice (Majer et al. 2012; Boese et al. 
2016). Similar, the upregulation of miR-16p-5p observed in sCJD by us, was also 
reported in pre-clinical disease stages of scrapie RML strain infected mice 
followed by downregulation during clinical stages (Majer et al. 2012). When 
considering these observations, the upregulation of miR-16p-5p and miR-124-3p 
could be a common feature in preclinical prion diseases. The upregulation of miR-
26a-5p in sCJD observed by us was also reported in BSE-infected macaques 
(Montag et al. 2009). Our detected upregulation of miR-342-3p in sCJD was also 
found in scrapie strain 22A infected mice (Saba et al. 2008). 
Common miRNA signatures might indicate common miRNA-regulated disease 
mechanisms in prion disease and the functional role of reported miRNA 
candidates deserve to be dissected in future studies (Kanata, Thüne et al. 2018). 
Overall, little overlap in differential expressed miRNAs was observed between 
different studies in prion disease (Kanata, Thüne et al. 2018). This is likely 
explained by the multitude of factors that vary between analyzed tissues or cells 
as source for RNA isolation (bulk tissue, neurons, synaptoneurosomes, etc.) and 
different miRNA profiling platforms. When comparing different profiling platforms, 
reproducibility of results is often not fully achieved between different miRNA 
detection technologies and even variations within the same platforms have been 
described (Chugh and Dittmer 2013). Standardized methodology for miRNA 
detection will improve miRNA signature accuracy (Pritchard, Cheng, and Tewari 
2012). 
Importantly, in our study, we successfully profiled miRNA expression patterns in 
two brain region in sCJD by a combination of different RNA quantification 
methodology obtaining high validation rates. Via RNAseq and qPCR validation, a 
total of 14 miRNAs in the frontal cortex and 18 miRNAs in cerebellum were 
validated in sCJD MM1 (n=15) and VV2 (n=10) in compare to controls (n=15). For 
a set of altered miRNAs in sCJD, the miRNA expression profiling on bulk tissue 
level was complemented with the identification of the cellular miRNA environment 
in sCJD via miRNA in situ hybridization.  In this way, the expression changes of 
miR-124-3p have been successfully validated in sCJD in a cellular- and tissue-
specific context by the usage of three different methodology approaches. 
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8.2.1.2    Common miRNA alterations in sCJD and alternative NDs 
 
We successfully demonstrated that specific sCJD-regulated miRNAs are 
commonly altered in alternative NDs, including AD, DLB and FFI (Fig. 10). 
Considering the need for standardized miRNA profiling procedures, we analyzed 
the miRNA expression in corresponding brain regions with uniform usage of 
methodology and normalization technique to ensure miRNA signature accuracy 
(Pritchard, Cheng, and Tewari 2012). By qPCR-based profiling of six miRNAs that 
was found altered in sCJD, we observed a common regulation of miR-877-5p and 
miR-323a-5p (downregulated) and miR-195-5p (upregulated) in the frontal cortex 
of sCJD and rpAD/AD, common regulation of miR-877-5p and miR-323a-5p 
(downregulated) was detected commonly in the frontal cortex of sCJD and DLB, 
and common regulation of miR-195-5p (upregulated) was found in the frontal 
cortex and cerebellum  in sCJD and FFI. 
Our results proofed that although the analysed neurodegenerative conditions 
represent distinct disease entities, with marked differences in affected neurons, 
pathology and clinical phenotype, there might be common miRNA-regulated 
pathways. The pathogenesis of these NDs shares many common features 
including disturbed protein homeostasis, the aggregation and deposition of 
pathological altered proteins, progressive neuroinflammation, and neuronal 
dysfunction and loss. In this context, our results shedding light into potential 
common miRNA-related mechanisms in the neurodegenerative processes 
(Dugger and Dickson 2017; Ramanan and Saykin 2013; Armstrong, Lantos, and 
Cairns 2005; R. J. Castellani et al. 2004). 
 
 
Figure 10: Cross-validation of sCJD-miRNA signatures in alternative NDs: A panel of 
six miRNAs that was found altered in sCJD, was profiled in alternative NDs via qPCR. 
miR-877-5p and miR-323a-5p (downregulated) and miR-195-5p (upregulated) appeared 
commonly in the frontal cortex of sCJD and rpAD/AD. Downregulation of miR-877-5p and 
miR-323a-5p was detected commonly in the frontal cortex of sCJD and DLB. Upregulation 
of miR-195-5p in was found in the frontal cortex and cerebellum in sCJD and FFI. 
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Our observed common differential miRNA expression patterns in sCJD and 
rpAD/AD (downregulation of miR-877-5p, miR-323a-5p and upregulation of miR-
195-5p) were also reported by Lau et al. in the prefrontal cortex of late-stage AD 
supporting the robustness of our observation (Lau et al. 2013). We provided strong 
evidence for meaningful common changes in miRNA expression during NDs, 
which deserve clearly further functional exploration to unravel potential common 
miRNA-mediated molecular pathways that are relevant to these conditions. 
 
8.2.2    Temporal- and cellular resolution of miRNA alterations in early stages 
of NFT pathology in AD 
 
Genome-wide studies, uncovering global gene expression profiles in AD, provide a 
vast amount of expression data, which are used to understand the complex 
impairments of biological pathways and key regulators driving disease. However, 
experimental validations of miRNA dysregulation and their biological 
consequences based on high-scale transcriptome analyses are mostly lacking for 
AD. In order to understand the disease, it is essential to consider the behavior of 
different brain cell types over different Braak stages in relevant AD-affected brain 
regions (De Strooper and Karran 2016). With our work, we attempted to dissect to 
what extend miRNA alterations accompanied early AD-associated pathology. 
We clearly demonstrated that a set of profiled miRNAs is altered in the first Braak 
NFT stages in a brain regional- and stage-dependent manner, whereby these 
miRNAs were identified by in situ hybridization technic to be localized in neurons. 
These results suggest that the observed miRNA changes are associated to 
regional- and time-dependent characteristics of early (I-II) and middle (III-IV) Braak 
NFT stages in AD and ageing. Braak stage dependent miRNA alterations were 
also observed by Lau et al., who performed temporal analysis of global miRNA 
expression, revealing major changes between Braak stage II and III in the 
prefrontal cortex during early AD (Lau et al. 2013; De Strooper and Karran 2016). 
We provided temporally miRNA expression analysis in neuropathological 
characterized brain regions including LC, EC, hippocampus and dentate gyrus at 
early and middle stages of NFT pathology. We used qPCR-technic to profile the 
miRNAs: miR-27a-3p, miR-124-3p, miR-132-3p and miR-143-3p in four brain 
regions in a sufficiently large cohort of human samples grouped by Braak stages, 
which included 31 cases at Braak stage I-II (69,2 ± 9,1 years), 25 cases at Braak 
stage III-IV (78,6 ± 7,1 years) and 19 middle-aged control cases (50,5 ± 7,3 
years). Due to limited available age-matched cases with no age- or disease-
related Tau-pathology, we included younger age cases in our control group. 
Therefore, age-connected processes as well as early AD evolution have to be 
considered as contributing factors for the observed miRNA expression changes. 
However, no correlation between profiled miRNA expression and age was 
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observed among control group (data not shown). The age-associated brain 
pathology, termed as PART, includes formation of NFTs (low NFT Braak 
stages I-III), atrophy, and no or minimal Aβ depositions. PART is almost universal 
detectable in elderly individuals independently of AD pathology and might progress 
to an “only tangles-dementia” when advanced (Reas 2017; Crary et al. 2014). 
During neuropathological characterization, brains with NFT pathology associated 
to PART appear often indistinguishable to early AD related NFT pathology. 
Moreover, neuropathological classification of PART and early AD is mostly not 
accompanied by symptomatic impairment (Jefferson-George et al. 2017; Besser et 
al. 2017; Heiko Braak and Del Tredici 2011). Therefore, we cannot state whether 
the analyzed individuals in our study would have developed towards AD, however, 
tau-pathology occurring in the LC, EC and hippocampal region is an invariant 
feature of AD and its development (Duyckaerts et al. 2015).  
We experimentally complement the regional miRNA expression profiling with 
miRNA in situ hybridization assays to gain insights in the cellular context of miRNA 
alterations in AD. Our observations indicate that neurons from different brain 
regions, including LC, EC and DG, display distinct miRNA expression changes 
during initial AD stages (Braak I-IV) before disease-associated major neuronal loss 
becomes evident, since no significant neuronal loss occurs in the LC until Braak 
stage III (Theofilas et al. 2016). 
The qPCR technic is a reliable method for the relative quantification of miRNA 
transcripts complementing RNAseq analyses. However, our qPCR results 
revealed miRNA expression changes from a pool of different brain cells, whereby 
information regarding the cellular context of miRNA changes and cell variably in 
miRNA expression remain undetected. Therefore, we extended our miRNA 
expression profiling in AD with miRNA in situ hybridization assays in human brain 
tissue enabling crucial insights in the cellular localization of miRNAs found to be 
altered in early NFT pathology. This technic is a low-throughput approach, in which 
miRNAs were detected with lesser sensitivity and specificity than qPCR analyses, 
and therefore it was not used to quantify miRNA expression. 
We attempted to obtain appropriate methodology to map systematically the cellular 
miRNA alterations in early AD progression by the combination of miRNA 
quantification via qPCR and the cellular identification of miRNA alterations via in 
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8.3 Dysregulated miRNA patterns and their functional 
implications in sCJD and early AD 
 
In order to unravel the biological role of miRNA dysfunction and to develop 
miRNA-based drug therapeutics it is essential to understand the contribution of 
specific miRNA – mRNA target interactions as well as complex miRNA-controlled 
gene networks involved in the dysregulation of biological processes during NDs. 
However, the identification and functional characterization of miRNA dysregulation 
during disease progression remains challenging. The discovery of specific 
miRNA-gene target interactions, contributing to disease mechanisms, requires a 
broad range of experimental methods that are able to reflect in vivo disease 
processes, as well as allowing unbiased functional miRNA investigations (Seitz 
2017; Akbari Moqadam, Pieters, and Den Boer 2013). Thereby, it is important to 
identify disease-associated miRNA signatures and to investigate the cause-
consequence relationship between miRNA dysfunction and disease pathology in 
order to unravel the role of specific miRNA-controlled pathways in disease. 
Multiple miRNAs can mediate their biological function cooperatively by targeting 
the same gene, and on the other hand, each miRNA has the potential to target 
and repress the expression of up to hundred mRNAs (Davis, Haas, and Pocock 
2015; Jonas and Izaurralde 2015b). In this regard, integrative network analysis of 
the miRNA–mRNA interactome are necessary to understand the biological effects 
of miRNA dysfunction in disease context considering not only a pure miRNA 
perspective, but rather a systemic view including target genes and pathways. 
Computational prediction tools can provide a way to identify putative miRNA 
targets, which is usually based on sequence complementarity and on the selection 
of evolutionary conserved miRNA binding sites (Akbari Moqadam, Pieters, and 
Den Boer 2013; Riffo-Campos, Riquelme, and Brebi-Mieville 2016). In this regard, 
a functional miRNA enrichment analysis was performed in publication I predicting 
biological functions, such as cell death/survival and cellular development, are 
potentially affected by reported differential expressed miRNAs in sCJD. A further 
possible approach to identify miRNA targets are correlation studies between 
miRNA and mRNA/protein expression levels (Akbari Moqadam, Pieters, and Den 
Boer 2013). Using computational approaches, we could not detect obvious 
anticorrelations between miRNA and mRNA/protein expression signatures in 
sCJD. These observations could be explained by the fact that most genes have 
multiple regulators and their expression levels are functions of multiple inputs 
(Naumova et al. 2013). Moreover, it needs to be stressed that computational 
predicted miRNA targets often appear biologically irrelevant (Pinzón et al. 2017). 
Therefore, true miRNA targets can only be validated by different experimental 
procedures resembling disease conditions. 
 
  Discussion 
118 
 
8.3.1    Profiling functionally active miRNAs in sCJD 
 
One important question related to the present work is to what extent the recorded 
miRNA alterations in sCJD reflect disease related processes. The observed 
regional and disease subtype-dependent miRNA signatures have the potential to 
be directly involved in the molecular mechanisms underlying disease etiology. 
Thereby, the distinct miRNA patterns might influence the molecular pathways 
leading to the selective vulnerability of different brain regions in sCJD MM1 and 
VV2 connected to the phenotypic differences of clinical and neuropathological 
features in sCJD. On the other hand, the observed miRNA alterations might also 
result as a secondary effect of disease pathology such as the modifications of 
cellular composition, neuronal damage and/or uncontrolled neuroinflammation in 
the affected sCJD brain regions.  
We attempted to characterize the observed miRNA signatures in sCJD by different 
experimental methods, which will lead to a greater understanding of the 
contributions of miRNA dysregulation in sCJD and other NDs diseases. Our work 
provided for the first time an approach towards profiling functionally active miRNAs 
in sCJD. In this regard, we performed RISC immunoprecipitations in the frontal 
cortex of control and sCJD MM1 cases by using two different antibodies targeting 
Ago proteins (Ago-2 and Ago1-4). We analyzed the presence of miRNAs in the 
immunoprecipated Ago-containing complex and we observed that globally 
upregulated miRNAs in sCJD are also found to be enriched at their RISC complex, 
which included miR-146-5p, miR-26a-5p, miR-195-5p and miR-154-5p. We 
successfully provided a proof that alterations of miRNA signatures in sCJD are 
also leading to changed binding of mature miRNA their silencing complex. In 
follow-up studies, the purifications of functional active miRNA-mRNA complexes 
from brains can be analyzed via gene expression assays or deep sequence, which 
would enable the discovery of possible, multiple miRNAs bound to their mRNA 
target transcripts, that can be regulated by both mRNA degradation and 
translational inhibition (Akbari Moqadam, Pieters, and Den Boer 2013). 
It needs to be stressed that the used immunoprecipitation approach might not 
necessarily reflect the in vivo miRNA-Ago interactions in sCJD afflicted brain, since 
non-specific and artificial miRNA-RISC associations might be formed upon tissue 
lysis (Beitzinger et al. 2007). Furthermore, a productive miRNA-mRNA binding 
does not mean that the protein level changes substantially, since various cellular 
mechanisms are able to compensate the effects of miRNA targeting, for instance 
through an increased mRNA expression. Moreover, the biological outcome of 
miRNA–mRNA interactions can get affected by multiple factors, such as RISC 
assembly, the presence of p-bodies or stress granules can affect the miRNA-
mediated gene silencing (Gulyaeva and Kushlinskiy 2016; Schanen and Li 2011a). 
In publication I, we observed strong evidence for an impaired miRNA biogenesis in 
sCJD brains. Ago-proteins appeared to change partially their subcellular 
distribution and localization during disease. 
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Our work highly suggests that upregulated miRNAs in sCJD are effectively 
incorporated into the functional miRNA-regulated gene silencing complex and 
thereby likely participate in the disease associated gene expression landscape. 
We provided important impulses for the field of miRNA research in NDs by pointing 
out the crucial need for profiling miRNA-mRNA interactions in their functionally 
active silencing complexes instead of the analyses of mere expression levels 
profiled in bulk tissue. Moreover, by our observations of partially translocated Ago 
that likely affects Ago functionality in sCJD, we proofed the importance of studying 
miRNA function in a well-defined context.  
Recently, other studies have performed screenings for functionally active miRNAs 
and miRNA targets by their co-immunoprecipitation with Ago proteins in different 
human tissue samples during healthy and disease states and in disease models 
such as for cancer (Chiyomaru et al. 2014; Fan et al. 2013; Kanematsu et al. 
2014; Dzikiewicz-Krawczyk et al. 2018), cardiovascular diseases (Ling et al. 2017; 
Dangwal, Bang, and Thum 2012), diabetes (Ofori et al. 2017) or neurological 
conditions (Burak et al. 2018; Gross et al. 2016). Combined with high-throughput 
RNAseq analyses, Ago immunoprecipitation assays can provide a way to identify 
the global miRNA-mRNA targetome in complex neurological diseases (Boudreau 
et al. 2014; Londin et al. 2015). For instance, the global miRNA regulatory network 
was identified upon ischemia injury in mouse brain revealing changes of over one 
thousand miRNA-mRNA interactions involved in mediation of neuroprotective 
responses upon stroke injury (Kobayashi et al. 2018). Until today, most screenings 
for functional active miRNAs in human diseases were performed in in vitro models. 
We provided the first mapping of functional miRNAs in the context of NDs in 
human.   
 
8.3.2    Temporal miRNA expression analysis in a CJD mouse model 
 
miRNA alterations in prion disease models represents a unique tool to investigate 
the cause-consequence relationships of miRNA dysregulation in prion disease 
pathology, and to evaluate the use of miRNAs in diagnosis as biomarkers (Watts 
and Prusiner 2014; Brandner and Jaunmuktane 2017). We successfully validated 
the miRNA expression patterns observed in sCJD MM1, in a CJD MM1 mouse 
model, which resembles the neuropathological, biochemical, and gene expression 
alterations reported in sCJD in a region- and subtype-specific manner (Padilla et 
al. 2011; Llorens et al. 2014; Llorens, Thüne, Tahir, et al. 2017; Kanata et al. 
2018). We validated expression changes of ten and eleven miRNAs via qPCR 
technic in the cortex and in the cerebellum of the CJD mouse model at one of the 
clinical stages (180 and/or 210 days post inoculation (dpi)), respectively. Temporal 
miRNA expression analysis from the CJD mouse revealed that the alterations 
mainly occur with the onset of symptoms, suggesting that the pool of analyzed 
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miRNAs specifically alters during clinical disease stages, which provides a link 
between regional pathology and stage of disease (Fig 11). 
 
Figure 11: Temporal profile of miRNA expression in CJD MM1 mouse model: miRNA 
expression time course analyses performed via qPCR in cortex of tg340-PRNP129MM 
mouse model at 120 (pre-clinical), 160 (early-clinical), 180 (clinical) and 210 (late-clinical) 
days post inoculation with sCJD MM1 brain homogenates in compare with control 
inoculated mice. Profiled miRNAs seem to change their expression with disease onset, 
suggesting that miRNA deregulation has the potential to shape molecular phenotypes 
during clinical disease stages. Key events in the pathogenesis of prion disease in CJD 
MM1 mice are: alterations in Ca2+ homeostasis and accumulation of pathological PrP 
forms evident during pre-clinical stages (Llorens, Thüne, Sikorska, et al. 2017), 
neuroinflammatory processes reported as pre-clinical and early-clinical events (Llorens et 
al. 2014; Llorens, Thüne, Tahir, et al. 2017), synaptic loss and neuronal death at clinical 
stages. 
Distinct prion disease phases have been suggested, in which brain cells respond 
with beneficial mechanisms upon early pathological stimuli, while during disease 
progression sustained detrimental conditions may trigger neurodegenerative 
pathways (De Strooper and Karran 2016; Majer et al. 2012). The underlying 
molecular mechanisms involved in the transition from neuroprotective signalling 
towards neuronal dysfunction and death during prion disease are still elusive. We 
successfully proofed that miRNA alterations are resembled in a CJD model system 
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that reflects faithfully in vivo disease processes and thereby providing highly 
valuable approaches to dissect the causative involvement and consequential 
effects of miRNA dysregulation in prion disease progression. Interestingly, among 
the pool of profiled miRNAs found to be altered in clinical sCJD, miR-124-3p 
(downregulated) and miR-16-5p (upregulated) change their expression during 
early symptomatic phase (160 dpi) in CJD mice, suggesting the contribution of 
miR-124-3p and miR-16-5p in pre- and early clinical prion disease mechanisms. 
Upregulation of miR-16-5p was also found in hippocampal neurons in a further 
prion disease animal model, a scrapie-infected mouse, during pre-clinical disease 
stages (Majer et al. 2012). In a recent publication, Burak et al. aimed to study the 
biological effects of miR-16-5p overexpression in a prion disease cell culture 
model. Lentiviral-based miR-16-5p upregulation in cultured hippocampal neurons, 
mimicking miR-16-5p increase observed in in vivo conditions, was inducing 
decreased neurite length and branching. Co-immunoprecipitation of miR-16-5p 
enriched Ago complexes with their associated mRNA transcripts revealed the 
presence of genes involved in the signaling pathway “mitogen-activated protein 
kinases/extracellular signal-regulated kinases” (MAPK/ERK) as miR-16-5p targets 
indicating that a miRNA-mediated mechanism might induce neuronal degeneration 
through MAPK/ERK pathway targeting (Burak et al. 2018). 
Certain factors need to be considered while studying and interpreting miRNA 
dysregulation in the transgenic mouse model. CJD MM1 mice are the result of 
non-physiological 4-fold PrPc overexpression (Padilla et al. 2011), which might 
lead to overexpression artifacts that not fully corresponding to the human situation 
(Brandner and Jaunmuktane 2017). In sCJD brain, PrP metabolism is impaired 
and highly variable PrP protein levels have been observed among sCJD subtypes 
and brain regions likely linked to disease-specific mechanisms. In sCJD MM1 
brain, PrP is decreased on mRNA and total protein levels, while high amounts of 
PrPsc accumulate (Llorens et al. 2013). A further challenging aspect when using 
the transgenic mouse model is their inoculation with brain homogenates at early 
ages (6-10 weeks) and development of symptoms at middle ages (around 160 dpi) 
(Padilla et al. 2011). The major risk factor of prion diseases is age and cellular 
senescence is supposed to promote neurodegenerative processes (G G Kovacs 
and Budka 2002). Brain aging is featured by decreased neuronal and synaptic 
density (Petralia, Mattson, and Yao 2014), increased numbers and reactivity of 
microglia and astrocytes (Spittau 2017; Clarke et al. 2018), and transcriptional 
changes with higher expression profiles for genes linked to inflammation, oxidative 
stress, DNA repair as well as decreased gene expression for pathways involved in 
neuronal function (Mohan et al. 2016). In order to consider the aging component 
while studying miRNA dysregulation in prion disease models, aged animals or 
mouse inbred strains with accelerated senescence can be useful (Shimada and 
Hasegawa-Ishii 2011). 
However, with our work, we clearly demonstrated that beside highly resembled 
neuropathological features between sCJD and CJD mouse model, also alterations 
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in disease associated molecular signatures were validated between human 
disease and mouse model (Llorens et al. 2014; Llorens, Thüne, Tahir, et al. 2017; 
Kanata et al. 2018; Llorens, Thüne, Sikorska, et al. 2017). 
 
8.3.3    Ex vivo models to study biological functions of miRNA alterations 
observed in sCJD 
 
Neurodegenerative phenotypes in sCJD reflect complex, spatial- and time-
dependent molecular processes and analysis of detailed molecular disease 
mechanisms is necessary for the identification of therapeutic targets. Modeling 
reported miRNA alterations in in vitro disease models may enable the investigation 
of miRNA-depend events and their biological effects during sCJD mechanism in a 
site specific-manner. 
Many studies have investigated miRNA functions in neurodegenerative processes 
by mimicking expression alterations of one or few miRNAs in cell-based assays 
and thereby focused on the role of individual genes and pathways possibly 
regulated by individual miRNAs (Krützfeldt, Poy, and Stoffel 2006). In contrast, we 
aimed to investigate the biological consequences of genome-wide changes in 
miRNA signatures observed in sCJD. Therefore, we transfected the miRNAome of 
sCJD patients into neuronal-like and glial-like cell lines to measure cell-type 
specific, biological effects of sCJD-connected miRNA changes and their putative 
targets. We observed that the neuronal-like cell line reacts much more sensitive on 
the presence of the sCJD connected miRNAome, than the glial-like cell line. Our 
experiment indicated that disease-associated abnormalities in the miRNAome 
might act as molecular driver triggering detrimental effects leading to neuronal 
degeneration in sCJD.  However, the transfected RNA from sCJD brains was 
isolated from bulk tissues and misexpression of miRNAs can occur in non-
physiological context. Additionally, through the manipulation of miRNA expression 
in an additive manner, the observed downregulation of miRNAs in sCJD is not 
resembled in this ex vivo model. 
 
8.3.4    Molecular alterations in the locus coeruleus during early and middle 
Braak stages of NFT pathology 
 
There is a critical need for the identification of early AD-associated changes 
preceding symptomatic disease in order to define potential therapeutic 
interventions, in which neural tissue remains intact and more likely responsive to 
treatment. How the switch towards irreversible AD processes is characterized and 
which molecular mechanisms define the transitional phase from early pathological 
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alterations towards mild cognitive impairment (MCI) and/or AD evolution remains 
elusive (Vickers et al. 2016). 
The LC is one brain region vulnerable for the appearance of NFTs and it has been 
suggested as an initial site for NFT formation during ageing and AD (Grudzien et 
al. 2007). Our work provided crucial insights into molecular alterations during the 
progression of early stages of NFT formation, especially in the LC, in which we 
observed the upregulation of four profiled miRNAs: miR-27a-3p, 124-3p, 132-3p, 
143-3p. The altered miRNAs were indicated to be expressed in LC neurons by in 
situ hybridization analyses, suggesting that these miRNAs have the potential to 
shape the molecular environment in LC neurons during transitional processes from 
normal aging into early AD (Fig 12). 
Andrés-Benito et al. analyzed molecular characteristics accompanying NFT 
formation in the LC revealing complex abnormalities during asymptomatic early 
stages of NFT that include: (1) activated tau kinases (2) truncated tau forms (3) 
increased oxidative stress and reduced stress response (4) microglia activation 
and proliferation (5) reduced mitochondria (6) upregulation of genes linked to 
protein folding, chaperone binding, ATP metabolism, (7) downregulation of genes 
coding for DNA-binding proteins and small nuclear RNAs with disease progression 
(Andrés-Benito et al. 2017). 
It can be speculated that our reported miRNA upregulations in LC during first 
Braak stages are linked to disease processes itself rather than being secondary 
effects of disease pathology, such as changes in cellular composition in disease-
affected brain regions, formation of amyloid plaques or neuronal loss. It also can 
be considered that the reported miRNA changes could be involved in 
compensatory mechanisms during early AD evolution and/or aging (Reddy et al. 
2017; WANG et al. 2014). However, in order to understand to what extent the 
recorded miRNA alterations reflect probable early AD-associated processes in LC 
neurons during early stages of NFT formation, it is necessary to dissect their 
functional role by a range of experimental methods.  




Figure 12: Schematic overview of molecular alterations in locus coeruleus neurons 
during first NFT pathology stages: The presents of hyperphosphorylated, misfolded 
and truncated tau in LC neurons is accompanied by cellular abnormalities at early and 
middle Braak NFT stages (Andrés-Benito et al. 2017). Aberrant molecular features, such 
as activated tau kinases, increased oxidative stress, reduced stress responses, reduced 
mitochondria and increased microglial activation might represent the molecular 
environment during transitional phase from early pathological alterations towards MCI 
and/or AD. We observed strong evidences for the upregulation of the miRNAs: miR-27a-
3p, 124-3p, 132-3p, 143-3p in LC neurons during these early NFT stages, suggesting the 
miRNA alterations underlying early AD-associated mechanisms. Weather the observed 
miRNA alterations are involved in neuroprotective compensatory pathways or in early 
disease evolution is not clear and need to be dissected by functional miRNA analysis.  
miR-132-3p has been supposed to target directly tau, as well as kinases involved 
in aberrant tau phosphorylation (Salta and De Strooper 2017). Smith et al. 
demonstrated that a deletion of miR-132-3p in a transgenic AD mice model is 
leading to increased tau expression, phosphorylation, and aggregation 
accompanied with an enhanced tau pathology (Smith et al. 2015). Overexpressing 
of miR-132-3p restored tau pathology and cognitive function in AD mice 
(Hernandez-Rapp et al. 2016).  
Similar, miR-124 was also implicated in the regulation of tau isoform levels by 
targeting regulatory and splicing factors (Smith et al. 2011). Additionally, miR-124-
3p has been shown to target Caveolin-1 in an in vitro AD model, and thereby, 
inhibiting aberrant tau hyperphosphorylation (Q. Kang et al. 2017). 
These observations indicate that observed miRNA upregulations may play a 
neuroprotective role in AD. However, these functional miRNA implications could 
be biased towards targeted analyses of key proteins involved in AD. 
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Comprehensive exploratory analyses of miRNAs and their targets in the context of 
early NFT formation are necessary to understand their true biological effects. 
 
8.4    Mechanisms of altered miRNA signatures in NDs 
 
The reported miRNA alterations during critical disease stages have the potential to 
be involved in initiation and progression of sCJD and AD. However, a clear 
understanding of the underlying mechanisms, involved in miRNA deregulation in 
NDs, will contribute greatly to the identification of relevant targets for successful 
disease modifying therapies (Cummings 2017). We focused on a comprehensive 
characterization of the miRNA biogenesis machinery during late stages of sCJD, 
revealing strong evidences for complex impairments of key proteins involved in 
miRNA biogenesis and function, which may contribute to miRNA dysregulation in 
sCJD (Fig 13).  
 
Reduced levels of the miRNA maturing proteins Drosha, its cofactor DGCR8, and 
Dicer were observed on mRNA and protein level in sCJD brains. These 
observations can be an explanation for the reported decreased miRNA levels in 
sCJD brain, although, more detailed cellular- and spatial resolution of observed 
miRNA signatures and status of biogenesis machinery are necessary to draw solid 
conclusions. 
Analyses of the subcellular contribution of Ago proteins in sCJD via gel-filtration 
chromatography and immunohistochemical staining revealed a switch of Ago-2 
containing protein complexes to higher molecular forms. Strong evidences for an 
enriched subcellular relocalization of Ago proteins to the nucleus in sCJD when 
compared with age-matched controls were shown. 
Subcellular localization and posttranslational modifications of Ago-proteins have 
been described to influence miRNA-mediated gene silencing, and thereby, 
coordinating gene expression (Meister 2013b; Jonas and Izaurralde 2015b; Detzer 
et al. 2011). One possible consequence of a nuclear increase of Ago proteins 
could be a lack of miRNA-mediated gene regulation of cytoplasmic mRNA targets 
in sCJD. Mature miRNAs and components of the miRNA biogenesis machinery 
have been described to be capable shuffling between cytoplasm and nucleus 
(Roberts 2014). In this context, observed nuclear located Ago-proteins in sCJD 
could be involved in gene regulation of nuclear transcripts or induction of 
epigenetic alterations (Leung 2015). Upon translational stress condition, Ago-
proteins are often recruited to stress granules, in order to enhance miRNA-
regulated gene silencing (Leung, Calabrese, and Sharp 2006). By observing 
stress granule markers, we could not find evidences for the formation of stress 
granules in sCJD. The heat heat-shock protein (Hsp) 90, a chaperone involved in 
protein quality control, is proposed as one crucial factor regulating the recruitment 
of Ago-proteins to stress granules and processing bodies (Pare et al. 2009). 
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Dysfunctional Hsp90 has been linked to sCJD pathogenesis (Gawinecka et al. 
2012), and could underlie aberrant subcellular localization of Ago-proteins.   
 
It is worth mentioning that PrPc has been demonstrated to associate with Ago 
proteins under physiological conditions, stabilizing RISC assembly and function 
(Gibbings et al. 2012). In prion disease, most pathological PrPsc aggregates as 
oligomers with typically high molecular weight (Silveira et al. 2005; Tzaban et al. 
2002). Therefore, a potential interaction of PrPsc with Ago could be an explanation 
for the observed switch of Ago-2 containing protein complexes to higher molecular 
forms. 
It seems likely that the presence of pathological PrPsc, as well as, the loss of PrPc 
function might directly contribute to miRNA dysregulation in sCJD, which clearly 
deserves further investigations (Fig 13). 
 
 
Figure 13: Schematic overview of impaired miRNA machinery in sCJD. Our 
observations showed strong indications for complex impairments of the miRNA machinery 
in sCJD, pointing out strong links between impaired miRNA regulatory pathways and 
altered miRNA patterns. Upregulation and activation of the transcription factor STAT3 
might induce miRNA expression. Decreased expression of Drosha, DGCR8 and Dicer 
may impair miRNA biogenesis. Abnormal subcellular localization of Ago-proteins can 
affect gene silencing efficiency. Co-localization of PrPc with Ago has been suggested for 
an effective miRNA-mediated gene silencing. Weather the presence of pathological PrPsc 
forms and PrPc loss-of-function have an impact on miRNA-mediated gene regulation is 
not clear (Gibbings et al. 2012). The absence of stress granules could reduce cellular 
clearance ability in sCJD. 
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Deregulated miRNA biogenesis also appeared during other forms of ND conditions 
(Tan, Yu, and Tan 2015); upregulation of Drosha, DGCR8 and Dicer was 
observed in the brain of multiples sclerosis (MS) patients (Jafari et al. 2015), as 
well as, aberrant subcellular distribution of Drosha (Porta et al. 2015) and Dicer 
malfunction in the brain of amyotrophic lateral sclerosis (ALS) patients (Emde et al. 
2015). It has been suggested that stress and stress granule formation can initiate 
alterations and dysfunction of miRNA biogenesis machinery, affecting neuronal 
integrity and driving ND processes (Emde et al. 2015; Olejniczak, Kotowska-
Zimmer, and Krzyzosiak 2018). By analyzing the subcellular localization and 
expression levels of stress granule markers eIF3 and Tia1, as well as, 
phosphorylation status of stress granule activator eIF2α, we could not find 
evidences for the formation of stress granules in sCJD brain. The ER stress 
sensor PERK can phosphorylate and activate eIF2α in order to reduce 
translational initiation of the majority of cellular proteins (McQuiston and Diehl 
2017). The activation of PERK and the mediation of an untranslated protein 
response appeared to be absent in human prion disease (Unterberger et al. 2006; 
Wiersma et al. 2016), which could underlie a lack of stress granules observed in 
sCJD. 
The occurrences of intracellular neuronal calcium overload and ER stress have 
been implicated in prion disease pathogenesis (Franc Llorens, Thüne, Sikorska, et 
al. 2017; Ferreiro, Oliveira, and Pereira 2008). Approaches in different cellular 
context revealed that ER stress can mediate alterations in miRNA biogenesis 
machinery and subsequently modify expression of miRNAs (Maurel and Chevet 
2013). In this context, it can be speculated that the accumulation of pathological 
PrPsc forms, accompanied by the failure of protein quality control machinery, 
could lead to deregulation of intracellular calcium and ER stress, which might 
trigger sCJD pathogenesis at multiple molecular levels including miRNA 
biogenesis dysfunction and miRNA expression changes. However, dissecting the 
cascade of pathological events in sCJD remains necessary in order to identify 
potential targets for therapeutic intervention. 
 
Beside miRNA regulation at the level of their biogenesis, miRNA expression and 
cellular abundance can be influenced by multiply regulatory mechanisms, such as 
genetic and epigenetic factors, RNA editing, transcription factors, miRNA turnover 
and subcellular miRNA localization (Bronevetsky and Ansel 2013; Gulyaeva and 
Kushlinskiy 2016; Schanen and Li 2011a; Tomaselli et al. 2015). 
 
We observed strong evidences that a pool of miRNAs, upregulated in sCJD brain, 
are potentially under transcriptional control of the transcription factor STAT3, 
which was found upregulated and activated in prion disease (Llorens et al. 2014; 
Carroll et al. 2015), indicating a STAT3-dependent mechanism of miRNA 
deregulation in sCJD. Nerveless, the potential interplay between miRNAs and 
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STAT3 need to be sustained by information according cellular context and 
characterization of in vivo STAT3 binding sites. 
 
8.5    Circulating miRNAs as potential biomarkers for human prion 
disease and early AD  
 
Peripheral circulating miRNAs have the potential to reflect brain abnormalities 
during disease states, including neurodegenerative dementias (Sheinerman et al. 
2017; Grasso et al. 2014; Zendjabil 2018). Our presented studies revealing miRNA 
alterations during critical disease stages during two types of neurodegenerative 
conditions, sCJD and early Braak NFT stages, suggest the possibility of 
pathology-associated differences in circulating miRNA levels that may serve as 
non-invasive biomarker for prediction, differential diagnosis and monitoring of 
these diseases and drug response.  
Extracellular miRNAs fit a number of criteria as promising biomarker for NDs: they 
are highly stable in biofluids, easy accessible through non-invasive approaches, 
cost efficient and reliable diagnostic assays enabling miRNA identification, such as 
microarray or qPCR, and miRNA signatures can be potential indicator for 
preclinical disease stages as well as disease progression or therapeutic response 
(Wang, Chen, and Sen 2016; Viswambharan et al. 2017). 
miRNAs can be released by cells through active and passive processes, entering 
the circulation by various pathways. Cellular release mechanisms include miRNA 
secretion (1) via encapsulated microvesicles, including exosomes, (2) vesicle-free 
miRNAs bound to proteins, such as Ago or lipoprotein complexes, and (3) upon 
apoptotic or necrotic cell death. Beside their role as biomarker for NDs, 
extracellular miRNAs are suggested to mediate intercellular communication over 
short and/or long distance within the nervous system or peripheral tissue, and can 
act both in physiological context as well as in diseases (Scott 2017). For instance, 
glia-to-neuron transfer of miRNAs has been proposed as a molecular mechanism 
underlying inflammation-induced alterations of synaptic integrity during brain 
inflammation (Prada et al. 2018). 
CSF as potential source of disease-specific miRNA signatures provides the 
advantage of the proximity to the extracellular brain space and regions of 
pathology (Gallego et al. 2012). The CSF is enriched with central nervous system-
specific miRNAs that might represent highly valid biomarkers for brain pathologies. 
miRNAs derived from blood, either plasma or serum fractions, are easier 
accessible and non-invasive, however, blood contains high numbers of miRNAs 
from peripheral tissues (Sorensen, Nygaard, and Christensen 2016). Investigating 
exosomal miRNAs in biofluids provides an appealing approach for the 
identification of disease-specific diagnostic signatures, since the cargo contained 
in exosomes includes distinct miRNA pools (Soria et al. 2017). 
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8.5.1    Profiling CSF-based miRNAs in sCJD 
 
Due to the rapidly evolving disease, high heterogeneity, and lack of a consistent 
geometrical spreading of neuropathology, biomarker research in prion disease 
faces significant challenges (Wadsworth and Collinge 2011; Gambetti et al. 2003; 
Parchi et al. 2012). Up to date, quantitative biomarkers that are able to diagnose 
and quantify disease progression are missing and hamper early prion disease 
diagnose (Canas et al. 2018). Disease-specific miRNA expression profiles provide 
the potential to be used as diagnostic, prognostic and therapeutic markers for 
prion disease.   
To date, no data on miRNA alterations in biofluids as potential disease biomarker 
in human prion disease are available. We provided the first study investigating the 
presence of disease-associated miRNAs in the CSF derived from sCJD and age-
matched control patients, revealing important information regarding the types of 
miRNAs detectable in cell-free CSF. Therefore, miRNAs that were found 
deregulated in sCJD brain, were analyzed in CSF of 12 sCJD patients and 12 age-
matched controls via qPCR technic. In our preliminary targeted CSF-based miRNA 
characterization we revealed robust detectable CSF miRNA expression of three 
miRNAs (miR-26a-5p, miR-204-5p, miR-378a-3p) out of eleven profiled 
candidates. Also the small nuclear RNA RNU6 was stable detectable via qPCR in 
the analyzed CSF samples. One out of three detectable CSF miRNAs (miR-204-
5p) appeared differentially expressed in sCJD in compare with control patients. In 
this regard, our results suggest that qPCR-based profiling of highly expressed 
CSF miRNAs could provide a potential diagnostic platform for sCJD. The detected 
CSF miRNAs in our study (miR-26a-5p, miR-204-5p, miR-378a-3p) have been 
described to be CSF enriched (Burgos et al. 2013). 
Overall, no correspondence between altered miRNAs in sCJD brain and CSF was 
observed. miRNAs, which we found increased in sCJD brain, such as miR-26a-5p, 
miR-195-5p, let-7i-3p, miR-378a-3p, miR-449a, miR-124-3p and miR-154-5p, did 
not show significant differences in sCJD CSF samples compared to control 
patients. On the other hand, miR-204-5p, which expression remained unchanged 
in sCJD brain, was found significantly diminished in the CSF of sCJD patients, 
suggesting this miRNA as a possible CSF biomarker discriminating sCJD from 
age-matched controls.  
The secretion of miRNAs into the CSF occurs in a selective manner and miRNA 
alterations in the brain are not necessarily mirrored in the CSF (Ng et al. 2013; 
Grasso et al. 2014). The source of miR-204-5p in the CSF and weather its 
reduced levels in the CSF derived from sCJD patients is associated to sCJD 
pathogenesis is unknown and needs further investigations. miR-204 has been 
reported to be expressed in various human cell types (Wang et al. 2010), including 
brain tissue, where it is found highly abundant in neuronal axons (Natera-Naranjo 
et al. 2010; Wang and Bao 2017). miR-204 has been also found highly abundant 
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in CSF, and therefore, suggested as a CSF enriched miRNA (Burgos et al. 2013; 
Yagi et al. 2017). In this regard, there is the possibility that miR-204 
downregulation in the CSF might result upon neuronal dysfunction in sCJD, which 
could lead to less released miRNA levels into CSF. The miR-204 expression in the 
brain, investigated by RNAseq and qPCR, remained unchanged in analyzed brain 
regions in sCJD, suggesting altered peripheral miRNA secretion mechanisms in 
sCJD as possible source for CSF miR-204 downregulation. However, specific 
expression changes of compartmented axonal miRNAs might not have been 
captured via RNAseq and qPCR of analyzed bulk tissue (Koshiol et al. 2010; 
Chugh and Dittmer 2013). In fact, the source of miR-204-5p could be diverse and 
might be derived from different brain cells (such as neurons or glia cells), blood 
cells or peripheral sources (Bekris et al. 2013). Up to now, CSF-based miR-204-5p 
downregulation has been also reported in genetic FTD patients, whereby profiled 
miRNAs were isolated from exosomes (Schneider et al. 2018). 
We aimed to establish a preliminary CSF miRNA screen for disease-specific 
miRNA candidates profiled in brain as a suitable tool for clinical approaches. 
Although peripheral circulating exosomal miRNAs might represent disease-specific 
signatures in sCJD (Soria et al. 2017; Hartmann et al. 2017), we focused on the 
isolation of total, cell-free miRNAs in the CSF. Ultracentrifugation-based exosome 
isolation methods can be time-consuming, requires specialized laboratory 
equipment and might result in low exosome yield, providing difficulties for miRNA 
quantification in routine diagnostic. Moreover, higher amounts of CSF starting 
material are necessary for the isolation of exosomal miRNAs in compare to total 
CSF miRNAs (Lin et al. 2015; Chen et al. 2017).  
Variability in CSF miRNA profiles in inter/intra-cohort studies has been described 
leading to conflicting data. Potential sources for miRNA fluctuations can be 
connected to different postmortem intervals, age, gender, or physiologic factors 
such as circadian rhythm, medication, exercise, etc. (Yoon et al. 2017). Associated 
to the high fluctuation of miRNAs in the CSF, the selection of endogenous 
reference genes is a critical step for the identification of true miRNA alterations 
between disease and control conditions. No universal invariant CSF miRNA 
calibrator for relative normalization purposes exist and the best combination of 
reference genes must be determined (Moldovan et al. 2014). The amounts of 
profiled miRNAs in our study were normalized relative to the amount of the small 
nuclear RNA RNU6, which we detected uniformly expressed in disease and 
control groups. RNU6 belongs to another RNA class with different biochemical and 
metabolic features, which might lead to bias during CSF miRNA quantification 
(Schwarzenbach et al. 2015; Gee et al. 2011). Further helpful normalization 
approaches could include the adding of synthetic miRNA spike-ins, the usage of 
global mean normalization of all profiled miRNAs, or empirical tools to select 
stable miRNA candidates as normalizer (Yoon et al. 2017). However, we found 
RNU6 stable abundant in the CSF of sCJD and control samples justifying its 
usage as reference gene for normalization procedure. 
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Our study is particularly important in this context, since we identified robust and 
reproducible miRNA candidates in the CSF. Despite relative low CSF miRNA 
concentrations and the small number of analyzed patients, we were able to detect 
uniform levels of miRNA candidates in CSF by qPCR, providing resources for 
future miRNA biomarker studies. If miRNAs reveal as reliable CSF biomarker for 
practical clinical applications in sCJD still needs to determine. Future studies 
should complemented our observations with 1) unbiased global approaches for 
miRNA profiling, such as RNAseq, to determine absolute miRNA expression 
profiles in the CSF, 2) introduction of standardized strategies of miRNA detection 
in clinical studies, 3) large-scale clinical validation studies. 
 
8.5.1.1 Altered miRNAs in biofluids as potential diagnostic tools in prion 
diseases 
 
miRNA alterations in body fluids of animal prion diseases and disease model 
systems offer opportunities for miRNA biomarker research that cannot be provided 
by examining disease in humans (Kanata, Thüne et al. 2018). Current progress in 
circulating miRNAs research in prion disease is summarized in Fig 14. 
  
Figure 14: Overview of studies on circulating miRNA alterations in prion diseases: 
With a preliminary CSF miRNA screen in sCJD, we observed reduced CSF miR-204-5p 
levels in sCJD and provided the first study revealing a differential expressed miRNA 
candidate in human prion disease biofluids. Upregulation of miR-342-3p and miR-21-5p in 
plasma was demonstrated in sheep affected by scrapie (Rubio et al. 2017). The presence 
of a distinct miRNA pool has been shown in exosomes released in vitro by prion-infected 
neuronal cells (Bellingham, Coleman, and Hill 2012). Upregulation of circulating miR-342-
3p and miR-21-5p was described in two prion disease studies.  
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Elevated levels of blood-based miR-342-3p and miR-21-5p during pre-clinical 
disease stages in sheep naturally affected by scrapie were detected, suggesting 
these miRNAs as potential plasma-based biomarker in animal and human prion 
diseases (Rubio et al. 2017). However, no data are available on blood-based 
miRNA signatures in human prion disease. Interestingly, increased amounts of 
miR-342-3p and miR-21-5p were also reported in exosomes secreted by a 
hypothalamic neuronal cell line infected with a human GSS prion strain (GSS-
GT1-7) (Bellingham, Coleman, and Hill 2012). Moreover, among analyzed miRNA 
changes, the upregulation of miR-322-5p and miR-21-5p in exosomes released in 
vitro by prion-infected neuronal cells appeared exclusively in prion disease model 
(Bellingham, Coleman, and Hill 2012) and, up to now, were not described in  other 
NDs, including AD (Nagaraj et al. 2017; Kiko et al. 2014; R. Guo et al. 2017; Zeng 
et al. 2017; Dong et al. 2015; Geekiyanage et al. 2012), MS (Vistbakka et al. 
2017), PD (Ma et al. 2016; Ding et al. 2016; Gao et al. 2016) and ALS 
(Freischmidt et al. 2013). On the other hand, common exosomal miRNAs 
alterations, including let-7i-5p, miR-128-3p (upregulated), and miR-146a-5p 
(downregulated), have been observed in prion disease cell culture model 
(Bellingham, Coleman, and Hill 2012), blood-based exosomes isolated from: MS 
patients (let-7i-5p, (Kimura et al. 2018)), primary progressive MS (miR-128-3p 
(Vistbakka et al. 2017)), AD (miR-146a-5p, (Kiko et al. 2014; Dong et al. 2015)), 
and PD (miR-146a-5p, (Ma et al. 2016)). 
 
8.5.2    Circulating miRNAs as potentially early AD biomarker 
 
There is the critical need for AD biomarkers that are able to identify pre-clinical 
disease-associated changes, and at the same time, to predict weather 
pathological alterations will progress towards MCI and/or AD. However, when the 
irreversible AD processes begin is unknown and the underlying mechanisms of the 
transitional phase from early pathological alterations towards MCI and/or AD 
evolution remains elusive (Fiandaca et al. 2014). 
We demonstrated miRNA alterations during the progression of first Braak NFT 
stages in compare to cases with no neuropathological lesions. One of four 
upregulated miRNAs in analyzed brains, miR-143-3p, was also found upregulated 
in exosomes isolated from blood in MCI and AD patients (Cheng et al. 2015). The 
observed upregulation of miR-143-3p in LC and EC during NFT Braak stage I-IV 
could be an explanation for elevated exosomal miRNA levels in AD blood, 
suggesting miR-143-3p as a possible pre-clinical and prognostic AD biomarker. 
Our work strongly suggests that the establishment of a miRNA screen in brain 
could help to identify miRNAs in biological fluids, which may indicate cognitively 
intact individuals at risk for AD, providing the possibility for the detection of 
therapeutic window for disease prevention.   
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The focus of our work was the assessment of miRNA alterations during early AD-
associated neuropathological changes unattached from neurophysiological 
assessments. However, it needs to be stressed that NFT stages I-II and even 
stages III-IV are asymptomatic, although individuals at stage IV might represent 
cognitive impairment (Braak and Braak 1991; Murayama and Saito 2004). 
Increasing number of miRNA biomarker studies have been focused on AD, 
suggesting circulating miRNAs in CSF and blood as promising disease-specific 
markers (Zendjabil 2018; Galimberti et al. 2014; Kumar and Reddy 2016; Dangla-
Valls et al. 2017; McKeever et al. 2018). Cogswell et al. identified 60 CSF-based 
miRNAs in AD patients, which were also detected in AD brain, showing regional- 
and stage-specific expression patterns (Cogswell et al. 2008). CSF-based miRNA 
changes have been demonstrated to be able to differentiate AD from age-matched 
controls, such as miR-222 and miR-125b upregulation in AD CSF (Dangla-Valls et 
al. 2017). A blood-based signature of 12 miRNAs was able to differentiate AD 
patients from healthy controls, as well as, AD patients from other neurological 
disorders with high diagnostic accuracy (Leidinger et al. 2013). Tan et al. profiled 
the miRNA expression in sera of 158 patients and 155 controls, revealing 6 
miRNAs (miR-98-5p, miR-885-5p, miR-483-3p, miR-342-3p, miR-191-5p, and 
miR-let-7d-5p) that present significantly different expressed miRNA signatures in 
AD patients in compare to controls (Tan et al. 2014). Lugli et al. revealed a panel 
of 7 exosomal miRNAs in the plasma fraction identifying AD patients with an 
accuracy of 83 to 89% (Lugli et al. 2015). However, when comparing circulating 
miRNA profiling data in different studies, it needs to be stressed that there is little 
overlap in miRNA signatures (Zendjabil 2018). The implementation of robust and 
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8.6    Using miRNAs to treat NDs 
 
Up to now, NDs, including prion disease and AD, remain incurable and successful 
therapies to delay or stop progression of these conditions still represent the most 
challenging goals. With their ability to regulate complex networks of genes and 
pathways simultaneously, miRNAs provide a promising potential as therapeutic 
applications (Ouellet et al. 2006). miRNAs could help to restore dysregulated 
pathways within critical disease stages, and in the same manner, targeting multiply 
aspects of multifactorial disease pathogenesis, such as imbalance in production 
and clearance of misfolded proteins, neuroinflammation and imbalance in 
degenerative and protective signaling (Goodall et al. 2013). 
Experimental evidences have shown that the build up and aggregation of 
misfolded amylogenic proteins during NDs processes could be mediated via 
miRNAs. Cell culture experiments showed that treatment with synthetic miRNAs, 
targeting PrPc, was capable to reduce PrPC expression, and thereby, inhibiting 
prion propagation in neuroblastoma cells (Kang et al. 2011) and in primary 
neuronal cultures (Kang et al. 2018; Pfeifer et al. 2006). With help of lentivector-
mediated RNA interference, endogenous PrPc expression was suppressed in 
scrapie-infected mice delaying disease progression (Pfeifer et al. 2006; Ridolfi and 
Abdel-Haq 2018). In context of miRNAs as therapeutic target in AD, miR-16 
mimics has been shown to downregulate the expression of tau, APP and Beta-
secretase 1 in cell culture and mice (Parsi et al. 2015). Pereira et al. showed that a 
treatment with pre-miR-29b resulted in reduced Beta-secretase 1 protein 
expression and Aβ levels in a neuronal cell line expressing human APP (Pereira et 
al. 2016). Additionally, rescuing impaired miRNA biogenesis, by enhancing DICER 
activity in disease model, has been suggested has potential therapeutic 
intervention for ALS (Emde et al. 2015). 
One approach that has been suggested for the delivery of miRNAs into the brain 
and into targeted cells vulnerable to NDs is via exosomes, which represent a 
delivery mechanism that is able to cross the blood brain barrier (Ha, Yang, and 
Nadithe 2016; Chen et al. 2017). In this context, a successful exosome-based 
delivery of miR-124 has been demonstrated in a Huntington’s disease mouse 
model resulting in the downregulation of miRNA targets in disease-affected brain 
regions (Lee et al. 2017). Moreover, exosome-mediated delivery of miRNA has 
been proposed as therapeutic treatment in other neurological conditions such as 
ischemic brain injury (Xin, Li, and Chopp 2014). In this context, the targeted 
delivery of miRNAs via exosomes has been shown to promote neurogenesis in 
ischemic regions in post-stroke mouse models (Chopp and Zhang 2015; Yang et 
al. 2017) 
Due to the complex nature of miRNA-mediated gene regulation, one major hurdle 
of miRNA-based therapies is the considerable risk of unspecific gene silencing 
due to off-target effects (Dubois et al. 2016). Therefore, a clear characterization of 
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miRNAs, their targets and functional outcome during spatial- and time-dependent 
molecular disease processes is necessary to achieve potential and reliable 
application of miRNA blockers or mimics as orchestrated and specific therapeutic 
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9.    Summary and Conclusions 
 
A major goal of our studies was to dissect to what extent miRNA changes 
accompany critical stages and progression of NDs in distinct brain regions 
vulnerable to disease. Thereby, we emphasized the importance of extensive 
characterizations of disease-associated miRNA signatures as a first indispensable 
approach for the development of future translational studies. For this purpose, we 
used a combination of different miRNA quantification approaches for a 
comprehensive screening and reliable validation of disease-associated miRNA 
signatures. We aimed to gain holistic insights in temporal, spatial and cellular 
aspects of miRNA alterations, as well as, to define factors potentially influencing 
miRNA biogenesis and function during neurodegenerative conditions, which will 
help to unravel biological consequences of miRNA dysregulation in disease.  
In publication I, we identified global miRNA expression alterations in the frontal 
cortex and cerebellum of sCJD. In particular, we demonstrated that the miRNA 
expression patterns in two sCJD subtypes, MM1 and VV2, are highly changed in a 
regional and disease subtype-dependent manner correlating with differential 
neuropathological affections. Our work strongly suggests that the observed miRNA 
alterations could shape the molecular disease phenotypes, and thereby, being 
directly involved in the molecular mechanisms underlying sCJD etiology.  
We aimed to emphasize that profiling of effectively incorporated miRNAs into their 
functional gene silencing complex is crucial in order to understand their 
contributions to the disease associated gene expression landscape. In this regard, 
the analyses of miRNAs in immunoprecipated Ago-containing complexes in sCJD 
brain revealed that globally upregulated miRNAs are also found enriched in their 
RISC complex. Thereby, we successfully proofed that alterations of miRNA 
signatures in sCJD are also leading to changed binding of mature miRNA their 
silencing complex and likely contribute in shaping gene expression. With our work, 
we provide innovative impulses for the field of miRNA research in NDs by pointing 
out the crucial need for profiling miRNA-mRNA interactions in their functionally 
active silencing complexes instead of interpreting mere expression levels profiled 
in brain tissue lysates. Additionally, we provided a way to identify the cellular 
environment of miRNAs, found to be altered in sCJD, via in situ hybridization 
assays in brain tissue, which essentially complement miRNA expression profiling 
on bulk tissue level.  
Clear characterization of potential underlying mechanisms and factors affecting 
miRNA mediated gene regulation in disease context is essential to dissect the 
contributions of miRNA dysregulation in sCJD pathology. By analyzing key proteins 
involved in miRNA biogenesis, we observed reduced levels of the miRNA-
processing RNases Dicer, Drosha and its cofactor DGCR8 in frontal cortex and 
cerebellum in sCJD. Additionally, we showed that Ago-proteins appeared to 
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change partially their subcellular distribution and localization during disease likely 
affecting Ago function, and thereby the miRNA-mRNA silencing machinery. 
In order to use a disease model highly relevant to human prion pathology, we 
investigated the miRNA expression patterns in a humanized mice model 
inoculated with sCJD prions. We clearly validated the miRNA expression 
signatures that were observed in sCJD, in the CJD mouse model. In this way, we 
demonstrated that beside highly resembled neuropathological features between 
sCJD and CJD mouse model, also alterations in disease associated molecular 
signatures are resembled between human disease and the corresponding mouse 
model. 
We provided the first investigations on the presence of disease-associated 
miRNAs in the CSF derived from sCJD and age-matched control patients, 
revealing important information regarding the types of miRNAs detectable in cell-
free CSF and provided evidences for miR-204 as a potential CSF prion biomarker.  
In cross-disease validation studies, we detected that specific sCJD-regulated 
miRNAs are commonly altered in alternative NDs including AD, DLB, and FFI 
shedding light shedding light into potential common miRNA-related mechanisms in 
the NDs. 
In publication II, we provided crucial insights into temporal miRNA expression 
alterations in brain regions vulnerable to early AD. Therefore, we performed 
targeted miRNA expression profiling in the LC, EC, hippocampal CA1 region and 
dentate gyrus during early and mid-stages of Braak NFT pathology. The profiled 
miRNAs were selected according to their described implications in pathological 
aspects in AD. With our work, we complemented knowledge about global miRNA 
expression analyses in AD brain performed in other studies, with targeted miRNA 
expression profiling in a temporal and cellular manner in brain regions vulnerable 
to early AD. 
In this way, we showed for the first time evidences for meaningful miRNA 
expression alterations in the LC during early NFT pathology before AD-associated 
neuronal death is evident. In the LC, the miRNA-27a-3p, miRNA-124-3p, and 
miRNA-143-3p showed a trend to increase their expression at early stages (Braak 
I-II) and they were found significantly upregulated at mid-stages (Braak III-IV) of 
disease. Among profiled miRNAs, only miRNA-143-3p was found upregulated in 
EC at mid-stages of disease. None of the profiled miRNAs revealed expression 
alterations in the hippocampal CA1 region, while miRNA-124-3p was 
downregulated in DG at early stages of NFT pathology.  
The characterization of the cellular miRNA environment via in situ hybridization 
assays revealed that the deregulated miRNAs are localized in the cytoplasm of 
neurons during NFT pathology progression. Additionally, miRNA-27a-3p has been 
shown to be localized in the nucleus.  
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Our work supplemented the current level of scientific knowledge on miRNA 
dysfunction in human prion disease and early AD. Additionally, we provided new 
important impulses that emphasize the screening for the effective miRNA 
interactome in the complex cellular context of the brain during NDs. We observed 
strong evidences that altered miRNA signatures, as well as, a dysfunctional 
miRNA biogenesis and silencing machinery are involved in the pathogenesis of 
NDs constituting one important factor in the complex network of multiply regulatory 
layers shaping gene expression.  
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